| Title |
Indication |
Intervention |
Actions |
PatientSelection |
Sponsor |
Collaborator |
Country |
StartDate |
EndDate |
Identifiers |
Phase |
Recruitment Status |
Sites |
Trial Duration |
Enrollment Count |
Contacts |
LastChanged |
| Combination therapy in COVID-19 |
Coronavirus disease 19 infection |
Variable regimens including atazanavir , hydroxychloroquine , lopinavir + ritonavir , oseltamivir , ritonavir |
Cytochrome P450 3A4 inhibitor, Exo-alpha sialidase inhibitor, HIV GAG POL polyprotein inhibitor, HIV GAG protein inhibitor, HIV protease inhibitor, HIV-1 protease inhibitor |
|
Tehran University of Medical Sciences |
|
Iran |
2020-03-15 |
|
IR.TUMS.VCR.REC.1398.1058, IRCT20100228003449N30 |
Phase 2/Phase 3 Clinical |
Recruiting |
0 |
|
50 |
Hossein Khalili |
2020-03-23 |
| DisCoVeRy: Trial of Treatments for COVID-19 in Hospitalized Adults |
Coronavirus disease 19 infection |
lopinavir + ritonavir alone, remdesivir alone, standard of care alone, interferon beta-1a plus lopinavir + ritonavir |
HIV protease inhibitor, RNA polymerase modulator |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
INSERM |
|
|
2020-03-31 |
2023-03-31 |
C20-15, DisCoVeRy, NCT04315948 |
Phase 3 Clinical |
Not yet recruiting |
0 |
36 Months |
3200 |
Florence Ader, MD, Hélène Espérou, MD |
2020-03-23 |
| Acute Kidney Injury in Patients Hospitalized With COVID-19 |
Coronavirus disease 19 infection, Renal injury |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Nanfang Hospital First Medical University of PLA |
|
China |
2020-02-26 |
2020-03-08 |
HKYY2020-005 AKI, NCT04316299 |
Phase Not Applicable |
Completed |
1 |
|
287 |
Zhenhua Zen |
2020-03-23 |
| Zedoary Turmeric Oil for Injection in the treatment of Novel Coronavirus Pneumonia (COVID-19): a randomized, open, controlled trial |
Coronavirus disease 19 infection, Viral pneumonia |
zedoary turmeric oil alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
The Second Hospital and Yuying Children's Hospital of Wenzhou Medical University |
|
China |
2020-02-29 |
2020-05-31 |
ChiCTR2000030518 |
Phase 0 Clinical |
Recruiting |
1 |
3 Months |
60 |
Lixue Zhang, Yuanrong Dai |
2020-03-23 |
| SAC-COVID: CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment |
Coronavirus disease 19 infection, SARS coronavirus infection |
CD24-IgFc alone |
Signal transducer CD24 modulator |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
OncoImmune Inc |
|
US |
2020-05-31 |
2022-05-31 |
CD24FC-007, NCT04317040, SAC-COVID |
Phase 3 Clinical |
Not yet recruiting |
0 |
24 Months |
230 |
Martin Devenport, PhD, Pan Zheng, MD, PhD, Shyamasundaran Kottilil |
2020-03-23 |
| Clinical Characteristics and Long-term Prognosis of 2019-nCoV Infection in Children |
Coronavirus disease 19 infection |
|
|
Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs) |
Beijing Children's Hospital |
Capital Institute of Pediatrics, Children's Hospital Of Hebei Province, Children's Hospital of Changchun, Children's Hospital of Chongqing Medical University, China Medical University (China), China-Japan Friendship Hospital, First Affiliated Hospital of Anhui Medical University, Guangzhou Women and Children's Medical, Hainan People's Hospital, Jiangxi Province Children's Hospital, Kunming Children's Hospital, Nanjing Children's Hospital, Shanxi Provincial Maternity and Children's Hospital, Shenzhen Children's Hospital, The First Affiliated Hospital of Guangxi Medical University, The First Affiliated Hospital of Xiamen University, The Second Hospital and Yuying Children's Hospital of Wenzhou Medical University, Tianjin Childrens Hospital, Tianjin Medical University, Wuhan medical care center for women and children, Xi'an Children's Hospital |
China |
2020-02-15 |
2020-12-31 |
BCH LUNG 012, NCT04270383 |
Phase Not Applicable |
Not yet recruiting |
1 |
10 Months |
500 |
Baoping Xu, MD,PhD, Kunling Shen, MD,PhD, Lina Wang, Tianyou Wang, MD,PhD |
2020-03-23 |
| HYDRA: Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection |
Coronavirus disease 19 infection, Respiratory disease |
hydroxychloroquine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
National Institute of Respiratory Diseases, Mexico |
Sanofi SA |
Mexico |
2020-03-23 |
2021-03-22 |
HIDROXYCLOROQUINACOVID19, HYDRA, NCT04315896 |
Phase 3 Clinical |
Not yet recruiting |
1 |
12 Months |
500 |
Carmen Hernandez-Cárdenas, MD. MSc, Carmen Hernandez-Cárdenas, MD. MSc., Cristobal Guadarrama, MD MSc, Ireri Thirion-Romero, MD. MSc, Joel Vasquez-Pérez, MD, Luis-Felipe Jurado-Camacho, MD, Rogelio Perez-Padilla, MD. PhD, Rogelio Perez-Padilla, MD. PhD., Sebastian Rodriguez-Llamazares, MD.MPH |
2020-03-23 |
| NO COVID-19: Norwegian Coronavirus Disease 2019 Study |
Coronavirus disease 19 infection, SARS coronavirus infection |
hydroxychloroquine sulfate (LIPIN1 disease/rhabdomyolysis), INSERM alone, standard of care alone |
TLR-9 antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Hospital, Akershus |
|
Norway |
2020-03-23 |
2025-03-03 |
NCT04316377, NO COVID-19, REC 121446 |
Phase 4 Clinical |
Not yet recruiting |
1 |
59 Months |
202 |
Olav Dalgard, MD PhD |
2020-03-23 |
| CCP-nCoV: Clinical Characterization Protocol for Severe Emerging Infections |
Coronavirus disease 19 infection |
|
|
|
INSERM |
|
France |
2020-02-07 |
2023-08-07 |
2020-A00256-33, C20-05, CCP-nCoV, NCT04262921 |
Phase Not Applicable |
Recruiting |
4 |
42 Months |
500 |
Denis MALVY, Eric CAUMES, Hélène ESPEROU, Jean-Francois TIMSIT, Yazdan YAZDANPANAH |
2020-03-23 |
| A clinical trial of hydroxychloroquine for treatment for coronavirus COVID-19 disease |
Coronavirus disease 19 infection |
hydroxychloroquine sulfate (LIPIN1 disease/rhabdomyolysis), INSERM alone |
TLR-9 antagonist |
|
University of Minnesota |
|
US |
|
|
|
Phase 3 Clinical |
Recruiting |
0 |
|
1500 |
David Boulware |
2020-03-23 |
| Evaluation of the effect of taking Newgen beta-gluten probiotic composite powder to nutrition intervention of patients with novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
Newgen beta-gluten probiotic composite powder alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
The 2nd People's Hospital of Ningbo |
|
China |
2020-02-01 |
2021-05-01 |
2020YJY0202, ChiCTR2000030897 |
Phase Not Applicable |
Recruiting |
1 |
15 Months |
20 |
Honghua Ye, Ting Cai |
2020-03-23 |
| Clinical Performance of the VivaDiag COVID-19 lgM / IgG Rapid Test in Early Detecting the Infection of COVID-19 |
Coronavirus disease 19 infection |
VivaDiag COVID-19 lgM/IgG Rapid Test kit alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centro Studi Internazionali |
VivaChek Laboratories, Inc |
Italy |
2020-03-31 |
2020-11-30 |
NCT04316728, VIVADIAG-2020 |
Phase Not Applicable |
Not yet recruiting |
1 |
8 Months |
200 |
Antonio V Gaddi, MD, MSc, Fabio V Capello, MD, PhD, Maurizio Cipolla, MD |
2020-03-23 |
| I-COVID: Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) in Pregnancy: The Italian Registry on Coronavirus in Pregnancy |
Coronavirus disease 19 infection |
|
|
Female, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Universita degli Studi di Napoli Federico II |
|
Italy |
2020-01-01 |
2020-04-30 |
5/20, I-COVID, NCT04315870 |
Phase Not Applicable |
Recruiting |
1 |
4 Months |
20 |
Gabriele Saccone, Gabriele Saccone, MD |
2020-03-23 |
| UMODCOVID19: Mechanisms for Organ Dysfunction in Covid-19 |
Coronavirus disease 19 infection, SARS coronavirus infection |
blood, urine and sputum sampling alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Uppsala University |
|
Sweden |
2020-03-12 |
2021-12-31 |
EPN 2017/043 COVID19, NCT04316884, UMODCOVID19 |
Phase Not Applicable |
Recruiting |
1 |
21 Months |
100 |
Michael Hultström, MD. PhD., Miklos Lipcsey, MD. PhD., Robert Frithiof, MD. PhD, Robert Frithiof, MD. PhD., Sara Bülow Anderberg, MD. |
2020-03-23 |
| Effects of different VTE prevention methods on the prognosis of hospitalized patients with novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
low molecular weight heparin alone, mechanical preventive anticoagulation therapy alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over), Asian Ancestry |
The First Affiliated Hospital of Guangzhou Medical College |
|
China |
2020-02-10 |
2020-04-10 |
ChiCTR2000030946 |
Phase 4 Clinical |
Recruiting |
1 |
2 Months |
120 |
Chunli Liu |
2020-03-23 |
| A clinical study of leronlimab in patients with respiratory illness due to Coronavirus Disease 2019 (COVID-19) |
Coronavirus disease 19 infection, Respiratory disease |
leronlimab alone |
CCR5 chemokine antagonist |
|
CytoDyn Inc |
|
US |
2020-03-19 |
|
|
Phase Not Applicable |
Status not specified |
0 |
|
2 |
|
2020-03-23 |
| A clinical study of BNT-162 for the prevention of COVID-19 infection |
Coronavirus disease 19 infection |
BNT-162 alone |
|
|
Shanghai Fosun Pharmaceutical (Group) Co Ltd |
BioNTech SE |
China |
|
|
|
Phase Not Applicable |
Planned |
1 |
|
|
|
2020-03-23 |
| A clinical trial of Remdesivir for potential treatment of COVID-19 |
Coronavirus disease 19 infection |
remdesivir alone |
RNA polymerase modulator |
|
StoneWise |
|
|
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-03-23 |
| Interferon in treatment of COVID-19 |
Coronavirus disease 19 infection |
Variable regimens including hydroxychloroquine , interferon beta-1a follow-on biologic (subcutaneous), CinnaGen , lopinavir + ritonavir , oseltamivir |
Exo-alpha sialidase inhibitor, HIV protease inhibitor, Interferon beta ligand |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Tehran University of Medical Sciences |
|
Iran |
2020-03-15 |
|
IR.TUMS.VCR.REC.1398.1052, IRCT20100228003449N28 |
Phase 2/Phase 3 Clinical |
Recruiting |
1 |
|
30 |
Hossein Khalili, Mohammad Ali Sahraian |
2020-03-23 |
| Evaluating efficacy and safety of sofosbuvir + ledipasvir in treatment of COVID-19 |
Coronavirus disease 19 infection |
Variable regimens including hydroxychloroquine , lopinavir + ritonavir , oseltamivir , sofosbuvir+ ledipasvir (Danesh Pharmaceutical Development Company) |
Exo-alpha sialidase inhibitor, HIV protease inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Tehran University of Medical Sciences |
|
Iran |
2020-03-18 |
|
IR.TUMS.VCR.REC.1398.1074, IRCT20100228003449N29 |
Phase 2/Phase 3 Clinical |
Recruiting |
1 |
|
50 |
Hossein Khalili, Mohammad Ali Sahraian |
2020-03-23 |
| RECOVERY: Randomized Evaluation Of COVID-19 Therapy |
Coronavirus disease 19 infection, SARS coronavirus infection |
Variable regimens including dexamethasone , interferon beta-1a , lopinavir + ritonavir |
HIV protease inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Oxford |
|
UK |
2020-03-17 |
|
2020-001113-21, NDPHRECOVERY, RECOVERY |
Phase 2/Phase 3 Clinical |
Recruiting |
1 |
|
|
|
2020-03-23 |
| TOCIVID-19: Tocilizumab in COVID-19 Pneumonia |
Coronavirus disease 19 infection, Pneumonia, SARS coronavirus infection |
tocilizumab alone |
|
|
National Cancer Institute of Naples |
|
Italy |
2020-03-19 |
2022-12-19 |
2020-001110-38, NCT04317092, TOCIVID-19, TOCIVID-19 |
Phase 2 Clinical |
Recruiting |
26 |
33 Months |
330 |
Antonio Mastroianni, MD, Arturo Montineri, MD, Carlo Salvarani, MD, Carmelo Iacobello, MD, Cristina Mussini, MD, Demetrio Labate, Demetrio Labate, MD, Elisabetta Bertelli, MD, Enrico Clini, MD, Evelina Tacconelli, MD, Fabio Franzetti, MD, Fabio Giuliano Numis, MD, Fiorentino Fragranza, MD, Francesco Cristini, MD, Francesco Dentali, MD, Francesco Perrone, MD, PhD, Giancarlo Titolo, MD, Giuseppe Carpinteri, MD, Luca Cabrini, MD, Maria Carmela Piccirillo, MD, Maria Concetta Monea, MD, Maria Danzi, MD, Massimo Girardis, MD, Maurizio Fusari, MD, Paola Faggioli, MD, Paolo Ascierto, MD, Paolo Grossi, MD, Roberto Cauda, MD, Roberto Parrella, MD, Salvo Nicosia, MD, Stobbione Paolo, MD, Vincenzo Montesarchio, MD, Walter Ageno, MD |
2020-03-23 |
| A clinical study to assess Ii-Key-SARS 2 peptide vaccine for the potential treatment of coronavirus disease 19 infection (COVID-19) |
Coronavirus disease 19 infection |
SARS-CoV-2 peptide vaccine (li-Key, COVID-19), Generex alone |
|
|
Generex Biotechnology Corp |
|
|
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-03-23 |
| STORY: Sero-epidemiological Survey of England in 2019/2020 |
Coronavirus disease 19 infection |
venepuncture alone |
|
Healthy volunteers accepted, Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs) |
University of Oxford |
|
UK |
2019-10-15 |
2020-11-30 |
ID 263097, NCT04061382, STORY |
Phase Not Applicable |
Recruiting |
1 |
13 Months |
2300 |
Helen Rafcliffe, Dr, Iason Vichos, Matthew Snape, Professor |
2020-03-23 |
| Humanistic Care in Patients With Coronavirus Disease 2019 |
Coronavirus disease 19 infection |
Psychological and physical rehabilitation based humanistic care alone, routine therapy alone |
|
|
The Second Hospital of Xi'An Jiaotong University |
|
China |
2020-02-22 |
|
NCT04283825, XJTU2H-WH1 |
Phase Not Applicable |
Terminated |
0 |
|
|
Shouping Gong, MD, PhD |
2020-03-23 |
| Blood Donor Recruitment During Epidemic of COVID-19 |
Coronavirus disease 19 infection |
questionnaire with precaution information alone, questionnaire without precaution information alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Guangzhou Blood Center |
|
China |
2020-03-12 |
2020-04-09 |
BLOOD DONOR RECRUITMENT, NCT04306055 |
Phase Not Applicable |
Not yet recruiting |
1 |
|
1500 |
OUYANG Jian |
2020-03-23 |
| Efficacy of a Self-test and Self-alert Mobile Applet in Detecting Susceptible Infection of COVID-19 |
Coronavirus disease 19 infection |
mobile internet survey on self-test (COVID-19 infection self-test and alert system) alone |
|
|
Tsinghua Changgung Hospital |
Chinese Medical Doctor Association, Tsinghua University |
China |
2020-02-01 |
2020-07-31 |
NCT04256395, RWS-BTCH-002 |
Phase Not Applicable |
Recruiting |
1 |
6 Months |
300000 |
Bin Yang, Ph.D, Jiahong Dong, M.D, Xiaobin Feng, M.D, bin yang, Ph.D, chenquan li, D.E, jiahong dong, M.D, xiaobin feng, M.D, xiaojuan wang, Ph.D |
2020-03-23 |
| Identifying Critically-ill Patients With COVID-19 Who Will Benefit Most From Nutrition Support Therapy: Validation of the NUTRIC Nutritional Risk Assessment Tool |
Coronavirus disease 19 infection |
NUTRIC nutritional risk assessment tool (COV_NUTRIC) alone, nutrition support therapy alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over), Asian Ancestry |
Peking University Third Hospital |
Peking University, Queen's University |
China |
2020-02-29 |
2020-07-31 |
COV_NUTRIC, NCT04274322 |
Phase Not Applicable |
Not yet recruiting |
1 |
5 Months |
100 |
Qinggang Ge, M.D., Xiaoxiao Li, M.Sc. |
2020-03-23 |
| Development of a Simple, Fast and Portable Recombinase Aided Amplification Assay for 2019-nCoV |
Coronavirus disease 19 infection, Viral pneumonia |
reverse-transcription RAA (RT-RAA) assay alone |
|
Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Beijing Ditan Hospital |
|
China |
2020-01-01 |
2020-12-31 |
DTXY022, NCT04245631 |
Phase Not Applicable |
Recruiting |
1 |
12 Months |
50 |
Xuejun Ma, phD, Yao Xie, Doctor |
2020-03-23 |
| Clinical Outcomes of Patients With COVID-19 |
Coronavirus disease 19 infection |
|
|
|
Guangzhou Institute Of Respiratory Disease, Huizhou Municipal Central Hospital, Guangdong |
|
China |
2020-02-22 |
|
GZHZ-COVID19, NCT04280913 |
Phase Not Applicable |
Terminated |
1 |
|
|
Luqian Zhou, MD |
2020-03-23 |
| Prognositc Factors in COVID-19 Patients Complicated With Hypertension |
Coronavirus disease 19 infection, Hypertension |
ACEI treatment alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Chongqing Medical University |
|
China |
2020-01-25 |
|
2020-02, NCT04272710 |
Phase Not Applicable |
Terminated |
1 |
|
|
Dongying Zhang |
2020-03-22 |
| A Survey of Psychological Status of Medical Workers and Residents in the Context of 2019 Novel Coronavirus Pneumonia |
Coronavirus disease 19 infection, Psychiatric disorder |
electronic questionnaire alone |
|
Healthy volunteers accepted |
Huazhong University of Science and Technology |
|
China |
2020-02-03 |
2020-04-20 |
IRBID:TJ-C 20200107, NCT04260308 |
Phase Not Applicable |
Recruiting |
1 |
2 Months |
30000 |
Xianglin Yuan, Yuhong Dai |
2020-03-23 |
| A New Screening Strategy for 2019 Novel Coronavirus Infection |
Coronavirus disease 19 infection |
minipool testing alone |
|
Healthy volunteers accepted |
No 307 Hospital of the Chinese People’s Liberation Army |
302 Military Hospital of China |
China |
2020-02-29 |
2020-03-31 |
307-NCOV, NCT04281693 |
Phase Not Applicable |
Not yet recruiting |
1 |
1 Month |
230 |
Xiaotian Sun, Yan Liu, Yan Liu, Ph.D., Zheng Lu |
2020-03-21 |
| Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 |
Coronavirus disease 19 infection, Fever, Viral pneumonia |
sarilumab alone, supportive care alone |
IL-6 receptor antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Regeneron Pharmaceuticals Inc, Sanofi SA |
|
US |
2020-03-16 |
2021-03-16 |
6R88-COV-2040, NCT04315298 |
Phase 2/Phase 3 Clinical |
Recruiting |
0 |
12 Months |
400 |
Clinical Trial Management, Clinical Trials Administrator |
2020-03-23 |
| CovidTox: Adverse Events Related to Treatments Used Against Coronavirus Disease 2019 |
Coronavirus disease 19 infection |
azithromycin alone, chloroquine alone, interferon beta-1a alone, lopinavir + ritonavir alone, remdesivir alone, Variable regimens including azithromycin , chloroquine , interferon beta-1a , lopinavir + ritonavir , remdesivir |
HIV protease inhibitor, RNA polymerase modulator |
|
Groupe Hospitalier Pitie-Salpetriere |
CMC Ambroise Pare |
France |
2020-03-17 |
2023-01-01 |
CIC1421-20-04, CovidTox, NCT04314817 |
Phase Not Applicable |
Recruiting |
1 |
33 Months |
1000 |
Joe-Elie Salem, MD, PhD, Lee S Nguyen, Lee S Nguyen, MD, PhDc |
2020-03-23 |
| Research for the influence of epidemic of novel coronavirus pneumonia (COVID-19) on sleep, psychological and chronic diseases among different populations |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Xiyuan Hospital China Academy Of Chinese Medical Sciences |
|
China |
2020-03-07 |
2020-12-01 |
ChiCTR2000030764 |
Phase Not Applicable |
Recruiting |
1 |
8 Months |
2800 |
Xia Hong |
2020-03-23 |
| Cancelled by the investigator Diagnosis and treatment of novel coronavirus pneumonia (COVID-19) in common and severe cases based on the theory of 'Shi-Du-Yi (damp and plague)' |
Coronavirus disease 19 infection, Viral pneumonia |
damp and plague alone |
|
Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
The Second Affiliated Hospital Of Guizhou Medical University |
|
China |
2020-12-01 |
2021-12-31 |
ChiCTR2000030762, ChiMCTR2000003128 |
Phase Not Applicable |
Not yet recruiting |
1 |
13 Months |
100 |
GuoLin Song |
2020-03-23 |
| Continuous renal replacement therapy (CRRT) alleviating inflammatory response in severe patients with novel coronavirus pneumonia (COVID-19) associated with renal injury: a prospective study |
Coronavirus disease 19 infection, Viral pneumonia |
continuous renal replacement therapy (CRRT) alone |
|
Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Lei Shen Shan Hospital, Renji Hospital |
|
China |
2020-04-01 |
|
ChiCTR2000030761 |
Phase Not Applicable |
Not yet recruiting |
1 |
|
20 |
Leyi Gu, Qin Wang |
2020-03-23 |
| Clinical research and preparation development of qingfei detoxification decoction (mixture) for prevention and treatment of novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
qingfei detoxification decoction (mixture) therapy alone |
|
Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Affiliated Hospital of Traditional Chinese Medicine of Southwest Medical University |
|
China |
2020-02-18 |
2020-12-31 |
ChiCTR2000030883, ChiMCTR2000003122 |
Phase Not Applicable |
Recruiting |
1 |
10 Months |
100 |
Wang Rao-Qiong, Yang Si-Jin |
2020-03-23 |
| A phase I clinical study of COVID-19 recombinant adenovirus type 5 vector vaccine for the prevention/ treatment of coronavirus disease (COVID-19) |
Coronavirus disease 19 infection |
COVID-19 recombinant adenovirus type 5 vector vaccine (oral enteric-coated tablet, SARS-CoV-2), Vaxart alone |
TLR-3 agonist |
|
Emergent BioSolutions Inc, Vaxart Inc |
|
|
2020-12-31 |
|
|
Phase 1 Clinical |
Planned |
0 |
|
|
|
2020-03-20 |
| COVID-19 Registry |
Coronavirus disease 19 infection |
therapeutic agent therapy alone |
|
|
National Center For Global Health & Medicine |
Japanese Ministry of Health, Labor and Welfare |
Japan |
2020-03-19 |
|
UMIN000039873 |
Phase Not Applicable |
Recruiting |
1 |
|
9999 |
Junko Terada, Norio Ohmagari |
2020-03-23 |
| Treatment of Acute Severe novel coronavirus pneuvirus (COVID-19) With Immunoglobulin From Cured COVID-19 Patients |
Coronavirus disease 19 infection, Viral pneumonia |
immunoglobulin therapy alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Union Hospital Tongji Medical School Huazhong University Of Science & Technology |
Huazhong University of Science and Technology |
China |
2020-02-17 |
2020-05-31 |
ChiCTR2000030841 |
Phase 0 Clinical |
Recruiting |
1 |
3 Months |
10 |
Xiang Cheng |
2020-03-23 |
| Preliminary screening of novel coronavirus pneumonia (COVID-19) by special laboratory examination and CT imaging before surgery |
Coronavirus disease 19 infection |
laboratory examination alone, pulmonary CT alone |
|
Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Shanghai Tongren Hospital |
|
China |
2020-03-01 |
2020-04-30 |
ChiCTR2000030839 |
Phase 0 Clinical |
Not yet recruiting |
1 |
2 Months |
100 |
Peng Sun, Yunpeng Zhang |
2020-03-23 |
| COVACTA: A randomized, double-blind, placebo-controlled to evaluate the safety and efficacy of Actemra (tocilizumab) plus standard of care in hospitalized adult patients with severe COVID-19 pneumonia compared to placebo plus standard of care |
Coronavirus disease 19 infection, Viral pneumonia |
standard of care alone, tocilizumab (intravenous), Roche/Chugai alone |
IL-6 receptor antagonist, IL-6 receptor modulator |
|
Genentech Inc, Roche Holding AG |
Biomedical Advanced Research and Development Authority (BARDA) |
US |
2020-03-18 |
|
COVACTA |
Phase 3 Clinical |
Not yet recruiting |
0 |
|
330 |
|
2020-03-23 |
| A phase II study of Metablok to target inflammation in the lungs caused by viral pneumonia and help reduce related mortality in COVID-19 |
Coronavirus disease 19 infection, Lung inflammation, Viral pneumonia |
Metablok alone |
Dehydropeptidase-1 modulator |
|
Arch Biopartners Inc |
|
|
|
|
|
Phase 2 Clinical |
Planned |
0 |
|
|
|
2020-03-20 |
| COVID MECH: Mechanisms to Morbidity and Mortality for Covid-19 |
Coronavirus disease 19 infection |
|
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Akershus University Hospital |
|
Norway |
2020-03-23 |
2021-12-31 |
117589, COVID MECH, NCT04314232 |
Phase Not Applicable |
Not yet recruiting |
1 |
21 Months |
200 |
Torbjorn Omland |
2020-03-23 |
| A clinical trial of SARS-CoV-2 mRNA vaccine (COVID-19), CureVac in the prevention of coronavirus infection in healthy subjects |
Coronavirus disease 19 infection |
SARS-CoV-2 mRNA vaccine (COVID-19), CureVac alone |
|
Healthy volunteers accepted |
CureVac AG |
|
|
2020-06-30 |
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-03-20 |
| Tocilizumab for SARS-CoV2 Severe Pneumonitis |
Coronavirus disease 19 infection, Viral pneumonia |
tocilizumab (intravenous), Roche/Chugai alone |
IL-6 receptor antagonist, IL-6 receptor modulator |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Universita Politecnica delle Marche |
Azienda Ospedali Riuniti Marche Nord |
Italy |
2020-03-31 |
2020-05-31 |
NCT04315480, TOCICOV-1 |
Phase 2 Clinical |
Not yet recruiting |
1 |
2 Months |
30 |
Armando Gabrielli |
2020-03-23 |
| Application of blood purification in the treatment of novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
blood purification alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Huashan Hospital |
Fudan University |
China |
2020-02-12 |
2020-07-12 |
ChiCTR2000030773 |
Phase Not Applicable |
Recruiting |
1 |
5 Months |
20 |
Jing Qian |
2020-03-23 |
| An anesthesia procedure and extubation strategy for reducing patient agitation and cough after extubation that can be used to prevent the spread of Novel Coronavirus Pneumonia (COVID-19) and other infectious viruses in the operating Room |
Coronavirus disease 19 infection, SARS coronavirus infection, Viral pneumonia |
sevoflurane alone |
|
Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Liaocheng People's Hospital |
|
China |
2020-03-16 |
2020-11-16 |
ChiCTR2000030681 |
Phase 0 Clinical |
Not yet recruiting |
1 |
8 Months |
240 |
Zunyuan Liu |
2020-03-23 |
| The Observational Study of Cardiac and Pulmonary Ultrasound and Evaluation of Treatment of Severe Patients With Novel Coronavirus Pneumonia |
Coronavirus disease 19 infection |
Cardiopulmonary ultrasound alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Xiangya Hospital Of Central South University |
|
China |
2020-03-20 |
2020-05-31 |
202003028, NCT04314271 |
Phase Not Applicable |
Recruiting |
1 |
2 Months |
80 |
Xiao, Zhang Li Na, MD, Zhao Ch Guang, MD |
2020-03-23 |
| A clinical study of mosedipimod for the treatment in patients with COVID-19 infection |
Coronavirus disease 19 infection |
mosedipimod alone |
CCL26 gene inhibitor |
|
Enzychem Lifesciences Corp |
|
South Korea |
|
|
|
Phase Not Applicable |
Planned |
1 |
|
|
|
2020-03-20 |
| SC2: Identification of host cell respiratory tract cell gene expression and epigenetic pattern after human SARS-CoV-2 infection |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
UniversitätsKlinikum Leipzig |
|
Germany |
2020-03-20 |
|
123/20-ek, DRKS00021134, SC2 |
Phase Not Applicable |
Not yet recruiting |
1 |
|
60 |
Sven Laudi |
2020-03-23 |
| Cohort study of Novel Coronavirus Pneumonia (COVID-19) in children |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs) |
Tongji Medical College, Wuhan Children's Hospital |
|
China |
2020-03-10 |
2021-12-31 |
ChiCTR2000030679 |
Phase Not Applicable |
Recruiting |
1 |
21 Months |
500 |
Liu Zhisheng, Xiao Han |
2020-03-23 |
| Clinical study for bronchoscopic alveolar lavage in the treatment of critically trachea intubation patients with new coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
fiberoptic bronchoscopy alone |
|
|
Huazhong University of Science and Technology |
|
China |
2020-03-01 |
2020-04-30 |
ChiCTR2000030857 |
Phase Not Applicable |
Recruiting |
1 |
2 Months |
|
Jingjun Yan, Shusheng Li |
2020-03-23 |
| Study for the Psychological Status of Medical Staff of Otolaryngology Head and Neck Surgery in Hubei Province under the Epidemic of novel coronavirus pneumonia (COVID-19) |
Anxiety disorder, Coronavirus disease 19 infection |
|
|
|
Zhangnan Hospital |
|
China |
2020-02-01 |
2021-02-01 |
ChiCTR2000030768 |
Phase Not Applicable |
Recruiting |
1 |
12 Months |
450 |
Xiong Chen, Xiuping Yang |
2020-03-23 |
| A clinical study to assess inhaled nitric oxide (NO) system, Lungfit Bro, in COVID-19 patients |
Coronavirus disease 19 infection |
Lungfit Bro alone, nitric oxide (inhalant formulation, cystic fibrosis/bronchiolitis/NTM/COPD/pulmonary hypertension), Beyond Air alone |
|
|
Beyond Air Inc |
|
US |
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-03-20 |
| An artificial intelligence assistant system for suspected novel coronavirus pneumonia (COVID-19) based on chest CT |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Tongji Hospital, Huazhong University of Science and Technology |
|
China |
2020-02-15 |
2020-05-15 |
ChiCTR2000030856 |
Phase 0 Clinical |
Recruiting |
1 |
3 Months |
700 |
Liming Xia, Shuchang Zhou |
2020-03-23 |
| A clinical multicenter study for the occurrence, development and prognosis of novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
Variable regimens including abidor,lopinavir/ritonavir , interferon alfa-2b , lopinavir/ritonavir |
Interferon alpha ligand modulator |
|
The First Affiliated Hospital of college of medicine Zhejiang University |
|
China |
2020-01-22 |
2020-03-15 |
ChiCTR2000030854 |
Phase Not Applicable |
No longer recruiting |
1 |
1 Month |
237 |
Li Lanjuan, Wei Runan |
2020-03-23 |
| A clinical study of remdesivir for the treatment in patients with 2019-nCoV infection |
Coronavirus disease 19 infection |
remdesivir alone |
RNA polymerase modulator |
|
Hong Kong Department of health |
|
Hong Kong |
|
|
|
Phase Not Applicable |
Planned |
2 |
|
|
|
2020-03-20 |
| Study for the effect of external diaphragmatic pacing assisted invasive ventilation and weaning in patients with severe novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
external diaphragmatic pacing alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Zunyi Medical University |
|
China |
2020-02-01 |
2020-05-01 |
ChiCTR2000030855 |
Phase 1 Clinical |
Not yet recruiting |
1 |
3 Months |
200 |
Wen Jianli |
2020-03-23 |
| The prediction value of prognosis of novel coronavirus pneumonia (COVID-19) in elderly patients by modified early warning score (MEWS): a medical records based retrospective observational study |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Sun Yat-Sen University |
|
China |
2020-03-09 |
2020-12-31 |
ChiCTR2000030683 |
Phase Not Applicable |
Not yet recruiting |
1 |
9 Months |
198 |
Chen Lei, Zhang Xiaofei |
2020-03-23 |
| A phase III clinical study to assess OT-101 in the treatment of subjects with COVID-19 infection |
Coronavirus disease 19 infection |
trabedersen alone |
TGFB2 gene inhibitor |
|
Mateon Therapeutics Inc |
|
US |
|
|
|
Phase 3 Clinical |
Planned |
0 |
|
|
|
2020-03-23 |
| SISCO: A retrospective, case-control, two cohorts trial of siltuximab for the treatment of patients infected with COVID-19 who develop serious respiratory complications |
Coronavirus disease 19 infection, Respiratory disease |
siltuximab alone |
Heat shock protein inhibitor, IL-6 receptor antagonist |
|
Ospedale Papa Giovanni XXIII |
EUSA Pharma |
Italy |
2020-03-18 |
|
SISCO |
Phase Not Applicable |
Recruiting |
1 |
|
|
Alessandro Rambaldi, MD, PhD |
2020-03-20 |
| A medical based analysis for influencing factors of death of novel coronavirus pneumonia (COVID-19) patients in Wuhan third hospital |
Coronavirus disease 19 infection, Viral pneumonia |
routine treatment of western medicine alone, traditional Chinese medicine alone |
|
|
Wuhan third Hospital |
|
China |
2020-03-01 |
2020-06-01 |
ChiCTR2000030859 |
Phase Not Applicable |
Not yet recruiting |
1 |
3 Months |
1305 |
Guoqin Sun, Meng Luo |
2020-03-23 |
| Clinical characteristics and outcomes of 483 mild patients with novel coronavirus pneumonia (COVID-19) in Wuhan, China during the outbreak: A single-center, retrospective study from the mobile cabin hospital |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hubei Cancer Hospital |
|
China |
2020-02-06 |
2020-03-15 |
ChiCTR2000030858 |
Phase Not Applicable |
Recruiting |
1 |
1 Month |
483 |
Tiejun Wang |
2020-03-23 |
| A medical records based study for clinical characteristics of 2019 novel coronavirus pneumonia (COVID-19) in Zhejiang province, China |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Zhejiang Hospital |
|
China |
2020-02-01 |
2020-03-02 |
ChiCTR2000030760 |
Phase Not Applicable |
No longer recruiting |
1 |
1 Month |
74 |
Hong Wang, Ling Chen |
2020-03-23 |
| A randomized, parallel controlled open-label trial for the efficacy and safety of Prolongin (Enoxaparin Sodium Injection) in the treatment of adult patients with novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection |
enoxaparin sodium alone, standard treatment alone |
Low molecular weight heparin |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Shenzhen Hepalink Pharmaceutical Group Co Ltd, The Third People’s Hospital of Shenzhen |
|
China |
2020-03-10 |
2020-09-30 |
ChiCTR2000030701 |
Phase 0 Clinical |
Not yet recruiting |
1 |
6 Months |
60 |
Cai Qingxian |
2020-03-23 |
| The Use PUL-042 Inhalation Solution to Prevent COVID-19 in Adults Exposed to SARS-CoV-2 |
Coronavirus disease 19 infection |
PUL-042 alone |
TLR agonist, TLR-2 agonist, TLR-6 agonist, TLR-9 agonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Pulmotect Inc |
|
|
2020-04-30 |
2020-10-31 |
NCT04313023, PUL-042-501 |
Phase 2 Clinical |
Not yet recruiting |
0 |
6 Months |
200 |
Brenton Scott, Ph D, Colin Broom, MD |
2020-03-23 |
| Effect of herbal syrup and solution in treatment of COVID-19 |
Coronavirus disease 19 infection |
standard treatment alone, Coroguard plus Corostop |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Iran University of Medical Sciences |
|
Iran |
2020-03-16 |
|
IR.IUMS.REC.1398.1399, IRCT20200316046792N1 |
Phase 2/Phase 3 Clinical |
Recruiting |
3 |
|
150 |
Amir Hossein Jamshidi, Seyed Abbas Motevalian |
2020-03-23 |
| A clinical study of virus-neutralizing monoclonal antibodies, for the potential treatment or prevention of coronavirus 19 infection |
Coronavirus disease 19 infection |
virus-neutralizing monoclonal antibodies (COVID-19), Columbia University alone |
|
|
Columbia University |
|
|
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-03-19 |
| A clinical trial of Polymerase inhibitors for the potential treatment/prevention of coronavirus 19 infection |
Coronavirus disease 19 infection |
Polymerase inhibitors (COVID-19), Columbia University alone |
RNA polymerase inhibitor |
|
Columbia University |
|
|
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-03-19 |
| A clinical study of protease inhibitors for the potential treatment/prevention of Coronavirus disease 19 infection |
Coronavirus disease 19 infection |
protease inhibitors (Coronavirus disease 19 infection), Columbia University alone |
Protease inhibitor |
|
Columbia University |
|
|
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-03-19 |
| Exploration of the Clinical Characteristics of Patients with Novel Coronavirus Pneumonia (COVID-19) and Its Differences from Patients with Severe Influenza A and MERS |
Coronavirus disease 19 infection, Influenza virus A infection, Respiratory disorder, SARS coronavirus infection |
|
|
Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Shandong Provincial Hospital |
Science and Technology Agency of Shandong Province |
China |
2020-02-01 |
2020-06-30 |
ChiCTR2000030739 |
Phase Not Applicable |
Recruiting |
4 |
5 Months |
100 |
Fenglin Liu, Wenqing Sun |
2020-03-23 |
| Prognosis Investigation and Intervention Study on Patients with novel coronavirus pneumonia (COVID-19) in recovery period Based on Community Health Management |
Coronavirus disease 19 infection, Viral pneumonia |
Glehnia littoralis alone, liriope alone, peach kernel alone, radix notoginseng alone, radix rehmanniae alone, schisandra alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Hubei province hospital of Traditional Chinese Medicine |
Ministry of Science and Technology of the People´s Republic of China |
China |
2020-03-01 |
2020-08-31 |
ChiCTR2000030720 |
Phase 0 Clinical |
Recruiting |
1 |
6 Months |
120 |
Mingzhong Xiao, Xiaodong Li |
2020-03-19 |
| Randomized controlled trial for Chloroquine Phosphate in the Treatment of novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
chloroquine phosphate alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Zhangnan Hospital |
|
China |
2020-02-12 |
2020-03-20 |
ChiCTR2000030718 |
Phase 4 Clinical |
Recruiting |
1 |
1 Month |
80 |
Zhao Yan, Zhou Xianlong |
2020-03-19 |
| A Medical Records Based analysis for Risk Factors for Outcomes After Respiratory Support in Patients with ARDS Due to Novel Coronavirus Pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Shandong Chest Hospital |
|
China |
2020-02-01 |
2020-08-31 |
ChiCTR2000030763 |
Phase Not Applicable |
Recruiting |
4 |
7 Months |
100 |
Fenglin Liu, Wenqing Sun |
2020-03-19 |
| Study for the therapeutic effect and mechanism of traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
Chinese medicine decoction alone, conventional supportive treatment alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
The First Affiliated Hospital of Wenzhou Medical University, The Second Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou Central Hospital, Wenzhou Hospital of Traditional Chinese Medicine, Wenzhou Scientific and Technologic Bureau |
|
China |
2020-02-15 |
2020-05-17 |
ChiCTR2000030759, ChiMCTR2000003129 |
Phase 0 Clinical |
Not yet recruiting |
3 |
3 Months |
70 |
Jing-Guo Cheng, Zheng-Zhong Yuan |
2020-03-20 |
| A medical records based study for epidemic and clinical features of novel coronavirus pneumonia (COVID-19) in Ningbo First Hospital |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
|
Ningbo First Hospital |
|
China |
2020-01-20 |
2020-02-29 |
ChiCTR2000030778 |
Phase Not Applicable |
No longer recruiting |
1 |
1 Month |
40 |
Guoqing Qian, Qian Guoqing |
2020-03-20 |
| Development of warning system with clinical differential diagnosis and prediction for severe type of novel coronavirus pneumonia (COVID-19) patients based on artificial intelligence and CT images |
Coronavirus disease 19 infection, Viral pneumonia |
intensive warning system alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Zhangnan Hospital |
|
China |
2020-02-06 |
2020-05-06 |
ChiCTR2000030838 |
Phase Not Applicable |
No longer recruiting |
1 |
3 Months |
500 |
Sun Wenbo, Xu Haibo |
2020-03-23 |
| Novel coronavirus pneumonia (COVID-19) combined with Chinese and Western medicine based on 'Internal and External Relieving - Truncated Torsion' strategy |
Coronavirus disease 19 infection |
Baidu truncated prescription therapy alone, Western medicine routine treatment alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Longhua Hospital Shanghai University of TCM |
|
China |
2020-02-01 |
2020-06-30 |
ChiCTR2000030836, ChiMCTR2000003126 |
Phase 4 Clinical |
Not yet recruiting |
3 |
5 Months |
300 |
Bangjiang Fang |
2020-03-20 |
| Clinical study for the efficacy of Mesenchymal stem cells (MSC) in the treatment of severe novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
human mesenchymal stem cells alone, routine treatment alone |
|
Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Health Commission of Henan Province, The First Affiliated Hospital of Xinxiang Medical University |
|
China |
2020-02-14 |
2021-02-14 |
201100311200, ChiCTR2000030835 |
Phase Not Applicable |
Recruiting |
4 |
12 Months |
20 |
Dou Qifeng, Zhao Jianhua |
2020-03-20 |
| NOpreventCOVID: NO Prevention of COVID-19 for Healthcare Providers |
Coronavirus disease 19 infection |
nitric oxide alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Massachusetts General Hospital |
|
US |
2020-03-20 |
2022-03-20 |
NCT04312243, NOPRECOVID-19, NOpreventCOVID |
Phase 2 Clinical |
Not yet recruiting |
0 |
24 Months |
460 |
Lorenzo Berra, Lorenzo Berra, MD |
2020-03-19 |
| Epidemiological Characteristics and Antibody Levels of novel coronavirus pneumonia (COVID-19) of Pediatric Medical Staff working in Quarantine Area |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
|
Tongji Hospital, Huazhong University of Science and Technology |
|
China |
2020-03-16 |
2020-03-31 |
ChiCTR2000030834 |
Phase Not Applicable |
Not yet recruiting |
1 |
|
500 |
Jinzhu Zhao, Yan Hao, Xiaoping Luo |
2020-03-23 |
| The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection |
Coronavirus disease 19 infection, SARS coronavirus infection |
PUL-042 alone, normal care alone |
TLR agonist, TLR-2 agonist, TLR-6 agonist, TLR-9 agonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Pulmotect Inc |
|
US |
2020-04-30 |
2020-10-31 |
NCT04312997, PUL-042-502 |
Phase 2 Clinical |
Not yet recruiting |
0 |
6 Months |
100 |
Brenton Scott, Ph D, Colin Broom, MD |
2020-03-20 |
| A Study for Clinical Characteristics of Novel Coronavirus Pneumonia (COVID-19) Patients Follow-up in Guangxi |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
|
People’s Hospital of Guangxi Zhuang Autonomous Region |
|
China |
2020-01-17 |
2022-01-17 |
ChiCTR2000030784 |
Phase Not Applicable |
Recruiting |
1 |
24 Months |
150 |
Guo Zhang |
2020-03-20 |
| Cancelled by the investigator clinical guidance of diagnose and treatment for novel coronavirus pneumonia (COVID-19) based on 'Shi-Du-Yi' |
Coronavirus disease 19 infection, Viral pneumonia |
traditional Chinese medicine alone |
|
|
The Second Affiliated Hospital Of Guizhou Medical University |
|
China |
2019-12-01 |
2021-12-31 |
ChiCTR2000030765 |
Phase Not Applicable |
Not yet recruiting |
2 |
25 Months |
|
GuoLin Song |
2020-03-20 |
| A double-blind, placebo-controlled clinical study to assess SNG-001 in the treatment of patients with COVID-19 |
Coronavirus disease 19 infection |
inhaled interferon beta (lung disorders/influenza), Synairgen alone |
Interferon beta ligand |
|
Synairgen plc |
|
UK |
|
|
|
Phase 2 Clinical |
Not yet recruiting |
1 |
|
|
|
2020-03-19 |
| The Value of CD4/CD8 cells, CRP/ALB and APACHE II in Novel Coronavirus Pneumonia (COVID-19) |
Coronavirus disease 19 infection, Respiratory failure, Viral pneumonia |
|
|
Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Cangzhou People's Hospital |
|
China |
2020-02-01 |
2020-03-31 |
ChiCTR2000030782 |
Phase 1 Clinical |
Recruiting |
1 |
2 Months |
20 |
Lihui Wang |
2020-03-20 |
| Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells |
Coronavirus disease 19 infection, SARS coronavirus infection |
Wharton's Jelly-mesenchymal stem cells alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Stem Cells Arabia |
|
Jordan |
2020-03-16 |
2020-09-30 |
COVID-19, NCT04313322 |
Phase 1 Clinical |
Recruiting |
1 |
6 Months |
5 |
Adeeb Al Zoubi, Adeeb M AlZoubi, Ph.D., Adeeb M Alzoubi, Ph.D., Ahmad AlGhadi, M.Sc., Ahmad Y AlGhadi, M.Sc., Mahasen Zalloum, B.Sc., Marwa E Tapponi, Pharm.D., Sameh N AlBakheet, B.Sc., Sumaya H Aldajah, M.Sc. |
2020-03-20 |
| AI-COVID-Xr: Artificial Intelligence Algorithms for Discriminating Between COVID-19 and Influenza Pneumonitis Using Chest X-Rays |
Coronavirus disease 19 infection |
Chest X-ray alone |
|
|
Grigore T. Popa University of Medicine and Pharmacy |
Falcon Trading Iasi |
Romania |
2020-03-18 |
2020-08-18 |
0110, AI-COVID-Xr, NCT04313946 |
Phase Not Applicable |
Recruiting |
1 |
5 Months |
200 |
Alexandru Burlacu, Lecturer, Alexandru Burlacu, MD, PhD, Alexandru Burlacu, Md, PhD, Professor Adrian Covic, Vice-rector |
2020-03-21 |
| PICTHA: Phase I Clinical Trial in Healthy Adult |
Coronavirus disease 19 infection |
Ad5-nCoV alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
CanSino Biologics Inc |
Hebei Provincial Center for Disease Control and Prevention, Institute of Biotechnology the Academy of Military Medical Sciences PLA, Jiangsu Province Centers for Disease Control and Prevention, Tongji Hospital |
China |
2020-03-19 |
2022-12-20 |
JSVCT088, NCT04313127, PICTHA |
Phase 1 Clinical |
Not yet recruiting |
1 |
33 Months |
108 |
Wang Wenjuan, Zhu Fengcai |
2020-03-20 |
| Myocardial Damage in COVID-19 |
Coronavirus disease 19 infection, Heart injury |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Wuhan Union Hospital, China |
|
China |
2020-01-01 |
2020-03-18 |
MD-COVID-19, NCT04312464 |
Phase Not Applicable |
Recruiting |
1 |
2 Months |
500 |
Xiang Cheng |
2020-03-20 |
| A clinical trial for Ulinastatin Injection in the treatment of patients with severe novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
Conventional treatment alone, Ulinastatin alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Shanghai Changzheng Hospital |
|
China |
2020-03-16 |
2020-05-31 |
ChiCTR2000030779 |
Phase 4 Clinical |
Recruiting |
2 |
2 Months |
100 |
Yi Shan, Zhaofen Lin,Wansheng Chen,Weifen Xie |
2020-03-20 |
| SOTSPC: Sequential Oxygen Therapy Strategy for Patients With COVID-19 |
Coronavirus disease 19 infection |
non-invasive positive pressure ventilation alone, oxygen alone, standard treatment alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Henan Province People's Hospital |
|
China |
2020-02-01 |
2021-02-28 |
NCT04312100, SOT-C, SOTSPC |
Phase Not Applicable |
Recruiting |
1 |
13 Months |
30 |
Li Li, Master, Xiaoju Zhang, PhD, Ziqi Wang, MD |
2020-03-23 |
| Plasma of the convalescent in the treatment of novel coronavirus pneumonia (COVID-19) common patient: a prospective clinical trial |
Coronavirus disease 19 infection, Viral pneumonia |
convalescent plasma alone, conventional treatment alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
China-Japan Friendship Hospital, Institute of Blood Transfusion, Chinese Academy of Medical Sciences |
|
China |
2020-02-15 |
2020-08-15 |
ChiCTR2000030702 |
Phase 0 Clinical |
Recruiting |
4 |
6 Months |
50 |
Cao Bin, Liu Zhong |
2020-03-20 |
| A phase II clinical trial to evaluate the safety and immunogenicity of mRNA-1273 in the treatment of patients with coronavirus COVID-19 infection |
Coronavirus disease 19 infection |
mRNA-1273 alone |
Moesin modulator |
|
ModeRNA Therapeutics |
|
|
|
|
|
Phase 2 Clinical |
Planned |
0 |
|
|
|
2020-03-19 |
| A clinical trial of HIV drug in combination with chloroquine for the treatment of patients with novel coronavirus COVID-19 infection |
Coronavirus disease 19 infection |
HIV drug alone, chloroquine alone |
|
|
University of Queensland Centre for Clinical Research |
|
Australia |
|
|
|
Phase Not Applicable |
Planned |
1 |
|
|
David Paterson |
2020-03-19 |
| CoV-19POC: Does point-of-care testing for coronavirus in hospital improve patient care compared to laboratory testing? |
Coronavirus disease 19 infection |
QIAstat-Dx Respiratory n-CoV Panel alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Hospital Southampton NHS Foundation Trust |
|
UK |
2020-02-07 |
2021-04-01 |
CoV-19POC, IRAS 280621, ISRCTN14966673, RHM MED1696 |
Phase Not Applicable |
Recruiting |
2 |
13 Months |
500 |
Dr Clark |
2020-03-20 |
| A randomized, blinded, controlled, multicenter clinical trial to evaluate the efficacy and safety of ixekizumab combined with conventional antiviral drugs in patients with novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
antiviral therapy alone, ixekizumab alone |
IL-17 antagonist, Interleukin 17A ligand inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
The Third Xiangya Hospital of Central South University, Xiangya Hospital Of Central South University |
|
China |
2020-03-10 |
2020-05-31 |
ChiCTR2000030703 |
Phase 0 Clinical |
Recruiting |
2 |
2 Months |
40 |
Pinhua Pan, Yehong Kuang |
2020-03-20 |
| Observation Of Clinical Efficacy And Safety Of Bufonis Venenum Injection In The Treatment Of Severe Novel Coronavirus Pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
Bufonis venenum alone |
|
Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Jiangsu Province Hospital of TCM |
|
China |
2020-02-10 |
2020-03-10 |
ChiCTR2000030704, ChiMCTR2000003105 |
Phase 2 Clinical |
Recruiting |
1 |
1 Month |
25 |
Hu Xingxing |
2020-03-20 |
| Study for the efficacy and safety of Prolongin (Enoxaparin Sodium Injection) in treatment of novel coronavirus pneumonia (COVID-19) adult common patients |
Coronavirus disease 19 infection, Viral pneumonia |
Prolongin alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Shenzhen Hepalink Pharmaceutical Group Co Ltd, Union Hospital Tongji Medical School Huazhong University Of Science & Technology |
|
China |
2020-03-09 |
2020-09-30 |
ChiCTR2000030700 |
Phase 0 Clinical |
Not yet recruiting |
1 |
6 Months |
60 |
Cao Guanhua, Zhang Yu |
2020-03-20 |
| Clinical validation and application of high-throughput novel coronavirus (2019-nCoV) screening detection kit |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Male |
Tongji Hospital, Huazhong University of Science and Technology |
|
China |
2020-03-22 |
2020-03-31 |
ChiCTR2000030833 |
Phase 0 Clinical |
Not yet recruiting |
1 |
|
400 |
Chen Guang, Ning Qin |
2020-03-20 |
| COVID-AIV: Intravenous Aviptadil for COVID-19 Associated Acute Respiratory Distress |
Coronavirus disease 19 infection, Respiratory distress syndrome |
aviptadil (inhaled, sarcoidosis/acute lung injury), Relief Therapeutics Holding alone, aviptadil (intravenous/peptide, acute respiratory distress syndrome/acute lung injury), mondoBIOTECH Holding alone, aviptadil (inhaled, sarcoidosis/acute lung injury), Relief Therapeutics Holding plus aviptadil (intravenous/peptide, acute respiratory distress syndrome/acute lung injury), mondoBIOTECH Holding |
Adrenergic receptor antagonist, VIP receptor agonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
NeuroRx Inc |
Relief Therapeutics Holding AG |
Israel, US |
2020-04-30 |
2020-09-30 |
COVID-AIV, COVID-AIV, NCT04311697 |
Phase 2 Clinical |
Not yet recruiting |
1 |
5 Months |
20 |
Asaf Miller, MD, Jonathan C Javitt, MD, MPH, Robert E Besthof, MIM |
2020-03-19 |
| Yinhu Qingwen Granula for the Treatment of Severe CoVID-19 |
Coronavirus disease 19 infection |
Yinhu Qingwen granula alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
China Academy of Chinese Medical Sciences |
Tangshan People's Hospital, The First Affiliated Hospital of Dalian Medical University |
China |
2020-03-20 |
2021-06-30 |
NCT04310865, YHQW-SEVERE-V2.0 |
Phase 2/Phase 3 Clinical |
Not yet recruiting |
4 |
15 Months |
116 |
Dong Shang, Dong Shang, M.D., Dong-Feng Shao, Gui-Fang Li, Jiang-Rong Huang, M.D., Jun Liu, M.D., Peiyan Du, Xiao-Dong Li, M.D., Xin-Rong Liu, Ya-Lan Song, Yan-Ling Hu, Yu Zhang, Zhong Wang, M.D. |
2020-03-19 |
| Randomized, Controlled Trial of Losartan for Patients With COVID-19 Requiring Hospitalization |
Coronavirus disease 19 infection |
losartan alone |
Angiotensin II AT-1 receptor antagonist, Angiotensin II receptor antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Minnesota |
|
US |
2020-03-16 |
2021-04-01 |
NCT04312009, SURG-2020-28675-I |
Phase 2 Clinical |
Not yet recruiting |
0 |
12 Months |
200 |
Christopher Tignanelli, MD, David Wacker, MD, Jeffrey Chipman, MD, Michael Puskarich, MD, MS, Michelle Biros, MD, MS, Nicholas Ingraham, MD, Ron Reikoff, MD, Timothy Schacker, MD |
2020-03-19 |
| Favipiravir Combined With Tocilizumab in the Treatment of Coronavirus Disease 2019 |
Coronavirus disease 19 infection |
favipiravir plus tocilizumab |
RNA polymerase inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Peking University First Hospital |
|
China |
2020-03-08 |
2020-05-31 |
2020YFC0844100, NCT04310228 |
Phase 2 Clinical |
Recruiting |
11 |
2 Months |
150 |
Dingyu Zhang, Guiqiang Wang, Haichao Li, Hong Zhao, Qin Ning, Qing Mao, Xi Zheng, Xianxiang Chen, Xihai Xu, Yu Hu, Yuhong Qin, Zhenshun Cheng |
2020-03-19 |
| Development and Verification of a New Coronavirus Multiplex Nucleic Acid Detection System |
Coronavirus disease 19 infection |
QIAstat-Dx alone |
|
Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Huashan Hospital |
|
China |
2020-03-14 |
2020-12-01 |
KY2020-COVID-19, NCT04311398 |
Phase Not Applicable |
Not yet recruiting |
1 |
8 Months |
100 |
Chao Qiu, Jiazhen Chen, Jing Wu, Jingwen Ai, Mengqi Zhu, Wen-hong Zhang, Wenhong Zhang, Doctor, Wenhong Zhang, PhD,MD, Yanmin Wan, Zhongliang Shen |
2020-03-19 |
| A diagnostic study to detect SARS-CoV-2, the virus that causes COVID-19 disease through Hologic’s Panther Fusion SARS-CoV-2 assay |
Coronavirus disease 19 infection |
Hologic’s Panther Fusion SARS-CoV-2 assay alone |
|
|
Hologic Inc |
|
US |
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-03-18 |
| A clinical trial of AmnioBoost, in patients with acute respiratory distress syndrome (ARDS) caused by coronavirus (COVID-19) |
Coronavirus disease 19 infection, Respiratory distress syndrome |
AmnioBoost alone |
|
|
Lattice Biologics Inc |
|
US |
|
|
|
Phase 1 Clinical |
Recruiting |
0 |
|
10 |
|
2020-03-19 |
| A phase II, proof-of-concept clinical study to assess RLF-100 for the treatment of Acute Respiratory Distress Syndrome (ARDS) in patients with COVID-19 infection |
Coronavirus disease 19 infection, Respiratory distress syndrome |
aviptadil (inhaled, sarcoidosis/acute lung injury), Relief Therapeutics Holding alone |
Adrenergic receptor antagonist, VIP receptor agonist |
|
Relief Therapeutics SA |
Government of Israel |
Israel |
|
|
|
Phase 2 Clinical |
Planned |
1 |
|
|
Dr. Boaz Lev, Dr. Miki Halberthal, MD, CEO, Prof. Jonathan Javitt, MD, MP |
2020-03-18 |
| A single-arm, Chinese clinical trial to assess the efficacy of tocilizumab in severe patients with Corona Virus Disease-19 (COVID-19) |
Coronavirus disease 19 infection |
routine therapy alone, tocilizumab alone |
|
Asian Ancestry |
2nd People's Hospital of Fuyang City, Anhui Provincial Hospital, South District of the First Affiliated Hospital of University of Science and Technology of China |
|
China |
|
|
|
Phase 2 Clinical |
Status not specified |
1 |
|
21 |
|
2020-03-18 |
| Evaluation of the protective effect of dexmedetomidine on patients with severe novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection |
dexmedetomidine alone |
Alpha 2 adrenoceptor agonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
The First People’s Hospital of Zunyi |
Zunyi science and technology bureau |
China |
2020-02-01 |
2020-05-31 |
ChiCTR2000030853 |
Phase 0 Clinical |
Not yet recruiting |
1 |
4 Months |
200 |
Wen Jianli |
2020-03-19 |
| Randomized, Controlled Trial of Losartan for Patients With COVID-19 Not Requiring Hospitalization |
Coronavirus disease 19 infection |
losartan alone |
Angiotensin II AT-1 receptor antagonist, Angiotensin II receptor antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Minnesota |
|
US |
2020-03-16 |
2021-04-01 |
NCT04311177, SURG-2020-28675-O |
Phase 2 Clinical |
Not yet recruiting |
0 |
12 Months |
478 |
Christopher Tignanelli, MD, David Wacker, MD, Jeffrey Chipman, MD, Michael Puskarich, MD, MS, Michelle Biros, MD, MS, Nicholas Ingraham, MD, Ron Reikoff, MD, Timothy Schacker, MD |
2020-03-19 |
| A clinical trial of Kevzara for the treatment of symptoms of novel coronavirus infections outside of the U.S |
Coronavirus disease 19 infection |
sarilumab alone |
IL-6 receptor antagonist |
|
Regeneron Pharmaceuticals Inc, Sanofi SA |
|
Italy |
|
|
|
Phase Not Applicable |
Planned |
1 |
|
|
|
2020-03-18 |
| Factors associated with death in patients with novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Beijing Anzhen Hospital, Capital Medical University |
|
China |
2020-01-27 |
2020-02-27 |
ChiCTR2000030852 |
Phase Not Applicable |
Completed |
1 |
1 Month |
150 |
Jiang Xie |
2020-03-20 |
| Impact of Novel Coronavirus Pneumonia (COVID-19) Epidemic Period on the Management of Investigator-Initiated Clinical Trial and the Resilience of Medical Service Providers |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
|
Clinical Research Institute, Shenzhen-Peking University |
|
China |
2020-03-13 |
2020-06-30 |
ChiCTR2000030757 |
Phase Not Applicable |
Not yet recruiting |
1 |
3 Months |
100 |
Zhang Yue |
2020-03-19 |
| A medical records based study for sedation and analgesia usage in critically ill patients with novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
sedation and analgesia treatment alone |
|
Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Tongji Hospital |
|
China |
2020-03-10 |
2020-04-30 |
ChiCTR2000030758 |
Phase Not Applicable |
Not yet recruiting |
3 |
1 Month |
200 |
Zhigang He |
2020-03-19 |
| Cross sectional study of dialysis treatment and mental status under the outbreak of novel coronavirus pneumonia (COVID-2019) in China |
Acute stress disorder, Anxiety disorder, Coronavirus disease 19 infection, Depression, Kidney dialysis |
dialysis alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
West China Hospital |
|
China |
2020-03-10 |
2020-04-02 |
ChiCTR2000030708 |
Phase Not Applicable |
Recruiting |
1 |
|
1000 |
Hui Zhong |
2020-03-19 |
| Retrospective study on novel coronavirus pneumonia (COVID-19) in Tibetan Plateau |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
|
West China Hospital |
|
China |
2020-03-20 |
2022-03-19 |
ChiCTR2000030707 |
Phase Not Applicable |
Not yet recruiting |
1 |
24 Months |
78 |
LIijia Deng, Teresa Teng |
2020-03-19 |
| Detection of SARS-CoV-2 in EPS/semen of patients with novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Male, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Shenzhen Hospital of Southern Medical University, Wuhan third Hospital, Xiangyang Central Hospital |
|
China |
2020-02-20 |
2020-08-20 |
ChiCTR2000030756 |
Phase 0 Clinical |
Recruiting |
3 |
6 Months |
60 |
Qingyou Zheng, Weihe Quan |
2020-03-19 |
| A medical records based study for characteristics, prognosis of ederly patients with Novel Coronavirus Pneumonia (COVID-19) in Wuhan area |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Tongji Hospital |
|
China |
2020-03-15 |
2020-09-15 |
ChiCTR2000030755 |
Phase Not Applicable |
Not yet recruiting |
1 |
6 Months |
400 |
Cuntai Zhang, Hongyu Gao |
2020-03-19 |
| Medical records based study for the accuracy of SARS-CoV-2 IgM antibody screening for diagnosis of novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
The Third Affiliated Hospital of Sun Yat-Sen University |
|
China |
2020-03-11 |
2020-06-30 |
ChiCTR2000030754 |
Phase Not Applicable |
No longer recruiting |
1 |
3 Months |
30 |
Dabiao Chen, Zhanlian Huang |
2020-03-19 |
| A medical records based analysis of the Incidence and Risk Factors of Ventilator-associated Pneumonia in ARDS Patients with Novel Coronavirus Pneumonia (COVID-19) |
Coronavirus disease 19 infection, Respiratory distress syndrome, Viral pneumonia |
|
|
Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Shandong Chest Hospital |
|
China |
2020-02-01 |
2020-08-31 |
ChiCTR2000030753 |
Phase Not Applicable |
Suspended |
4 |
7 Months |
100 |
Fenglin Liu, Wenqing Sun |
2020-03-19 |
| Correlation analysis of blood eosinophil cell levels and clinical type category of novel coronavirus pneumonia (COVID-19): a medical records based retrospective study |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over), Japanese Ancestry |
Tongji Hospital, Huazhong University of Science and Technology |
|
China |
2020-03-16 |
2020-06-16 |
ChiCTR2000030862 |
Phase Not Applicable |
Not yet recruiting |
1 |
3 Months |
150 |
Feng Gao, Zheng Li |
2020-03-20 |
| A medical records based analysis for risk factors for death in patients with Novel Coronavirus Pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Shandong Chest Hospital |
|
China |
2020-02-01 |
2020-08-31 |
ChiCTR2000030752 |
Phase Not Applicable |
Recruiting |
4 |
7 Months |
500 |
Fenglin Liu, Wenqing Sun |
2020-03-19 |
| Clinical research for traditional mongolian medicine in the treatment of novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
traditional mongolian medicine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
The Affiliated Hospital of Inner Mongolia Medical University |
|
China |
2020-01-25 |
2020-12-25 |
ChiCTR2000030751 |
Phase Not Applicable |
Not yet recruiting |
1 |
11 Months |
60 |
Burenbatu, Zhiqiang Han |
2020-03-19 |
| A medical records based study for clinical outcomes and follow-up of novel coronavirus pneumonia (COVID-19) patients |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Tongji Hospital, Huazhong University of Science and Technology |
|
China |
2020-02-18 |
2021-03-30 |
ChiCTR2000030809 |
Phase Not Applicable |
Recruiting |
1 |
13 Months |
1000 |
Xu Shuyun |
2020-03-23 |
| Clinical characteristics and prognosis of cancer patients with novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, SARS coronavirus infection, Viral pneumonia |
bioinformatics alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Tongji Medical College |
|
China |
2020-02-10 |
2020-03-30 |
ChiCTR2000030807 |
Phase Not Applicable |
Recruiting |
10 |
1 Month |
100 |
Xianglin Yuan, Zhihua Wang |
2020-03-19 |
| Investigation on psychological status of novel coronavirus pneumonia (COVID-19) rehabilitation patients in Zhengzhou City and research on coping strategies |
Coronavirus disease 19 infection, Viral pneumonia |
Psychological intervention alone |
|
Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
People’s Hospital of Zhengzhou |
|
China |
2020-03-01 |
2021-03-01 |
ChiCTR2000030849 |
Phase 0 Clinical |
Not yet recruiting |
1 |
12 Months |
81 |
Qingyan Pei, Yibin Hao |
2020-03-19 |
| Cancelled by the investigator Application of cas13a-mediated RNA detection in the assay of novel coronavirus nucleic acid (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
cas13a-mediated RNA application alone |
|
Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Zunyi Medical University |
|
China |
2020-02-09 |
2020-12-31 |
ChiCTR2000030706 |
Phase 0 Clinical |
Recruiting |
1 |
10 Months |
|
Guangtao huang, Jingjie Tan |
2020-03-19 |
| Study for immune cell subsets in convalescent patients with novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
The Third Affiliated Hospital of the Second Military Medical University |
|
China |
2020-02-10 |
2021-02-10 |
ChiCTR2000030690 |
Phase 2 Clinical |
Recruiting |
2 |
12 Months |
30 |
Tang Hao, Wang Hongyang |
2020-03-18 |
| Novel coronavirus pneumonia (COVID-19) associated kidney injury in children |
Coronavirus disease 19 infection, Hematuria, Proteinuria, Renal disease, Renal injury |
Bailing alone, renal replacement therapy alone |
|
Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs) |
Wuhan medical care center for women and children |
|
China |
2020-02-01 |
2020-10-31 |
ChiCTR2000030687 |
Phase 0 Clinical |
Not yet recruiting |
1 |
9 Months |
120 |
Qi Chang, Wang Xiaowen |
2020-03-18 |
| The effects of prevention and control measures on treatment and psychological status of cancer patients during the novel coronavirus pneumonia (COVID-19) outbreak |
Cancer, Coronavirus disease 19 infection, Viral pneumonia |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Peking University Third Hospital |
|
China |
2020-03-03 |
2020-07-03 |
ChiCTR2000030686 |
Phase Not Applicable |
Recruiting |
1 |
4 Months |
300 |
Baoshan Cao, Yane Liu |
2020-03-18 |
| A comparative study for the sensitivity of induced sputum and throat swabs for the detection of SARS-CoV-2 by real-time PCR in patients with novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection |
induced sputum alone, throat swab alone |
|
Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
The Affiliated Hospital of Guangdong Medical College |
|
China |
2020-03-16 |
2020-04-26 |
ChiCTR2000030721 |
Phase 0 Clinical |
Not yet recruiting |
2 |
1 Month |
|
Huanqin Han |
2020-03-18 |
| Development and application of novel coronavirus pneumonia (COVID-19) intelligent image classification system based on deep learning |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
|
The 2nd People's Hospital of Ningbo |
|
China |
2020-03-01 |
2020-12-31 |
ChiCTR2000030830 |
Phase Not Applicable |
Recruiting |
1 |
10 Months |
150 |
Jiaying Xu, Jingfeng Zhang |
2020-03-18 |
| The analysis of related factors on improving oxygenation status by endotracheal intubation ventilation in severe patients suffered from novel coronavirus pneumonia (COVID-19): a single-center and descriptive study in Wuhan |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Tongji Hospital, Huazhong University of Science and Technology |
|
China |
2020-03-16 |
2020-06-15 |
ChiCTR2000030831 |
Phase Not Applicable |
Not yet recruiting |
1 |
3 Months |
75 |
Ye Tu, Zheng Li |
2020-03-18 |
| A clinical study for effectiveness and safety evaluation for recombinant chimeric COVID-19 epitope DC vaccine in the treatment of novel coronavirus pneumonia |
Coronavirus disease 19 infection, Viral pneumonia |
COVID-19 epitope gene recombinant chimeric DC vaccine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
The Third People’s Hospital of Shenzhen |
|
China |
2020-03-01 |
2021-02-28 |
ChiCTR2000030750 |
Phase 1/Phase 2 Clinical |
Not yet recruiting |
2 |
12 Months |
120 |
Jing Yuan, Zhenlin Zhao |
2020-03-18 |
| A prospective cohort study for comprehensive treatment of Chinese medicine in the treatment of convalescent patients of novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
comprehensive TCM treatment alone, health education alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Hubei province hospital of Traditional Chinese Medicine |
|
China |
2020-02-01 |
2020-08-01 |
ChiCTR2000030747, ChiMCTR2000003108 |
Phase 0 Clinical |
Recruiting |
1 |
6 Months |
1500 |
Li Xiaodong, Xiao Mingzhong |
2020-03-19 |
| A clinical tral of clevudine for the potential treament of coronavirus infection-19 (COVID-19) |
Coronavirus disease 19 infection |
clevudine alone |
DNA polymerase inhibitor, Nucleoside reverse transcriptase inhibitor |
|
Bukwang Pharmaceutical Co Ltd |
|
|
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-03-17 |
| TT-NPC: Tetrandrine Tablets Used in the Treatment of COVID-19 |
Coronavirus disease 19 infection |
tetrandrine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Henan Province People's Hospital |
|
China |
2020-03-05 |
2021-05-01 |
NCT04308317, TT-NPC, TT-NPC |
Phase 4 Clinical |
Recruiting |
1 |
13 Months |
60 |
|
2020-03-18 |
| Clinical Application of ECMO (or Ultra-Protective Lung Mechanical Ventilation) in the Treatment of Patients with ARDS due to novel Coronavirus Pneumonia (COVID-19) |
Coronavirus disease 19 infection, Respiratory distress syndrome, Viral pneumonia |
ECMO therapy alone |
|
Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Shandong Chest Hospital |
|
China |
2020-02-01 |
2020-08-31 |
ChiCTR2000030744 |
Phase Not Applicable |
Recruiting |
4 |
7 Months |
30 |
Fenglin Liu, Wenqing Sun |
2020-03-18 |
| Retrospective analysis of digestive system symptoms in 600 cases of novel coronavirus pneumonia (COVID-19) in Guanggu district, Wuhan |
Coronavirus disease 19 infection, Liver disease, Viral pneumonia |
|
|
Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Wuhan third Hospital |
|
China |
2020-03-01 |
2020-12-31 |
ChiCTR2000030819 |
Phase Not Applicable |
Not yet recruiting |
1 |
10 Months |
600 |
Xia Tian |
2020-03-19 |
| Characteristics, prognosis, and treatments effectiveness of critically ill patients with Novel Coronavirus Pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Tongji Hospital |
|
China |
2020-03-15 |
2020-04-15 |
ChiCTR2000030742 |
Phase Not Applicable |
Not yet recruiting |
1 |
1 Month |
200 |
Hongyu Gao, Qi Yan |
2020-03-18 |
| A medical records based study for the value of Lymphocyte subsets in the diagnose and treatment of novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, SARS coronavirus infection, Viral pneumonia |
|
|
Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
The first affiliated hospital of henan university of TCM |
|
China |
2020-01-31 |
2020-02-24 |
ChiCTR2000030818 |
Phase Not Applicable |
Not yet recruiting |
1 |
|
10 |
Zhengrong Mao |
2020-03-18 |
| Multicenter clinical study of evaluation of multi-organ function in patients with novel coronavirus pneumonia (COVID-19) by ultrasound |
Coronavirus disease 19 infection, Multiple organ failure, Viral pneumonia |
ultrasound alone |
|
|
Union Hospital Tongji Medical School Huazhong University Of Science & Technology |
|
China |
2020-02-28 |
2022-02-28 |
ChiCTR2000030817 |
Phase 0 Clinical |
Recruiting |
1 |
24 Months |
800 |
Li Zhang, Mingxing Xie |
2020-03-19 |
| A clinical trial of TJM-2 for cytokine storm in severe and critically ill patients with COVID-19 |
Coronavirus disease 19 infection |
TJM-2 alone |
GM-CSF ligand inhibitor |
|
I-Mab Biopharma |
|
US |
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-03-17 |
| Observational Study for Prone Position Ventilation and Conventional Respiratory Support in ARDS Patients with Novel Coronavirus Pneumonia (COVID-19) |
Coronavirus disease 19 infection, Respiratory distress syndrome, Viral pneumonia |
invasive mechanical ventilation alone, non-invasive mechanical ventilation alone, transnasal high-flow oxygen therapy alone |
|
Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Shandong Chest Hospital |
|
China |
2020-02-01 |
2020-08-31 |
ChiCTR2000030741 |
Phase 0 Clinical |
Recruiting |
4 |
7 Months |
100 |
Fenglin Liu, Wenqing Sun |
2020-03-18 |
| Nutritional risk assessment and outcome prediction of critically ill novel coronavirus pneumonia (COVID-19) patients |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Tongji Hospital, Huazhong University of Science and Technology |
|
China |
2020-02-24 |
2021-02-23 |
ChiCTR2000030816 |
Phase Not Applicable |
Not yet recruiting |
1 |
12 Months |
200 |
Ping Zhang, Yi Bian |
2020-03-18 |
| Screening and identification of peripheral blood biomarkers in patients with COVID-19 infection based on multiomics studies |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
The Second XiangYa Hospital of Central South University |
Hunan Provincial Science and Technology Department |
China |
2020-03-01 |
2021-03-01 |
ChiCTR2000030771 |
Phase Not Applicable |
Not yet recruiting |
2 |
12 Months |
30 |
Kaili Chen, Qianjin Lu |
2020-03-18 |
| Clinical and CT imaging Characteristics of novel coronavirus pneumonia (COVID-19): An Multicenter, Cohort Study |
Coronavirus disease 19 infection, Viral pneumonia |
chest CT scan alone |
|
|
Jinling Hospital, Medical School of Nanjing University |
|
China |
2020-01-22 |
2021-03-31 |
ChiCTR2000030863 |
Phase Not Applicable |
Recruiting |
38 |
14 Months |
5000 |
Lu Guangming, Xie Yuan |
2020-03-19 |
| Retrospective study for the efficacy of ulinastatin combined with 'clear lung detoxification soup' in the treatment of novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
qingfei detoxification soup plus ulinastatin |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Wuhan third Hospital |
|
China |
2020-02-01 |
2020-03-31 |
ChiCTR2000030806, ChiMCTR2000003127 |
Phase 1 Clinical |
Recruiting |
1 |
2 Months |
20 |
JIAN PENG, LEILEI YANG |
2020-03-18 |
| Traditional Chinese Medicine for novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
Qingfei Paidu decoction alone, Western medicine alone |
|
|
Xiangyang First People's Hospital |
|
China |
2020-02-01 |
2020-07-31 |
ChiCTR2000030864, ChiMCTR2000003118 |
Phase Not Applicable |
Recruiting |
1 |
6 Months |
50 |
Zhou Wei, Zhu Bo |
2020-03-19 |
| Post-exposure Prophylaxis for SARS-Coronavirus-2 |
Coronavirus disease 19 infection, SARS coronavirus infection |
hydroxychloroquine alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Minnesota |
|
US |
2020-03-17 |
2021-05-31 |
NCT04308668, PEP-CORONA, STUDY00009267 |
Phase 2/Phase 3 Clinical |
Recruiting |
0 |
14 Months |
1500 |
David Boulware, MD, MPH |
2020-03-20 |
| Establishment of an early warning model for maternal and child vertical transmission of COVID-19 infection |
Coronavirus disease 19 infection |
|
|
|
Tongji Hospital, Huazhong University of Science and Technology |
|
China |
2020-02-01 |
2020-04-30 |
ChiCTR2000030865 |
Phase Not Applicable |
Recruiting |
1 |
3 Months |
200 |
Luo Xiaoping, Rong Zhihui |
2020-03-19 |
| A clinical study to assess BNT-162 for the prevention of COVID-19 |
Coronavirus disease 19 infection |
BNT-162 alone |
|
|
BioNTech SE |
Pfizer Inc |
Germany, US, China |
2020-04-30 |
|
|
Phase Not Applicable |
Planned |
2 |
|
|
|
2020-03-20 |
| Open-label, observational study of human umbilical cord derived mesenchymal stem cells in the treatment of severe and critical patients with novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
umbilical cord mesenchymal stem cells alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
First Hospital of Changsha, Guang Xiu Gao Xin Life Science Co Ltd Hunan |
Hunan Provincial Science and Technology Department |
China |
2020-02-01 |
2020-12-31 |
ChiCTR2000030866 |
Phase 0 Clinical |
Recruiting |
1 |
11 Months |
30 |
Ouyang Qi, Xie yuanlin |
2020-03-19 |
| Analysis of the incidence and risk factors of ARDS in patients with Novel Coronavirus Pneumonia (COVID-19) |
Coronavirus disease 19 infection, Respiratory distress syndrome, Viral pneumonia |
|
|
Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Shandong Chest Hospital |
|
China |
2020-02-01 |
2020-08-31 |
ChiCTR2000030740 |
Phase Not Applicable |
Recruiting |
4 |
7 Months |
100 |
Fenglin Liu, Wenqing Sun |
2020-03-18 |
| Development and application of a new intelligent robot for novel coronavirus (2019-nCOV) oropharygeal sampling |
Coronavirus disease 19 infection |
intelligent robot system alone, throat swab alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Shenyang Institute of Automation of The Chinese Academy of Sciences, The First Affiliated Hospital of Guangzhou Medical College |
|
China |
2020-03-01 |
2020-07-01 |
ChiCTR2000030861 |
Phase 0 Clinical |
Recruiting |
1 |
4 Months |
90 |
Shaoqiang Li, Shiyue Li |
2020-03-19 |
| Interferon Beta in treatment of COVID-19 |
Coronavirus disease 19 infection |
Variable regimens including hydroxychloroquine , interferon beta-1a , lopinavir + ritonavir , oseltamivir |
Exo-alpha sialidase inhibitor, HIV protease inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Tehran University of Medical Sciences |
|
Iran |
2020-03-15 |
|
IR.TUMS.VCR.REC.1398.1053, IRCT20100228003449N27 |
Phase 2/Phase 3 Clinical |
Recruiting |
1 |
|
30 |
Hossein Khalili, Mohammad Ali Sahraian |
2020-03-23 |
| Quantitative CT characteristic estimate the severity of novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
|
Tongji Medical College |
|
China |
2020-02-15 |
2020-06-30 |
ChiCTR2000030805 |
Phase Not Applicable |
No longer recruiting |
1 |
4 Months |
200 |
Liang Wang, Xi Yin |
2020-03-18 |
| A medical records based study for investigation of dynamic profile of RT-PCR test for SARS-CoV-2 nucleic acid of novel coronavirus pneumonia (COVID-19) patients |
Coronavirus disease 19 infection, SARS coronavirus infection, Viral pneumonia |
Real-time PCR testing alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Tongji Hospital |
|
China |
|
|
ChiCTR2000030860 |
Phase 0 Clinical |
Recruiting |
1 |
|
100 |
Zhang Sheng |
2020-03-19 |
| Exocarpium Citri Grandis Relieves Symptoms of Novel Coronavirus Pneumonia (COVID-19): a Randomized, Controlled, Clinical Trial |
Coronavirus disease 19 infection, Viral pneumonia |
exocarpium citri grandis alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Maoming Affiliated Hospital of Southern Medical University |
|
China |
2020-02-01 |
2021-03-31 |
ChiCTR2000030804, ChiMCTR2000003112 |
Phase 4 Clinical |
Recruiting |
1 |
14 Months |
128 |
Hu Linhui |
2020-03-18 |
| Collection and analysis of clinical data in severe and critically ill patients with novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Union Hospital Tongji Medical School Huazhong University Of Science & Technology |
|
China |
2020-01-31 |
2020-04-30 |
ChiCTR2000030803 |
Phase Not Applicable |
Recruiting |
1 |
3 Months |
400 |
Xin Li, Xuefeng Yang |
2020-03-18 |
| A retrospective study of clinical drug therapy in patients with novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
clinical drug therapy alone |
|
|
Tongji Hospital, Tongji Hospital, Huazhong University of Science and Technology |
|
China |
2020-03-14 |
2020-06-30 |
ChiCTR2000030802 |
Phase Not Applicable |
Not yet recruiting |
1 |
3 Months |
2000 |
CHEN QIAN, LIU DONG |
2020-03-18 |
| Analysis of risk factors affecting prognosis of elderly patients infected with novel coronavirus pneumonia (COVID-19): a single-center, retrospective, observational study |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Wuhan third Hospital |
|
China |
2020-01-23 |
2020-02-29 |
ChiCTR2000030801 |
Phase 1 Clinical |
Recruiting |
1 |
1 Month |
100 |
Gao Shan, Peng Jian |
2020-03-18 |
| A medical records based analysis of clinical evidence of human-to-human transmission of 2019 novel coronavirus pneumonia (COVID-19) by conjunctival route |
Coronavirus disease 19 infection, SARS coronavirus infection, Viral pneumonia |
|
|
Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Tongji Hospital, Huazhong University of Science and Technology |
|
China |
2020-02-25 |
2020-04-30 |
ChiCTR2000030814 |
Phase Not Applicable |
No longer recruiting |
1 |
2 Months |
100 |
Chaohua Deng, Junming Wang |
2020-03-18 |
| Cancelled by the investigator Study on levels of inflammatory factors in peripheral blood of patients with novel coronavirus pneumonia (COVID-19) and their diagnostic and prognostic value |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
|
The First People’s Hospital of Zunyi, Zunyi science and technology bureau |
China |
2020-02-01 |
2021-03-31 |
ChiCTR2000030800 |
Phase 0 Clinical |
No longer recruiting |
1 |
14 Months |
|
Wu Kaifeng |
2020-03-18 |
| Establishment and validation of Premonitory model of deterioration of the 2019 novel corona virus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
artificial intelligence prediction model alone |
|
|
Tongji Hospital, Tongji Medical College |
|
China |
2020-01-20 |
2020-06-30 |
ChiCTR2000030799 |
Phase Not Applicable |
Not yet recruiting |
1 |
5 Months |
1000 |
TAO WANG |
2020-03-18 |
| A medical records based study for clinical characteristics of novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Wuhan third Hospital |
|
China |
2020-02-10 |
2020-05-01 |
ChiCTR2000030798 |
Phase 1 Clinical |
Recruiting |
1 |
2 Months |
100 |
Wang Hua-bing |
2020-03-18 |
| Clinical study for hemodynamics and cardiac arrhythmia of novel coronavirus pneumonia (COVID-19) patients |
Coronavirus disease 19 infection, Heart arrhythmia, Viral pneumonia |
Noninvasive hemodynamic monitoring alone |
|
|
The Fifth Peoples’ Hospital of Shanghai, Fudan University |
Fudan University |
China |
2020-03-07 |
2021-07-07 |
ChiCTR2000030797 |
Phase Not Applicable |
Recruiting |
1 |
16 Months |
100 |
Yingjia Xu |
2020-03-18 |
| Clinical characteristics and treatment of novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
|
Second Hospital of Hebei Medical University |
Science and Technology Department of Hebei Province of China |
China |
2020-01-01 |
2022-01-31 |
ChiCTR2000030796 |
Phase Not Applicable |
Recruiting |
1 |
25 Months |
500 |
Gong Xiaowei, Yuan Yadong |
2020-03-18 |
| A multicenter, retrospective, study of rheumatic patients with novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Rheumatoid arthritis |
|
|
Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Dongfeng General Hospital of Sinopharm, Tongji Hospital, Union Hospital Tongji Medical School Huazhong University Of Science & Technology, Zhangnan Hospital |
National Natural Science Foundation of China |
China |
2020-03-20 |
2020-05-31 |
ChiCTR2000030795 |
Phase Not Applicable |
Not yet recruiting |
3 |
2 Months |
90 |
Cong Ye, Lingli Dong |
2020-03-18 |
| Acute Respiratory Failure and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Real Life |
Coronavirus disease 19 infection, Respiratory failure, SARS coronavirus infection |
CPAP therapy alone, antibiotic drugs alone, antiviral drugs alone, bronchodilators alone, enteral nutrition alone, hydration alone, non invasive ventilation alone, xantines alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Universita degli Studi di Milano |
|
Italy |
2020-03-19 |
2020-12-31 |
02-PNSNP-2020, NCT04307459 |
Phase Not Applicable |
Not yet recruiting |
2 |
9 Months |
50 |
Dejan Radovanovic, MD, Elisa Franceschi, MD, Pierachille Santus, MD PhD, Pierachille Santus, MD, PhD |
2020-03-18 |
| CTOROTSADTOC: Clinical Trial on Regularity of TCM Syndrome and Differentiation Treatment of COVID-19 |
Coronavirus disease 19 infection, Viral pneumonia |
IFN-alpha alone, arbidol alone, chloroquine phosphate alone, lopinavir + ritonavir alone, nasal catheter alone, ribavirin alone, routine oxygen therapy alone, routine support therapy alone, Variable regimens including Baijiezi , Cangzhu , Dongguazi , Fabanxia , Gualoupi , Houpo , Huangqi , Huangqin , Huoxiang , IFN-alpha , Jinyinhua , Lianqiao , Qianhu , Qinghao , Suye , Suzi , Taoren , Tinglizi , Xiangfu , Xingren , Xuanfuhua , Yujin , Zhimahuang , arbidol , chloroquine phosphate , lopinavir + ritonavir , ribavirin |
HIV protease inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Jiangsu Famous Medical Technology Co., Ltd |
|
China |
2020-03-02 |
2020-05-31 |
CTOROTSADTOC, JSZYJ202001, NCT04306497 |
Phase Not Applicable |
Recruiting |
2 |
2 Months |
340 |
Haibo Cheng, phD, Lei Cui, phD, Zhe Feng, phD |
2020-03-18 |
| Study to Evaluate the Safety and Efficacy of Sofosbuvir/Daclatasvir in Participants with Moderate to Severe Coronavirus Disease (COVID-19) |
Coronavirus disease 19 infection |
Sovodak alone, standard of care alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Digestive disease research center (DDRC), Fannavaran Rojan Mohaghegh Daru |
|
Iran |
2020-03-26 |
|
IR.TUMS.VCR.REC.1398.1035, IRCT20200128046294N2 |
Phase 3 Clinical |
Not yet recruiting |
1 |
|
70 |
Dr Anahita Sadeghi, Dr Hossein Poustchi, Shirin Afhami |
2020-03-23 |
| TACOS: Tocilizumab versus CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19 |
Coronavirus disease 19 infection, Inflammatory disease |
standard of care alone, tocilizumab alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Tongji Hospital |
Hubei Xinhua Hospital, Wuhan Central Hospital, Wuhan Integrated Traditional Chinese Medicine & Western Medicine Hospital |
China |
2020-02-20 |
2020-06-20 |
NCT04306705, TACOS, WHTJCOVID-19 |
Phase Not Applicable |
Recruiting |
1 |
4 Months |
120 |
AIHUA DU, M.D, CONG YE, M.D, FEI YU, M.D, GUIFEN SHEN, M.D, LINGLI DONG, M.D, RUI XING, M.D, SHAOXIAN HU, M.D, WEI TU, M.D, YIHAN YU, M.D, YIKAI YU, M.D, YUJIE DAI, M.D, ZHENG WANG, M.D |
2020-03-20 |
| Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19) |
Coronavirus disease 19 infection |
lopinavir + ritonavir alone |
HIV protease inhibitor |
Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Asan Medical Center |
|
South Korea |
2020-03-11 |
2020-05-31 |
NCT04307693, S2020-0472-0001 |
Phase 2 Clinical |
Recruiting |
1 |
2 Months |
150 |
Sung-Han Kim, Sung-Han Kim, MD.PhD |
2020-03-17 |
| Study for the virus molecular evolution which driven the immune-pathological responses and the protection mechanisms of novel coronavirus pneumonia (COVID-19) patients |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Shanghai 9th People's Hospital |
|
China |
2020-01-31 |
2021-01-31 |
ChiCTR2000030812 |
Phase Not Applicable |
Recruiting |
1 |
12 Months |
50 |
Xu Jie, YangXue |
2020-03-17 |
| Clinical observation and evaluation of traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19) in Hubei 672 Orthopaedics Hospital of Integrated Chinese and Western Medicine |
Coronavirus disease 19 infection, Viral pneumonia |
traditional oral medicine therapy alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hubei 672 Orthopaedics Hospital of Integrated Chinese＆Western Medicine |
|
China |
2020-02-23 |
2020-03-30 |
ChiCTR2000030810, ChiMCTR2000003113 |
Phase 1 Clinical |
Recruiting |
1 |
1 Month |
100 |
Li Xugui, Zhou Shijing |
2020-03-18 |
| COVISTRESS: Influence of the Covid-19 Epidemic on Stress |
Acute stress disorder, Coronavirus disease 19 infection |
|
|
Healthy volunteers accepted |
University Hospital Clermont-Ferrand |
Faculty of Medicine, Clermont-Ferrand, LAPSCO-UMR UBP-CNRS 6024, Wittyfit |
France |
2020-03-11 |
2022-03-31 |
2020 COVISTRESS, COVISTRESS, NCT04308187 |
Phase Not Applicable |
Not yet recruiting |
1 |
24 Months |
50000 |
Frederic DUTHEIL, Fréderic DUTHEIL, Lise Laclautre |
2020-03-17 |
| Multicenter Clinical Study on the Treatment of Patients with Novel Coronavirus Pneumonia (COVID-19) by Ebastine |
Coronavirus disease 19 infection, Viral pneumonia |
Variable regimens including ebastine , interferon-alpha , lopinavir |
Histamine H1 receptor antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Mianyang Central Hospital, West China Hospital, Wuzhou Red Cross Hospital |
|
China |
2020-02-20 |
2020-03-30 |
ChiCTR2000030535 |
Phase 4 Clinical |
Recruiting |
1 |
1 Month |
100 |
Xu Zhihua, Zhang Dan |
2020-03-17 |
| Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia-RCT |
Coronavirus disease 19 infection, Viral pneumonia |
bevacizumab plus sodium chloride |
VEGF ligand inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Qilu Hospital of Shandong University |
Renmin Hospital of Wuhan University |
China |
2020-03-12 |
2020-05-31 |
NCT04305106, QLEMER |
Phase 2 Clinical |
Not yet recruiting |
1 |
2 Months |
118 |
Jiaojiao Pang, PHD |
2020-03-17 |
| Application of TCM Nursing Scheme in Patients with Novel Coronavirus Pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
Auricular acupressure alone, Baduanjin alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Guangdong Provincial Hospital of Chinese Medicine |
|
China |
2020-03-06 |
2020-05-25 |
ChiCTR2000030528 |
Phase Not Applicable |
Not yet recruiting |
1 |
2 Months |
60 |
Meizhen Lin, Minggui Chen |
2020-03-17 |
| Psychological Intervention of Children with Novel Coronavirus Disease (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
psychological intervention alone |
|
Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs) |
Tongji Hospital |
|
China |
2019-12-01 |
2020-06-30 |
ChiCTR2000030564 |
Phase Not Applicable |
Recruiting |
1 |
7 Months |
120 |
Lina Tang, Xiaoping Luo, Yan Hao |
2020-03-16 |
| A clinical study of TZLS-501 for treatment of patients infected with coronavirus COVID-19 |
Coronavirus disease 19 infection |
TZLS-501 alone |
IL-6 receptor antagonist |
|
Tiziana Life Sciences PLC |
|
|
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-03-16 |
| ERS-COVID-19: Early risk stratification of the novel coronavirus infected diseases (COVID-19): a multicenter, retrospective study |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Renmin Hospital of Wuhan University, West China Hospital, Wuhan Red Cross Hospital |
|
China |
2020-03-01 |
2020-04-01 |
ChiCTR2000030494, ERS-COVID-19 |
Phase Not Applicable |
Not yet recruiting |
3 |
1 Month |
600 |
Dongze Li, Rui Zeng |
2020-03-18 |
| Survey for sleep, anxiety and depression status of Chinese residents during the outbreak of novel coronavirus infected diseases (COVID-19) |
Anxiety disorder, Coronavirus disease 19 infection, Depression, Sleep disorder |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Asian Ancestry |
Renmin Hospital of Wuhan University |
|
China |
2020-03-04 |
2020-03-09 |
ChiCTR2000030493 |
Phase Not Applicable |
Not yet recruiting |
1 |
|
1300 |
Wenqin Song, Zhongyuan Xia |
2020-03-18 |
| Retrospective study for integrate Chinese and conventional medicine treatment of novel coronavirus pneumonia (COVID-19) in Hu'nan province |
Coronavirus disease 19 infection, Viral pneumonia |
Chinese medicine treatment alone, Western medicine treatment alone |
|
|
The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine |
Hunan Provincial Science and Technology Department |
China |
2020-03-04 |
2020-06-30 |
ChiCTR2000030492 |
Phase Not Applicable |
Not yet recruiting |
1 |
3 Months |
200 |
CAI Huzhi, CHEN Xinyu |
2020-03-18 |
| A Medical Records Based Study for Comparing Differences of Clinical Features and Outcomes of Novel Coronavirus Pneumonia (COVID-19) Patients between Sichuan Province and Wuhan City |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
|
Renmin Hospital of Wuhan University, West China Hospital |
|
China |
2020-03-03 |
2022-02-01 |
ChiCTR2000030491 |
Phase 0 Clinical |
Recruiting |
2 |
22 Months |
100 |
Cheng Jiangli, Kang Yan |
2020-03-18 |
| To evaluate the efficacy and safety of diammonium glycyrrhizinate enteric-coated capsules combined with hydrogen-rich water in the treatment of novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
diammonium glycyrrhizinate enteric-coated capsule plus hydrogen-rich water |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Wuhan Huoshenshan Hospital |
McGill University Health Center |
China |
2020-02-01 |
2020-03-31 |
ChiCTR2000030490 |
Phase 0 Clinical |
Recruiting |
1 |
2 Months |
100 |
Wang Hao, Yan HongLi |
2020-03-18 |
| a Multicenter, Long- term Follow-up and Registration Study for Myocardial Injury and Prognosis of Novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Heart injury, Viral pneumonia |
|
|
|
Peking University First Hospital |
China Cardiovascular Association |
China |
2020-03-01 |
2023-12-31 |
ChiCTR2000030482, GUSU20001 |
Phase Not Applicable |
Not yet recruiting |
6 |
46 Months |
8000 |
Yi Wang, Yong Huo |
2020-03-16 |
| The clinical value of corticosteroid therapy timing in the treatment of novel coronavirus pneumonia (COVID-19): a prospective randomized controlled trial |
Coronavirus disease 19 infection, Viral pneumonia |
corticosteroid therapy alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Zhangnan Hospital |
|
China |
2020-03-01 |
2020-04-30 |
ChiCTR2000030481 |
Phase 4 Clinical |
Recruiting |
3 |
2 Months |
200 |
Chen Zhenshun |
2020-03-16 |
| Study for the route of ocular surface transmission of novel coronavirus pneumonia (COVID-19) infection and related eye diseases |
Coronavirus disease 19 infection, Ocular infection, SARS coronavirus infection, Viral pneumonia |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Tongji Hospital, Huazhong University of Science and Technology |
National Natural Science Foundation of China |
China |
2020-02-01 |
2020-06-30 |
ChiCTR2000030489 |
Phase 0 Clinical |
Recruiting |
2 |
5 Months |
1000 |
Liwen Chen, Xufang Sun |
2020-03-16 |
| Randomized, open, blank controlled trial for the efficacy and safety of recombinant human interferon alpha 1beta in the treatment of Wuhan patients with novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
cerrokin alone, standard treatment alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over), Asian Ancestry |
Tongji Hospital, Huazhong University of Science and Technology |
|
China |
2020-03-03 |
2020-07-03 |
ChiCTR2000030480 |
Phase 4 Clinical |
Recruiting |
1 |
4 Months |
328 |
Huilan Zhang, Jianping Zhao |
2020-03-16 |
| Study for the Effectiveness and Safety of Yi-Qi Hua-shi Jie-Du-Fang in the Treatment of the Novel Coronavirus Pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
Yiqi Huashi Jiedu Fang alone, western medicine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Nanjing University of Chinese Medicine |
|
China |
2020-02-26 |
2021-02-25 |
ChiCTR2000030479 |
Phase 0 Clinical |
Not yet recruiting |
1 |
12 Months |
100 |
Zhijun Fang |
2020-03-16 |
| A single-center, single-arm clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
azvudine alone, conventional treatment alone |
Nucleoside reverse transcriptase inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
The first affiliated hospital of henan university of TCM |
HeNan Sincere Biotech Co., Ltd |
China |
2020-03-04 |
2020-05-04 |
ChiCTR2000030487 |
Phase 0 Clinical |
Recruiting |
1 |
2 Months |
10 |
Li Suyun, Wan Yuanhao |
2020-03-16 |
| Risk Factors for Outcomes of Novel Coronavirus Pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
|
Shandong Provincial Hospital |
|
China |
2020-02-01 |
2020-05-01 |
ChiCTR2000030579 |
Phase Not Applicable |
Not yet recruiting |
1 |
3 Months |
200 |
Jiang Shujuan, Wei Yuanhui |
2020-03-16 |
| Clinical Prediction and Intervention of Pulmonary Function Impairment in Patients with Novel Coronavirus Pneumonia (COVID-19) |
Coronavirus disease 19 infection, Lung disease, Viral pneumonia |
conventional treatment alone, lung rehabilitation training alone |
|
|
Shandong Provincial Hospital |
|
China |
2020-02-01 |
2021-02-01 |
ChiCTR2000030578 |
Phase Not Applicable |
Not yet recruiting |
1 |
12 Months |
40 |
Liu Yi, Yan Mengdie |
2020-03-18 |
| Study for the Effectiveness and Safety of Compound Yuxingcao Mixture in the Treatment of the Novel Coronavirus Pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
Western medicine alone, Yuxingcao mixture alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Nanjing University of Chinese Medicine |
|
China |
2020-02-26 |
2021-02-25 |
ChiCTR2000030478 |
Phase 0 Clinical |
Not yet recruiting |
2 |
12 Months |
120 |
Haibin Ni, Jiangning Hu |
2020-03-20 |
| oXiris Membrane in Treating Critically Ill Hospitalized Adult Patients with novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
oXiris membrane alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Chinese Academy of Medical Sciences & Peking Union Medical College |
|
China |
2020-03-04 |
2020-06-25 |
ChiCTR2000030477 |
Phase 0 Clinical |
Not yet recruiting |
1 |
3 Months |
19 |
Xuemei Li, Yangzhong Zhou |
2020-03-16 |
| Clinical Study of NK Cells in the Treatment of Novel Coronavirus Pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
NK cells infusion alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
The First Affiliated Hospital of Harbin Medical University |
|
China |
2020-02-01 |
2021-01-01 |
ChiCTR2000030509 |
Phase 0 Clinical |
Not yet recruiting |
1 |
11 Months |
40 |
Fenglin Cao, Kaijiang Yu |
2020-03-16 |
| Efficacy and Safety of Adalimumab Combined With Tocilizumab in Severe and Critical Patients With Novel Coronavirus Pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
adalimumab plus tocilizumab |
TNF alpha ligand inhibitor, TNF binding agent |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Shanghai First People's Hospital |
Zhejiang University |
China |
2020-02-01 |
2020-04-30 |
ChiCTR2000030580 |
Phase 4 Clinical |
Recruiting |
1 |
3 Months |
60 |
Aihua Bao, Min Zhang |
2020-03-16 |
| Study for timing of mechanical ventilation for critically ill patients with novel coronavirus pneumonia (COVID-19): a medical records based retrospective, cohort study |
Coronavirus disease 19 infection, Viral pneumonia |
aggressive mechanical ventilation alone |
|
Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Tongji Hospital, Huazhong University of Science and Technology |
|
China |
2020-03-03 |
2021-02-01 |
ChiCTR2000030485 |
Phase Not Applicable |
Not yet recruiting |
3 |
10 Months |
90 |
Shusheng Li, Yi Bian |
2020-03-16 |
| Study for emotion regulation of traditional Chinese medicine assists for the rehabilitation of patients with novel coronaviruse pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
Standard treatment of traditional Chinese alone, Western Medicine alone, meditation alone |
|
Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Longhua Hospital Shanghai University of TCM |
|
China |
2020-03-01 |
2020-07-01 |
ChiCTR2000030476, ChiMCTR2000003078 |
Phase 0 Clinical |
Not yet recruiting |
2 |
4 Months |
200 |
Jia Lijun, Yang Xi |
2020-03-16 |
| Cytosorb in Treating Critically Ill Hospitalized Adult Patients with novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
cytosorb alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Chinese Academy of Medical Sciences & Peking Union Medical College |
|
China |
2020-03-04 |
2020-06-25 |
ChiCTR2000030475 |
Phase 0 Clinical |
Not yet recruiting |
1 |
3 Months |
19 |
Xuemei Li, Yangzhong Zhou |
2020-03-16 |
| The Immediate Psychological Impact of Novel Coronavirus Pneumonia (COVID-19) Outbreak on Medical Students in Anesthesiology and How the Cope |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Young Adults (18-44 yrs) |
Sichuan University |
|
China |
2020-02-02 |
2021-03-02 |
ChiCTR2000030581 |
Phase Not Applicable |
Recruiting |
1 |
13 Months |
192 |
Yang Xi, Yunxia Zuo |
2020-03-16 |
| NoCovid: Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19 Infection |
Coronavirus disease 19 infection |
continuous airway pressure system alone, nitric oxide alone, standard of care alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Massachusetts General Hospital |
Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico, Xijing Hospital |
US |
2020-03-13 |
2022-04-01 |
NCT04305457, NOGAS MILDCOVID-19, NoCovid |
Phase 2 Clinical |
Not yet recruiting |
0 |
24 Months |
240 |
Lei Chong, Lorenzo Berra |
2020-03-20 |
| An open and controlled clinical study to evaluate the efficacy and safety of Ganovo combined with ritonavir in the treatment of novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
danoprevir plus ritonavir |
Hepatitis C virus NS3 protease inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
The sixth people's hospital of Shenyang |
|
China |
2020-02-25 |
2020-06-30 |
ChiCTR2000030472 |
Phase Not Applicable |
Recruiting |
1 |
4 Months |
20 |
Yan Wang, Ye Gu |
2020-03-16 |
| NOSARSCOVID: Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19 |
Coronavirus disease 19 infection, SARS coronavirus infection, Viral pneumonia |
nitric oxide (inhaled), Ikaria alone |
Hemoglobin modulator |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Massachusetts General Hospital |
Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico, Niguarda Hospital, Xijing Hospital |
US |
2020-03-10 |
2022-03-10 |
NCT04306393, NO-SARS-COV2, NO-SARS-COVID-19, NOSARSCOVID |
Phase 2 Clinical |
Not yet recruiting |
0 |
24 Months |
200 |
Chong Lei, MD, PhD, Lorenzo Berra, MD |
2020-03-19 |
| Social Media Use During COVID-19 |
Coronavirus disease 19 infection |
|
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Yale-NUS College |
|
Singapore |
2020-03-08 |
2020-05-31 |
2020-CERC-001, NCT04305574 |
Phase Not Applicable |
Recruiting |
1 |
2 Months |
5000 |
Jean Liu, PhD |
2020-03-18 |
| Efficacy and safety of lipoic acid injection in reducing the risk of progression in common patients with novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Coronavirus infection |
lipoic acid alone, routine therapy alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Maoming Affiliated Hospital of Southern Medical University |
|
China |
2020-03-02 |
|
ChiCTR2000030471 |
Phase 4 Clinical |
Recruiting |
5 |
|
394 |
Chen Chunbo, Hu Linhui |
2020-03-20 |
| A randomized, parallel-controlled trial for Liushenwan in Treatment of Novel Coronavirus Pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
coventional treatment alone, liushenwan alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Shanghai University of Traditional Chinese Medicine |
|
China |
2020-02-27 |
2020-05-27 |
ChiCTR2000030469 |
Phase 0 Clinical |
Recruiting |
1 |
3 Months |
96 |
Xiuming Song, Xuan Chen |
2020-03-16 |
| Safety of artificial liver cluster nursing in critically ill patients with novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
clustering nusing progremm alone, in vitro blood purification alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
National Clinical Research Center for Infectious Disease, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital of college of medicine Zhejiang University |
|
China |
2020-03-01 |
2020-06-30 |
ChiCTR2000030559 |
Phase Not Applicable |
Recruiting |
1 |
4 Months |
12 |
Huafen Zhang, Zhang Huafen |
2020-03-16 |
| Study for the key technique of integrative therapy of Novel Coronavirus Pneumonia (COVID-19): the TCM symptoms and treatment regulation |
Coronavirus disease 19 infection, Viral pneumonia |
Chinese medicine preventive decoction alone, TCM syndrome differentiation treatment alone, Western medicine treatment alone, general prevention methods alone |
|
Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Shandong University of Traditional Chinese Medicine |
|
China |
2020-02-28 |
2020-07-30 |
2020SFXGFY04-1, ChiCTR2000030468 |
Phase Not Applicable |
Recruiting |
4 |
5 Months |
950 |
Zhang Wei, Zhu Xue |
2020-03-16 |
| HUMSCs and Exosomes Treating Patients with Lung Injury following Novel Coronavirus Pneumonia (COVID-19) |
Coronavirus disease 19 infection, Lung injury, Viral pneumonia |
HUMSCs alone, HUMSCs plus exosomes |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Taihe Hospital |
Beijing Darwin Cell Biotechnology Co Ltd |
China |
2020-01-31 |
2021-01-31 |
ChiCTR2000030484 |
Phase 2 Clinical |
Not yet recruiting |
1 |
12 Months |
90 |
Jianjun Li, Jie Luo |
2020-03-16 |
| A multicenter, randomized, controlled trial for the Ba-Duan-Jin in the adjunctive treatment of patients with common type novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
Ba-Duan-Jin alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
The first affiliated hospital of Guangzhou university of Traditional Chinese medicine |
|
China |
|
|
ChiCTR2000030483 |
Phase 1 Clinical |
Not yet recruiting |
2 |
|
16 |
He jing, Kang Liang |
2020-03-13 |
| SARS-CoV2quine: Hydroxychloroquine as a treatment for coronavirus disease COVID-19 |
Coronavirus disease 19 infection |
hydroxychloroquine sulfate (LIPIN1 disease/rhabdomyolysis), INSERM alone |
TLR-9 antagonist |
Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Fondation Mediterranee Infection |
|
France |
|
|
2020-000890-25, 202002102, SARS-CoV2quine |
Phase 3 Clinical |
Recruiting |
1 |
|
25 |
IHU Méditerranée Infection |
2020-03-13 |
| COPCOV: Chloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting |
Coronavirus disease 19 infection |
chloroquine alone |
|
Healthy volunteers accepted, Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Oxford |
|
|
2020-05-31 |
2022-05-31 |
COPCOV, NCT04303507, VIR20001 |
Phase 2 Clinical |
Not yet recruiting |
0 |
24 Months |
10000 |
William Schilling, MD |
2020-03-13 |
| HCQ4COV19: Treatment of Mild Cases and Chemoprophylaxis of Contacts as Prevention of the COVID-19 Epidemic |
Coronavirus disease 19 infection, Viral pneumonia |
hydroxychloroquine alone, standard public health measures alone, darunavir + cobicistat plus hydroxychloroquine |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Lihir Medical Center |
Department of Health, Generalitat de Catalunya, FUNDACIÓN FLS DE LUCHA CONTRA EL SIDA, LAS ENFERMEDADES INFECCIOSAS Y LA PROMOCIÓN DE LA SALUD Y LA CIENCIA, Germans Trias i Pujol Hospital, Laboratorios Gebro Pharma S.A, Laboratorios Rubio SA |
Spain |
2020-03-15 |
2020-07-15 |
CQ4COV19, HCQ4COV19, HCQ4COV19, NCT04304053 |
Phase 3 Clinical |
Not yet recruiting |
1 |
4 Months |
3040 |
Laia Bertran, Oriol Mitja, oriol Mitja, PhD |
2020-03-19 |
| Epidemiological research of novel coronavirus pneumonia (COVID-19) suspected cases based on virus nucleic acid test combined with low-dose chest CT screening in primary hospital |
Coronavirus disease 19 infection, Viral pneumonia |
ow-dose chest CT screening alone, swab virus nucleic acid test alone |
|
Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Guangzhou Panyu Center Hospital |
|
China |
2020-03-07 |
2025-04-07 |
ChiCTR2000030558 |
Phase Not Applicable |
Recruiting |
1 |
61 Months |
264 |
Chen Huang, Hanwei Chen |
2020-03-13 |
| A retrospective study on virus typing, Hematological Immunology and case Review of novel coronavirus infected and convalescent patients (COVID-19) |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
The Third Affiliated Hospital of the Second Military Medical University |
|
China |
2020-03-01 |
2021-03-10 |
ChiCTR2000030557 |
Phase Not Applicable |
Recruiting |
2 |
12 Months |
1030 |
Tang Hao, Wang Hongyang |
2020-03-13 |
| Clinical study of nano-nose and its extended technology in diagnosis of novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
nano-nasal COVID-19 diagnostic screening model alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Anhui Cancer Hospital |
|
China |
2020-03-15 |
2020-06-01 |
ChiCTR2000030556 |
Phase 0 Clinical |
Not yet recruiting |
2 |
2 Months |
400 |
Hu Liu |
2020-03-13 |
| THDMS-COVID19: Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Chloroquin for Treatment of COVID19: a Randomized, Control Trial |
Coronavirus disease 19 infection |
Variable regimens including chloroquine , darunavir , favipiravir , lopinavir , oseltamivir , ritonavir |
Cytochrome P450 3A4 inhibitor, Exo-alpha sialidase inhibitor, HIV protease inhibitor, HIV-1 protease inhibitor, RNA polymerase inhibitor |
Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Rajavithi Hospital |
|
Thailand |
2020-03-15 |
2020-11-30 |
NCT04303299, TH-DMS-COVID19 STUDY, THDMS-COVID19 |
Phase 3 Clinical |
Not yet recruiting |
1 |
8 Months |
80 |
Dr Subsai Kongsaengdao, Narumol Sawanpanyalert, M.D., M.P.H, Subsai Kongsaengdao, M.D. |
2020-03-13 |
| A clinical study to assess Panaphix for the potential treatment of coronavirus (Covid-19) |
Coronavirus disease 19 infection |
sodium meta-arsenite (cancer/ pain/ COVID-19), Komipharm alone |
|
|
Komipharm International Co Ltd |
NOVOTECH ASIA KOREA CO. LTD. |
South Korea |
|
|
|
Phase Not Applicable |
Planned |
1 |
|
|
|
2020-03-12 |
| A clinical study of ifenprodil injectable for the treatment in patients with coronavirus (COVID-19) infection |
Coronavirus disease 19 infection |
ifenprodil (injectable, COVID-19/acute lung injury), Nash Pharmaceuticals alone |
NMDA receptor epsilon 2 subunit inhibitor |
|
Algernon Pharmaceuticals |
|
US |
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-03-12 |
| A clinical study of ifenprodil long-acting oral release formulation for the treatment in patients with coronavirus (COVID-19) infection |
Coronavirus disease 19 infection |
ifenprodil (long-acting, oral, COVID-19/acute lung injury), Nash Pharmaceuticals alone |
NMDA receptor epsilon 2 subunit inhibitor |
|
Algernon Pharmaceuticals |
|
US |
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-03-12 |
| A Pilot Study of Sildenafil in COVID-19 |
Coronavirus disease 19 infection |
sildenafil citrate alone |
PDE 5 inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Tongji Hospital |
|
China |
2020-02-09 |
2020-11-09 |
GST-G1, NCT04304313 |
Phase 3 Clinical |
Recruiting |
1 |
9 Months |
10 |
Meifang Han, Professor, Meifang Han, professor, Qin Ning, Qin Ning, professor, Qing Ning, Professor |
2020-03-18 |
| Efficacy and safety of Ma-Xing-Gan-Shi decoction in the treatment of novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection |
Conventional Western Medicine Treatment alone, Ma-Xing-Gan-Shi alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
The Affiliated Hospital of Chengdu University of Traditional Chinese Medicine |
|
China |
2020-03-09 |
2020-09-09 |
ChiCTR2000030522, ChiMCTR2000003088 |
Phase 0 Clinical |
Recruiting |
3 |
6 Months |
100 |
Chuantao Zhang |
2020-03-12 |
| Critical ultrasound in evaluating cardiopulmonary function in critical patients infected with 2019 novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Tongji Hospital |
Huazhong University of Science and Technology |
China |
2020-03-08 |
2020-05-08 |
ChiCTR2000030552 |
Phase 0 Clinical |
Recruiting |
1 |
2 Months |
70 |
Li Shusheng, Ran Xiao |
2020-03-12 |
| Expanded Access Remdesivir (RDV, GS-5734) |
Coronavirus disease 19 infection |
remdesivir alone |
RNA polymerase modulator |
|
US Army Medical Research and Development Command |
|
|
|
|
NCT04302766, S-20-01 |
Phase Not Applicable |
Recruiting |
0 |
|
|
Sandi K Parriott |
2020-03-23 |
| A phase IIa, randomized, single-arm, double-blind, placebo-controlled, multicenter study to assess safety and efficacy leronlimab (PRO-140) in patients with mild-to-moderate symptoms of respiratory illness caused by coronavirus 2019 infection |
Coronavirus disease 19 infection, Respiratory disorder |
leronlimab alone |
CCR5 chemokine antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
CytoDyn Inc |
|
US |
|
|
|
Phase 2a Clinical |
Planned |
0 |
|
75 |
|
2020-03-19 |
| Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells |
Coronavirus disease 19 infection |
dental pulp mesenchymal stem cells alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
CAR-T (Shanghai) Biotechnology Co.,Ltd |
|
|
2020-03-05 |
2021-07-30 |
KT005HB001, NCT04302519 |
Phase 0 Clinical |
Not yet recruiting |
0 |
16 Months |
24 |
Liwei cheng, doctor, Xiaoyang Zhou, doctor |
2020-03-12 |
| Efficacy and safety of honeysuckle oral liquid in the treatment of novel coronavirus pneumonia (COVID-19): a multicenter, randomized, controlled, open clinical trial |
Coronavirus disease 19 infection, Viral pneumonia |
basic treatment alone, honeysuckle oral liquid alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Hubei province hospital of Traditional Chinese Medicine |
|
China |
2020-02-24 |
|
ChiCTR2000030545 |
Phase Not Applicable |
Recruiting |
3 |
|
300 |
Qiu Tao, Yang Yi |
2020-03-12 |
| Accurate Classification System for Patients With COVID-19 Pneumonitis |
Coronavirus disease 19 infection |
|
|
|
Renmin Hospital of Wuhan University |
|
China |
2019-12-10 |
2020-03-04 |
COVID-19 WU1, NCT04302688 |
Phase Not Applicable |
Completed |
1 |
2 Months |
669 |
Qiong Gong, MD. |
2020-03-12 |
| Study for the risk factors of critically ill patients with novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Healthy volunteers accepted, Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Tongji Hospital |
|
China |
2020-02-01 |
2021-02-01 |
ChiCTR2000030544 |
Phase Not Applicable |
Not yet recruiting |
3 |
12 Months |
1500 |
Minghao Fang, Yi Bian |
2020-03-19 |
| Novel coronavirus pneumonia (COVID-19) antiviral related liver dysfunction: a multicenter, retrospective, observational study |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
The First Affiliated Hospital of college of medicine Zhejiang University |
|
China |
2020-03-10 |
2020-04-09 |
ChiCTR2000030593 |
Phase Not Applicable |
Not yet recruiting |
1 |
1 Month |
150 |
Dongsheng Hong, Xiaoyang Lu |
2020-03-13 |
| Extracorporeal blood purification therapy using Li's Artifical Liver System for patients with severe novel coronavirus pneumonia (COVID19) patient |
Coronavirus disease 19 infection, Viral pneumonia |
Li's Artifical Liver System alone, conventional treatment alone, extracorporeal blood purification therapy alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
The First Affiliated Hospital of college of medicine Zhejiang University |
|
China |
2020-01-20 |
2022-06-30 |
ChiCTR2000030503 |
Phase 0 Clinical |
Recruiting |
2 |
29 Months |
60 |
Liang YU, Xiaowei XU |
2020-03-13 |
| Detection of coronavirus in simultaneously collecting tears and throat swab samples collected from the patients with novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
reverse transcription polymerase chain reaction alone |
|
|
Central Theater Command General Hospital of the Chinese People's Liberation |
|
China |
2020-02-14 |
2020-03-31 |
ChiCTR2000030543 |
Phase Not Applicable |
Recruiting |
1 |
1 Month |
35 |
Chen Xiao, Xiao Chen |
2020-03-12 |
| Safety and Immunity of Covid-19 aAPC Vaccine |
Coronavirus disease 19 infection, SARS coronavirus infection |
Covid-19/artificial antigen presenting cell vaccine alone |
|
Healthy volunteers accepted, Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Shenzhen Geno-Immune Medical Institute |
Shenzhen Second People's Hospital, The Third People’s Hospital of Shenzhen |
China |
2020-02-15 |
2024-12-31 |
GIMI-IRB-20002, NCT04299724 |
Phase 1 Clinical |
Recruiting |
1 |
58 Months |
100 |
Lung-Ji Chang |
2020-03-13 |
| A clinical study about the diagnosis and prognosis evaluation of novel coronavirus pneumonia (COVID-19) based on viral genome, host genomic sequencing, relative cytokines and other laboratory indexes |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Healthy volunteers accepted |
West China Hospital |
|
China |
2020-03-09 |
2020-07-30 |
ChiCTR2000030542 |
Phase Not Applicable |
Recruiting |
1 |
4 Months |
600 |
Li Mengjiao, Ying binwu |
2020-03-12 |
| Novel coronavirus pneumonia (COVID-19) epidemic survey of medical students in various provinces and municipalities throughout the country |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Adolescents (13-17 yrs), Young Adults (18-44 yrs) |
MinDong Hospital, Xiamen University |
|
China |
2020-03-06 |
2020-03-13 |
ChiCTR2000030541 |
Phase Not Applicable |
Not yet recruiting |
3 |
|
1300 |
Ye Wan, Ye Xinxin |
2020-03-12 |
| Research for the mechanism of improvement of novel coronavirus pneumonia (COVID-19) patients' pulmonary exudation by continuous renal replacement therapy |
Coronavirus disease 19 infection, Respiratory distress syndrome, Viral pneumonia |
continuous renal replacement therapy (CRRT) alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Tongji Hospital |
Huazhong University of Science and Technology |
China |
2020-03-08 |
2020-06-08 |
ChiCTR2000030540 |
Phase 0 Clinical |
Not yet recruiting |
1 |
3 Months |
152 |
Li Shusheng, Ran Xiao |
2020-03-11 |
| Study for using the healed novel coronavirus pneumonia (COVID-19) patients plasma in the treatment of severe critical cases |
Coronavirus disease 19 infection, Viral pneumonia |
convalescent plasma therapy alone, routine treatment alone |
|
|
The First Affiliated Hospital of Zhengzhou University |
Science and Technology Department of Henan Province |
China |
2020-02-01 |
2020-05-30 |
ChiCTR2000030627 |
Phase 0 Clinical |
Recruiting |
1 |
3 Months |
30 |
Guojun Zhang |
2020-03-11 |
| Mental Health and Its Correlates Among Chinese Adolescents Exposed to the Novel Coronavirus Disease 2019 |
Anxiety disorder, Coronavirus disease 19 infection, Depression, Post traumatic stress disorder, Psychiatric disorder |
|
|
Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Asian Ancestry |
University Of Macau |
|
Macau |
2020-10-15 |
2022-03-15 |
NCT04299711, SW888999 |
Phase Not Applicable |
Not yet recruiting |
1 |
17 Months |
3428 |
Vivian SHI, Dr |
2020-03-11 |
| Medical records based study for the correlation between Chinese medicine certificate and lung image of novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
Integrated Chinese medicine treatment alone, Traditional Chinese medicine treatment alone, Western medicine treatment alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Chinese Academy of Medical Sciences, Xiyuan Hospital China Academy Of Chinese Medical Sciences |
|
China |
2020-03-09 |
2021-12-31 |
ChiCTR2000030606, ChiMCTR2000003097 |
Phase Not Applicable |
Not yet recruiting |
1 |
21 Months |
120 |
Miao Qing, Yuan Shasha |
2020-03-12 |
| Study for clinical oral characteristics of patients with novel coronavirus pneumonia (COVID-19) and Effect of 3% hydrogen peroxide gargle on the Intraoral novel coronavirus |
Coronavirus disease 19 infection, Viral pneumonia |
3% hydrogen peroxide alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Guangzhou No.8 People's Hospital |
|
China |
2020-03-06 |
2021-03-05 |
ChiCTR2000030539 |
Phase 0 Clinical |
Not yet recruiting |
1 |
12 Months |
40 |
Fan Zhong |
2020-03-11 |
| Research on Peripheral Immunity Function Monitoring And its Clinical Application in Patients with Novel Coronavirus Pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Huazhong University of Science and Technology |
|
China |
2020-03-08 |
2021-03-08 |
ChiCTR2000030574 |
Phase 0 Clinical |
Recruiting |
1 |
12 Months |
500 |
Mei Heng, Tang Lu |
2020-03-11 |
| A medical records based real world study for the characteristics and correlation mechanism of traditional Chinese medicine combined with western medicine in the treatment of patients with novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
traditional Chinese medicine therapy alone, western medicine therapy alone |
|
|
First Affiliated Hospital Bengbu Medical College |
|
China |
2020-03-01 |
2020-05-31 |
ChiCTR2000030619, ChiMCTR2000003099 |
Phase Not Applicable |
No longer recruiting |
1 |
3 Months |
160 |
Liang MA, Qingping Shi |
2020-03-10 |
| Stem Cell Educator Therapy Treat the Viral Inflammation Caused by Severe Acute Respiratory Syndrome Coronavirus 2 |
Coronavirus disease 19 infection, SARS coronavirus infection, Viral pneumonia |
Mononuclear Cells Apheresis alone, Stem Cell Educator therapy alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
jinan tianhe stem cell biotechnology ltd |
Hackensack Meridian Health |
|
2020-04-10 |
2020-11-10 |
2020-TH-001, NCT04299152 |
Phase 2 Clinical |
Not yet recruiting |
0 |
7 Months |
20 |
YONG ZHAO, MD,PhD |
2020-03-10 |
| Safety-Related Factors of Endotracheal Intubation in Patients With Severe COVID-19 Pneumonia |
Coronavirus disease 19 infection, Viral pneumonia |
endotracheal intubation alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Tongji Hospital |
|
China |
2020-03-07 |
2020-07-30 |
COVEI, NCT04298814 |
Phase Not Applicable |
Not yet recruiting |
1 |
4 Months |
120 |
Aijun Xu |
2020-03-10 |
| Identification and Clinical Treatment of Severe novel coronavirus pneumonia (COVID-19) Patients |
Coronavirus disease 19 infection, Viral pneumonia |
conventional treatment alone, conventional western medicine treatment alone, nasal high-flow oxygen therapy alone, non-invasive ventilation and respiratory support therapy alone, traditional Chinese medicine therapy alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Xinyang Central Hospital |
|
China |
2020-03-01 |
2020-12-31 |
ChiCTR2000030322 |
Phase 0 Clinical |
Recruiting |
1 |
10 Months |
|
Li Mengdie, Lu Yibin |
2020-03-10 |
| Clinical application of inhaled acetylcysteine solution in the treatment of novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection |
acetylcysteine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Tongji Medical College |
|
China |
2020-02-28 |
|
ChiCTR2000030328 |
Phase 4 Clinical |
Not yet recruiting |
1 |
|
60 |
ShuJun Sun, Yun Lin |
2020-03-09 |
| Analysis of clinical characteristics of novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection |
|
|
|
Second Affiliated Hospital of Anhui Medical University |
|
China |
2020-03-02 |
2020-03-08 |
ChiCTR2000030327 |
Phase Not Applicable |
Recruiting |
2 |
|
200 |
Yafei Zhang, Zhenhua Zhang |
2020-03-18 |
| A survey of mental health of first-line medical service providers and construction of crisis intervention model for novel coronavirus pneumonia (COVID-19) in Xiangyang |
Coronavirus disease 19 infection, Viral pneumonia |
Psychological intervention alone |
|
|
Hubei University of Arts & Science, Xiangyang Central Hospital |
|
China |
2020-02-28 |
2020-04-28 |
ChiCTR2000030325 |
Phase Not Applicable |
Not yet recruiting |
1 |
2 Months |
500 |
Ming Chen |
2020-03-10 |
| Traditional Chinese Medicine 'Zang-Fu Point-pressing' massage for children with novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
Zang-Fu Point-pressing' massage alone |
|
Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hubei University of Arts & Science, Xiangyang Central Hospital |
|
China |
2020-02-28 |
2020-05-28 |
ChiCTR2000030324 |
Phase 0 Clinical |
Not yet recruiting |
1 |
3 Months |
40 |
Ming Chen |
2020-03-10 |
| Medical Masks Versus N95 Respirators for COVID-19 |
Coronavirus disease 19 infection |
Medical Mask alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
McMaster University |
Dalhousie University, University of Alberta, Vancouver Coastal Health |
Canada |
2020-04-01 |
2021-01-01 |
20006014, NCT04296643 |
Phase Not Applicable |
Not yet recruiting |
1 |
9 Months |
576 |
Mark B Loeb, Mark Loeb, MD |
2020-03-11 |
| Clinical Reseach of Acupuncture in the treatment of Novel Coronavirus Pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
acupunture alone, conventional treatment alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Shanghai University of Traditional Chinese Medicine |
|
China |
2020-02-14 |
2020-12-31 |
ChiCTR2000030225 |
Phase 0 Clinical |
Not yet recruiting |
1 |
10 Months |
186 |
Zhang Chunyan, Zhou Jia |
2020-03-11 |
| Study for evaluation of integrated traditional Chinese and Western Medicine in the treatment of Novel Coronavirus Pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
Traditional Chinese Medicine alone, Western medicine alone |
|
Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin Haihe Hospital |
|
China |
2020-01-01 |
2020-12-31 |
ChiCTR2000030219 |
Phase Not Applicable |
Recruiting |
1 |
12 Months |
120 |
Bi Ying-fei |
2020-03-10 |
| Clinical research of 6-min walk training on motor function of novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
6-min walk training alone |
|
|
Anhui Provincial Hospital |
|
China |
2020-02-28 |
|
ChiCTR2000030330 |
Phase Not Applicable |
Recruiting |
1 |
|
10 |
Ming Wu, Yang Zhang |
2020-03-10 |
| A randomized, double-blind, placebo-controlled trial for evaluation of the efficacy and safety of bismuth potassium citrate capsules in the treatment of patients with novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
bismuth potassium citrate alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Wuhan Jinyintan Hospital |
|
China |
2020-02-27 |
|
ChiCTR2000030398 |
Phase Not Applicable |
Not yet recruiting |
1 |
|
340 |
Liu Ying, Zhang Dingyu |
2020-03-10 |
| Clinical Study for Traditional Chinese Medicine in the Prevention and Treatment of Novel Coronavirus Pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
routine treatment of western medicine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Affiliated Hospital of Changchun University of Traditional Chinese Medicine |
Jilin Institute of Biology |
China |
2020-01-01 |
2020-01-31 |
ChiCTR2000030315 |
Phase 0 Clinical |
Recruiting |
1 |
1 Month |
120 |
Shi Li, Wang Tan |
2020-03-06 |
| Traditional Chinese medicine Ma-Xing-Shi-Gan-Tang and Sheng-Jiang-San in the treatment of children with novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
Western medicine alone, Ma-Xing-Shi-Gan-Tang plus Sheng-Jiang-San |
|
Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs) |
Xiangyang Central Hospital |
|
China |
2020-02-28 |
2020-04-28 |
ChiCTR2000030314 |
Phase 0 Clinical |
Not yet recruiting |
1 |
2 Months |
40 |
Rui Pan |
2020-03-10 |
| Combination of Tocilizumab, IVIG and CRRT in severe patients with novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection |
continuous renal replacement therapy (CRRT) alone, immunoglobulin plus tocilizumab |
|
|
The Second Hospital of Xi'An Jiaotong University |
|
China |
2020-03-05 |
2020-05-15 |
ChiCTR2000030442 |
Phase 0 Clinical |
Not yet recruiting |
1 |
2 Months |
100 |
Ma Xiaorong |
2020-03-09 |
| A Comparative Study for the Effectiveness of 'triple energizer treatment' Method in Repairing Lung Injury in Patients with Novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
triple energizer treatment alone, western medicine routine treatment alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hubei province hospital of Traditional Chinese Medicine |
State Administration of Traditional Chinese Medicine People's Republic of China |
China |
2020-02-23 |
2020-08-23 |
ChiCTR2000030389, ChiMCTR2000003068 |
Phase 0 Clinical |
Recruiting |
8 |
6 Months |
120 |
Jianzhong Liu, Yahan Gao |
2020-03-10 |
| Clinical study for a new type of Gastroscope isolation mask for preventing and controlling the novel coronavirus pneumonia (COVID-19) Epidemic period |
Coronavirus disease 19 infection, Viral pneumonia |
self-made gastroscope mask alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
West China Hospital |
|
China |
2020-03-01 |
2021-03-30 |
ChiCTR2000030317 |
Phase Not Applicable |
Not yet recruiting |
1 |
12 Months |
300 |
Hu Bing, Liao Ke |
2020-03-09 |
| Epidemiological and clinical characteristics of COVID-19: a large-scale investigation in epicenter Wuhan, China |
Coronavirus disease 19 infection |
|
|
|
Third Military Medical University of the Chinese PLA |
|
China |
2020-02-01 |
2020-03-31 |
ChiCTR2000030256 |
Phase Not Applicable |
Recruiting |
1 |
2 Months |
1000 |
Cao Guoqiang |
2020-03-09 |
| A medical records based analysis for antiviral therapy effect on novel coronavirus pneumonia COVID-19 patients |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
|
Lishui Central Hospital |
|
China |
2020-03-01 |
|
ChiCTR2000030391 |
Phase Not Applicable |
Not yet recruiting |
2 |
|
100 |
Chuxiao Shao, Xiu Lan |
2020-03-09 |
| Clinical research of pulmonary rehabilitation in survivors due to severe or critial novel coronavirus pneumonia (COVID-19) |
Anxiety disorder, Coronavirus disease 19 infection, Depression, Viral pneumonia |
health education alone, pulmonary rehabilitation alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
West China Hospital |
|
China |
2020-02-24 |
2020-02-24 |
ChiCTR2000030198 |
Phase 0 Clinical |
Not yet recruiting |
1 |
|
60 |
Chengqi He, Yi Li |
2020-03-09 |
| A multicenter, single-arm, open-label trial for the efficacy and safety of CMAB-806 in the treatment of cytokine release syndrome of novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
conventional therapy alone, tocilizumab biosimilar (rheumatoid arthritis/COVID-19), Jinyu Biotechnology alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Zhangnan Hospital |
Jinyu Biotechnology Co Ltd |
China |
2020-02-20 |
2020-05-31 |
ChiCTR2000030196 |
Phase 2 Clinical |
Not yet recruiting |
1 |
3 Months |
60 |
Yingjun Pan, Zhiyong Peng |
2020-03-09 |
| Clinical study of mesenchymal stem cells in treating severe novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
mesenchymal stem cell therapy alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Huazhong University of Science and Technology |
|
China |
2020-02-14 |
2020-05-31 |
ChiCTR2000030224 |
Phase 2 Clinical |
Not yet recruiting |
2 |
3 Months |
32 |
Chengyun Liu |
2020-03-10 |
| Efficacy and safety of Xue-Bi-Jing injection in the treatment of severe cases of novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
Xuebijing injection alone, routine treatment alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
The First People's Hospital of Jingzhou |
|
China |
2020-03-01 |
|
ChiCTR2000030388 |
Phase 0 Clinical |
Recruiting |
1 |
|
60 |
Zhijian Luo |
2020-03-09 |
| A Clinical Trial Study for the Influence of TCM Psychotherapy on Negative Emotion of Patients with Novel Coronavirus Pneumonia (COVID-19) Based on Network Platform |
Coronavirus disease 19 infection, Viral pneumonia |
Conventional integrated traditional Chinese and western medicine treatment alone, traditional chinese medicine psychological intervention therapy alone, western medicine psychological intervention therapy alone |
|
|
Dalian Medical University, China |
Liaoning University of Science and Technology |
China |
2020-03-01 |
2020-08-31 |
ChiCTR2000030420 |
Phase Not Applicable |
Not yet recruiting |
1 |
6 Months |
60 |
Dong Shang, Fenglin Hu |
2020-03-09 |
| Clinical observation and research of multiple organs injury in severe patients with novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Immune disorder, Multiple organ failure, Viral pneumonia |
Conventional treatment alone, intensive care alone |
|
|
Tongji Hospital |
|
China |
2020-03-01 |
2020-12-31 |
ChiCTR2000030387 |
Phase Not Applicable |
Recruiting |
1 |
10 Months |
130 |
Ziqiang Zhang |
2020-03-10 |
| Study for moxibustion in the preventing of novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
moxibustion alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Hunan University of Chinese Medicine, The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine |
|
China |
2020-02-01 |
2020-12-31 |
AMCTR-IPN-20000331, ChiCTR2000030386 |
Phase 0 Clinical |
Not yet recruiting |
1 |
11 Months |
1000 |
Mailan Liu, Xiaorong Chang |
2020-03-10 |
| Efficacy and Safety of Jing-Yin Granule in the treatment of novel coronavirus pneumonia (COVID-19) wind-heat syndrome |
Coronavirus disease 19 infection |
Jing-Yin Granule alone, Routine treatment alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Shanghai University of Traditional Chinese Medicine |
Shanghai Xingling Sci & Tech Pharmaceutical Co Ltd |
China |
2020-03-01 |
2020-07-31 |
ChiCTR2000030255 |
Phase 4 Clinical |
Not yet recruiting |
1 |
5 Months |
300 |
Liu Hua/Wang Qian, Zhu Guoqin |
2020-03-09 |
| Application of rehabilitation lung exercise eight-segment exercise in patients with novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection |
free activities alone, lung exercise alone, rehabilitation exercise alone |
|
Male, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
First Affiliated Hospital of Fujian Medical University |
|
China |
2020-03-01 |
2021-03-01 |
ChiCTR2000030418 |
Phase Not Applicable |
Recruiting |
1 |
12 Months |
80 |
Ni Jun |
2020-03-10 |
| A randomized, open-controlled trial for favipiravir tablets in the treatment of novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
favipiravir alone |
RNA polymerase inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Zhangnan Hospital |
Chinese Ministry of Science and Technology |
China |
2020-02-20 |
2020-03-20 |
ChiCTR2000030254 |
Phase 0 Clinical |
Recruiting |
1 |
1 Month |
240 |
Kai Lei, Xinghuan Wang |
2020-03-23 |
| Efficacy and safety of chloroquine phosphate inhalation combined with standard therapy in the treatment of novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
chloroquine phosphate alone, standard therapy alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Harbin Peiyou Jiandi Biotechnology Co., Ltd |
|
China |
2020-03-01 |
2020-06-30 |
ChiCTR2000030417 |
Phase 0 Clinical |
Not yet recruiting |
1 |
4 Months |
30 |
Jing Xu, Lishan Liu |
2020-03-09 |
| Exploration and Research for a new method for detection of novel coronavirus (COVID-19) nucleic acid |
Coronavirus disease 19 infection |
eye swabs, pharyngeal swabs, oral saliva, feces, urine and plasma sampling alone |
|
|
West China Hospital |
|
China |
2020-02-27 |
2021-02-26 |
ChiCTR2000030253 |
Phase 0 Clinical |
Not yet recruiting |
1 |
12 Months |
|
Lijia Deng |
2020-03-09 |
| Mechanism of novel coronavirus pneumonia (COVID-19) virus with silent latent immune system induced by envelope protein and vaccine development |
Coronavirus disease 19 infection, Viral pneumonia |
animal vaccine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Shenzhen Second People's Hospital |
|
China |
2020-03-19 |
2020-09-22 |
ChiCTR2000030306 |
Phase 0 Clinical |
Not yet recruiting |
1 |
6 Months |
15 |
Bi Xiaohui |
2020-03-10 |
| Study for sleep status of medical staffs of hospitals administrating suspected cases of Novel Coronavirus Pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Guangzhou Panyu Center Hospital |
|
China |
2020-01-31 |
2020-03-24 |
ChiCTR2000030221, SIMSC-COVID-19 |
Phase 0 Clinical |
Recruiting |
1 |
1 Month |
960 |
Zhu Haibing |
2020-03-11 |
| Multiomics study and emergency plan optimization of spleen strengthening clearing damp and stomach therapy combined with antiviral therapy for novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
The Fourth Affiliated Hospital of Medical College of Zhejiang University |
Jinhua science and technology bureau |
China |
2020-03-01 |
2020-12-31 |
ChiCTR2000030305 |
Phase 0 Clinical |
Not yet recruiting |
1 |
10 Months |
20 |
Li Caixia |
2020-03-11 |
| Study of Pinavir / Ritonavir Tablets (Trade Name: Kelizhi) Combined with Xiyanping Injection for Novel Coronavirus Pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
Xiyanping plus lopinavir / ritonavir |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
The Fifth People's Hospital of Ganzhou |
|
China |
2020-01-22 |
2020-06-25 |
ChiCTR2000030218 |
Phase 2 Clinical |
Recruiting |
1 |
5 Months |
80 |
Xie Liangdong |
2020-03-10 |
| Clinical Study on Syndrome Differentiation of TCM in Treating Severe and Critical Novel Coronavirus Pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
Western medicine basic treatment alone, syndrome differential treatment of Chinese Medicine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Guangdong Provincial Hospital of Chinese Medicine |
|
China |
2020-02-15 |
2020-03-30 |
ChiCTR2000030188, ChiMCTR2000003050 |
Phase Not Applicable |
Recruiting |
1 |
1 Month |
120 |
Donghui Huang |
2020-03-10 |
| Protective factors of mental resilience in first-line nurses with novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
The Third Affiliated Hospital of Sun Yat-Sen University |
Chinese Association for Life Care |
China |
2020-03-01 |
2022-12-31 |
ChiCTR2000030304 |
Phase 0 Clinical |
Not yet recruiting |
1 |
34 Months |
300 |
Pang Yong-li |
2020-03-10 |
| Study for the efficacy of Kangguan No. 1-3 prescription in the treatment of novel coronavirus pneumonia (COVID19) |
Coronavirus disease 19 infection, Viral pneumonia |
Kanguan No. 1 alone, Kanguan No. 2 alone, Kanguan No. 3 alone, Routine treatment alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Nanchang University |
|
China |
2020-01-01 |
2020-12-31 |
ChiCTR2000030215 |
Phase 0 Clinical |
Not yet recruiting |
1 |
12 Months |
120 |
Shao Yi |
2020-03-10 |
| A single-center, single-arm clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
azvudine alone |
Nucleoside reverse transcriptase inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Henan Provincial Eye Hospital |
|
China |
2020-03-02 |
2022-05-02 |
ChiCTR2000030424 |
Phase Not Applicable |
Not yet recruiting |
1 |
26 Months |
30 |
Shao Fengmin, Wan Yuanhao |
2020-03-11 |
| Clinical study for lopinavir and ritonavir in the treatment of novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
lopinavir + ritonavir alone |
HIV protease inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
The First People's Hospital of Jingzhou |
|
China |
2020-02-25 |
2020-03-10 |
ChiCTR2000030187 |
Phase 0 Clinical |
Not yet recruiting |
1 |
|
60 |
Wei Xiao, Zhijian Luo |
2020-03-10 |
| The Value of Critical Care Ultrasound in Rapid Screening, Diagnosis, Evaluation of Effectiveness and Intensive Prevention of Novel Coronavirus Pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
ultrasound alone |
|
|
West China Hospital |
|
China |
2020-02-03 |
2020-12-31 |
ChiCTR2000030185 |
Phase 0 Clinical |
Recruiting |
8 |
10 Months |
40 |
Tongjuan Zou, Wanhong Yin |
2020-03-10 |
| Application of flash glucose monitoring to evaluate the effect of blood glucose changes on prognosis in patients with novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Non-insulin dependent diabetes, Viral pneumonia |
flash glucose monitoring alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over), Asian Ancestry |
Shanghai Sixth People’s Hospital |
|
China |
2020-03-06 |
2020-05-31 |
ChiCTR2000030436 |
Phase Not Applicable |
Not yet recruiting |
1 |
2 Months |
100 |
ZHOU JIAN |
2020-03-10 |
| A randomized, open-label, controlled and single-center trial to evaluate the efficacy and safety of anti-SARS-CoV-2 inactivated convalescent plasma in the treatment of novel coronavirus pneumonia (COVID-19) patient |
Coronavirus disease 19 infection, Viral pneumonia |
Conventional treatment alone, anti-SARS-CoV-2 virus inactivated plasma therapy alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
First People's Hospital of Jiangxia District, Wuhan (Union Jiangnan Hospital), Sinopharm Wuhan Blood Products Co., Ltd. |
|
China |
2020-02-29 |
2020-05-31 |
ChiCTR2000030381 |
Phase Not Applicable |
Not yet recruiting |
1 |
3 Months |
40 |
Bende Liu, Lianghao Zhang |
2020-03-10 |
| Key techniques of umbilical cord mesenchymal stem cells for the treatment of novel coronavirus pneumonia (COVID-19) and clinical application demonstration |
Coronavirus disease 19 infection, Viral pneumonia |
umbilical cord mesenchymal stem cells alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
The Second Affiliated Hospital of Nanhua University |
|
China |
2020-02-17 |
2020-04-17 |
ChiCTR2000030173 |
Phase 0 Clinical |
Not yet recruiting |
1 |
2 Months |
60 |
Li Weilin, Xue Zhigang |
2020-03-10 |
| Application of Rehabilitation and Lung Eight-segment Exercise in Home Rehabilitation of Survivors from novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
lung eight-segment exercise alone, rehabilitation alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
First Affiliated Hospital of Fujian Medical University |
|
China |
2020-03-01 |
2020-10-01 |
ChiCTR2000030433 |
Phase 1 Clinical |
Not yet recruiting |
1 |
7 Months |
80 |
Nijun, XIAHUA LIU |
2020-03-10 |
| Application of rehabilitation and lung eight-segment exercise in front-line nurses in the prevention of novel coronavirus pneumonia (COVID-19) epidemic |
Coronavirus disease 19 infection, Viral pneumonia |
Lung eight-segment exercise alone, rehabilitation alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
First Affiliated Hospital of Fujian Medical University |
|
China |
2020-02-27 |
2020-08-27 |
ChiCTR2000030432 |
Phase 1 Clinical |
Not yet recruiting |
1 |
6 Months |
80 |
Jun Ni, RongJin Lin |
2020-03-10 |
| Clinical trial for umbilical cord blood CIK and NK cells in the treatment of mild and general patients infected with novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
Umbilical cord blood CIK cells alone, Umbilical cord blood NK cells alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
The Second Hospital of Xi'An Jiaotong University |
Xi' An Medical University |
China |
2020-03-01 |
2021-02-17 |
ChiCTR2000030329 |
Phase 0 Clinical |
Not yet recruiting |
2 |
11 Months |
90 |
Gao Jun |
2020-03-10 |
| Novel Coronavirus Infected Disease (COVID-19) in children: epidemiology, clinical features and treatment outcome |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs) |
Huazhong University of Science and Technology |
|
China |
2019-12-01 |
2020-06-30 |
ChiCTR2000030363 |
Phase Not Applicable |
Recruiting |
1 |
7 Months |
120 |
Jinzhu Zhao, Yan Hao, Xiaoping Luo |
2020-03-10 |
| ECMOCARD Study |
Coronavirus disease 19 infection |
|
|
Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Critical Care Research Group, The Prince Charles Hospital |
|
Europe, Asia, Australia, Japan |
2020-02-01 |
|
UMIN000039686 |
Phase Not Applicable |
Recruiting |
2 |
|
500 |
Keibun Liu, Shingo Ichiba |
2020-03-10 |
| Construction and application of non-contact doctor-patient interactive diagnosis and treatment mode of moxibustion therapy for novel coronary pneumonia (COVID-19) based on mobile internet |
Coronavirus disease 19 infection, Viral pneumonia |
indirect moxibustion alone, routine treatment alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Wuhan Hospital of Traditional Chinese Medicine |
|
China |
2020-02-01 |
2020-05-31 |
AMCTR-OCN-20000332, ChiCTR2000030382 |
Phase 0 Clinical |
Recruiting |
1 |
4 Months |
50 |
Xia Chen, Zhongyu Zhou |
2020-03-10 |
| Umbilical cord mesenchymal stem cells (hucMSCs) in the treatment of high risk novel coronavirus pneumonia (COVID-19) patients |
Coronavirus disease 19 infection, Pulmonary fibrosis, Viral pneumonia |
umbilical cord mesenchymal stem cells alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Nangjing Second Hospital Affiliated Southeast Medical University |
|
China |
2020-02-19 |
2021-02-20 |
ChiCTR2000030300 |
Phase 1 Clinical |
Recruiting |
1 |
12 Months |
9 |
Yongxiang Yi |
2020-03-10 |
| Study for safety and efficacy of Jakotinib hydrochloride tablets in the treatment severe and acute exacerbation patients of novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
jackotinib hydrochloride alone, routine standard therapy alone |
|
Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Shanghai Public Health Clinical Center |
Suzhou Zelgen Biopharmaceuticals Co Ltd |
China |
2020-02-15 |
2020-07-31 |
ChiCTR2000030170 |
Phase 0 Clinical |
Recruiting |
1 |
5 Months |
16 |
Lu Hongzhou |
2020-03-10 |
| Health related quality of life and its influencing factors among front line nurses caring patients with new coronavirus pneumonia (COVID-19) from two hospitals in China |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Asian Ancestry |
Xiamen University |
|
China |
2020-02-11 |
2020-02-27 |
ChiCTR2000030290 |
Phase Not Applicable |
No longer recruiting |
2 |
|
2000 |
Jiemin Zhu |
2020-03-08 |
| Clinical Trial for Recombinant Human Interleukin-2 in the Treatment of Novel Coronavirus Pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
conventional treatment alone, recombinant human Interleukin-2 alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Renmin Hospital of Wuhan University |
|
China |
2020-03-02 |
2020-09-01 |
ChiCTR2000030167 |
Phase 0 Clinical |
Not yet recruiting |
1 |
6 Months |
80 |
Linzhi Cai, Qianxue Chen |
2020-03-10 |
| Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe) |
Coronavirus disease 19 infection, Viral pneumonia |
Variable regimens including Xiyanping , alpha-interferon , lopinavir , ritonavir |
Cytochrome P450 3A4 inhibitor, HIV protease inhibitor, HIV-1 protease inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Jiangxi Qingfeng Medical Investment Group |
|
|
2020-03-14 |
2021-04-14 |
NCT04295551, QF-XYP1990-1 |
Phase 2 Clinical |
Not yet recruiting |
0 |
13 Months |
80 |
|
2020-03-05 |
| Randomized, parallel-control, open trial for Qing-Wen Bai-Du-Yin combined with antiviral therapy in the treatment of novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
Qing-Wen Bai-Du-Yin plus lopinavir + ritonavir |
HIV protease inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Chinese PLA General Hospital |
|
China |
2020-02-25 |
2020-05-14 |
20EP006, ChiCTR2000030166 |
Phase 0 Clinical |
Not yet recruiting |
1 |
2 Months |
20 |
Manyi Jing, Yanling Zhao |
2020-03-10 |
| A parallel-group, randomized, double-blind, clinical trial of chloroquine phosphate tablets for the treatment of coronavirs COVID-19 infection |
Coronavirus disease 19 infection |
chloroquine phosphate alone, standard therapy alone |
|
|
Guangdong Zhongsheng Pharmaceutical Co Ltd |
Peking University Third Hospital |
China |
|
|
|
Phase Not Applicable |
Recruiting |
1 |
|
|
|
2020-03-05 |
| A clinical trial to evaluate the efficacy and safety of hzVSF-v13 in the treatment of patients with coronavirus infection - COVID-19 |
Coronavirus disease 19 infection |
chimeric humanized virus suppressing factor, ImmuneMed alone |
|
|
Seoul National University Hospital |
ImmuneMed Inc |
South Korea |
2020-03-03 |
|
|
Phase Not Applicable |
Recruiting |
1 |
|
|
|
2020-03-05 |
| Clinical study for combination of anti-viral drugs and type I interferon and inflammation inhibitor TFF2 in the treatment of novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
IFN-kappa plus Trefoil factor 2 |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Shanghai Public Health Clinical Center |
Shanghai Municipal Health Bureau |
China |
2020-02-01 |
2021-01-31 |
ChiCTR2000030262 |
Phase 0 Clinical |
Recruiting |
1 |
12 Months |
30 |
Jianqing Xu, Weihui Fu |
2020-03-05 |
| Study for continuous renal replacement therapy with adsorption filter in the treatment of the novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
High inflammation oXiris CRRT treatment alone, adsorption filter alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
The First Affiliated Hospital of Harbin Medical University |
|
China |
2020-02-24 |
2021-02-23 |
ChiCTR2000030265 |
Phase 0 Clinical |
Not yet recruiting |
1 |
12 Months |
30 |
Kaijiang Yu |
2020-03-05 |
| A study for the key technology of mesenchymal stem cells exosomes atomization in the treatment of novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
mesenchymal stem cells exosomes alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Wuxi Hospital for Infectious Diseases |
|
China |
2020-02-28 |
2020-05-31 |
ChiCTR2000030261 |
Phase 0 Clinical |
Not yet recruiting |
1 |
3 Months |
26 |
Meiping Chu, Yigang Chen |
2020-03-06 |
| A trial of brilacidin as a potential novel coronavirus COVID-19 treatment |
Coronavirus disease 19 infection |
brilacidin alone |
PDE 3 inhibitor, PDE 4 inhibitor |
|
Innovation Pharmaceuticals Inc |
National Institute of Allergy and Infectious Diseases |
US |
|
|
|
Phase 2 Clinical |
Status not specified |
0 |
|
|
|
2020-03-10 |
| Clinical Progressive Characteristics and Treatment Effects of 2019-novel Coronavirus (2019-nCoV) |
Coronavirus disease 19 infection, Pneumonia |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Fujian Provincial Hospital |
|
China |
2020-01-01 |
2020-07-31 |
KY-2020-24.01, NCT04292327 |
Phase Not Applicable |
No longer recruiting |
1 |
7 Months |
400 |
Xiuling Shang |
2020-03-05 |
| Clinical study for individualized nutritional assessment and supportive treatment of novel coronavirus pneumonia (COVID-19) patients in Tibetan Plateau |
Coronavirus disease 19 infection, Viral pneumonia |
tpf-t alone |
|
|
Ganzi Tibetan Autonomous Prefecture People's Hospital |
|
China |
2020-02-27 |
2021-02-26 |
ChiCTR2000030260 |
Phase 0 Clinical |
Not yet recruiting |
1 |
12 Months |
20 |
Lijia Deng |
2020-03-06 |
| Evaluation danoprevir sodium tablets combined with ritonavir in the treatment of novel coronavirus pneumonia (COVID-19): a randomized, open and controlled trial |
Coronavirus disease 19 infection, Viral pneumonia |
danoprevir plus ritonavir |
Cytochrome P450 3A4 inhibitor, HIV protease inhibitor, HIV-1 protease inhibitor, Hepatitis C virus NS3 protease inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Shanghai Changzheng Hospital |
Ascletis Pharma Inc |
China |
2020-02-22 |
2020-04-30 |
ChiCTR2000030259 |
Phase 2 Clinical |
Recruiting |
1 |
2 Months |
60 |
Junxue Wang |
2020-03-05 |
| . .: Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment |
Coronavirus disease 19 infection, Viral pneumonia |
remdesivir alone, standard of care alone |
RNA polymerase modulator |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Gilead Sciences Inc, Gilead Sciences Singapore Pte Ltd |
|
Taiwan, Hong Kong, Italy, US, Spain, South Korea, Singapore |
2020-03-15 |
2020-05-31 |
. ., 2020-000842-32, GS-US-540-5774, NCT04292730 |
Phase 3 Clinical |
Recruiting |
15 |
2 Months |
600 |
Clinical Trials Mailbox, Dr David Lye Chian Boon, Gilead Clinical Study Information Center, Gilead Study Director, Louis Chai, Shirin Kalimuddin |
2020-03-20 |
| Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of COVID-19 |
Coronavirus disease 19 infection, SARS coronavirus infection, Viral pneumonia |
anti-SARS-CoV-2 inactivated convalescent plasma alone |
|
|
Shanghai Public Health Clinical Center |
|
China |
2020-02-01 |
2020-12-31 |
ANTI-SARS-COV-2, NCT04292340 |
Phase Not Applicable |
Recruiting |
1 |
11 Months |
15 |
Hongzhou Lu, Ph.D, Jun Chen |
2020-03-05 |
| A clinical trial of Ampligen in the treatment of patients with COVID-19 infection |
Coronavirus disease 19 infection |
rintatolimod alone |
2,5-Oligoadenylate synthetase stimulator, Interferon type I receptor agonist, Ribonuclease stimulator, TLR-3 agonist |
|
AIM ImmunoTech Inc |
|
China |
|
|
|
Phase Not Applicable |
Planned |
1 |
|
|
|
2020-03-04 |
| . .: Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19) |
Coronavirus disease 19 infection |
remdesivir alone, standard of care alone |
RNA polymerase modulator |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Gilead Sciences Inc, Gilead Sciences Singapore Pte Ltd |
|
Hong Kong, Taiwan, Italy, Spain, US, South Korea, Singapore |
2020-03-06 |
2020-05-31 |
. ., 2020-000841-15, GS-US-540-5773, NCT04292899 |
Phase 3 Clinical |
Recruiting |
15 |
2 Months |
400 |
Clinical Trials Mailbox, Dr David Lye Chian Boon, Gilead Clinical Study Information Center, Gilead Study Director, Louis Chai, Shirin Kalimuddin |
2020-03-20 |
| Prognostic Factors of Patients With COVID-19 |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Chongqing Medical University |
|
China |
2020-03-01 |
2020-03-13 |
2020-02-2, NCT04292964 |
Phase Not Applicable |
Completed |
1 |
|
201 |
Dongying Zhang |
2020-03-18 |
| Therapy for Pneumonia Patients Infected by 2019 Novel Coronavirus |
Coronavirus disease 19 infection, Viral pneumonia |
conventional treatment alone, umbilical cord-derived mesenchymal stem cells (intravenous, COVID-19), Wuhan Hamilton Bio-technology alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Wuhan Puren Hospital |
Wuhan Hamilton Biotechnology Co., Ltd |
China |
2020-02-24 |
2020-02-25 |
NCT04293692, PR20200225 |
Phase 2 Clinical |
Terminated |
1 |
|
|
|
2020-03-19 |
| Efficacy and Safety of IFN-alpha2beta in the Treatment of Novel Coronavirus Patients |
Coronavirus disease 19 infection |
interferon alpha1beta alone, standard therapy alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Tongji Hospital |
|
China |
2020-03-01 |
2020-06-30 |
NCT04293887, ZHAOJP |
Phase 0 Clinical |
Not yet recruiting |
1 |
4 Months |
328 |
Huilan Zhang, Ph.D., Jianping Zhao, Ph.D., Zhao Jianping |
2020-03-05 |
| Influence of nasal high-fow preoxygenation on video laryngoscope for emergency intubation in patients with critical novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
Nasal high-flow oxygen-assisted tracheal intubation alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
The first affiliated hospital of Guangzhou university of Traditional Chinese medicine |
|
China |
2020-03-02 |
|
ChiCTR2000030465 |
Phase Not Applicable |
Not yet recruiting |
1 |
|
70 |
Li Kunhong, Wu Caineng |
2020-03-05 |
| A multicenter, randomized, controlled trial for efficacy and safety of hydrogen inhalation in the treatment of novel coronavirus pneumonia (COVID-19) patients |
Coronavirus disease 19 infection, Viral pneumonia |
Conventional drug therapy alone, hydrogen alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Fourth affiliated Hospital of Harbin Medical University |
|
China |
2020-02-21 |
2020-08-20 |
ChiCTR2000030258 |
Phase 0 Clinical |
Not yet recruiting |
3 |
6 Months |
60 |
Wei Yang |
2020-03-04 |
| The coagulation function of novel coronavirus pneumonia (COVID-19) patients |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
|
Wuhan Puren Hospital |
|
China |
2020-03-09 |
2020-05-31 |
ChiCTR2000030257 |
Phase Not Applicable |
Not yet recruiting |
1 |
2 Months |
100 |
Cui He, Li Jiangping |
2020-03-04 |
| The Efficacy and Safety of Huaier in the Adjuvant Treatment of COVID-19 |
Coronavirus disease 19 infection |
Huaier Granule alone, standard therapy alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Tongji Hospital |
|
China |
2020-04-01 |
2020-09-01 |
NCT04291053, TJ-IRB20200205 |
Phase 2/Phase 3 Clinical |
Not yet recruiting |
1 |
5 Months |
550 |
Chen Xiaoping, Lin Chen |
2020-03-18 |
| NoCovid: Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID19 Infection |
Coronavirus disease 19 infection |
nitric oxide alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Xijing Hospital |
Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico |
China, US |
2020-03-01 |
2022-02-01 |
COVID19 NOGAS MILD, NCT04290858, NoCovid |
Phase 2 Clinical |
Not yet recruiting |
1 |
23 Months |
240 |
Lei Chong, MD, PhD, Lorenzo Berra, MD |
2020-03-12 |
| Evaluation of Ganovo (Danoprevir) Combined With Ritonavir in the Treatment of Novel Coronavirus Infection |
Coronavirus disease 19 infection |
Novaferon alone, lopinavir + ritonavir alone, peginterferon alfa-2a alone, Variable regimens including danoprevir , interferon , ritonavir |
Cytochrome P450 3A4 inhibitor, HIV protease inhibitor, HIV-1 protease inhibitor, Hepatitis C virus NS3 protease inhibitor, Interferon alpha 2 ligand |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Nanchang Ninth Hospital |
Ascletis Pharmaceutical Co Ltd |
China |
2020-02-17 |
2020-04-30 |
ASC-CTP-NC-01, NCT04291729 |
Phase 4 Clinical |
Recruiting |
1 |
2 Months |
50 |
Hongyi Chen, MD, Yahong Chen, MD, Zhicheng Zhang, MD |
2020-03-12 |
| NOSARSCOVID: Nitric Oxide Gas Inhalation for Severe Acute Respiratory Syndrome in COVID-19 |
Coronavirus disease 19 infection, Respiratory distress syndrome |
nitric oxide alone, standard of care alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Xijing Hospital |
Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico, Massachusetts General Hospital |
US, China |
2020-03-01 |
2022-03-01 |
NCT04290871, NO-SARS-COVID-19, NO-SARS-COVID-2019, NOSARSCOVID |
Phase 2 Clinical |
Not yet recruiting |
2 |
24 Months |
104 |
Chong Lei, MD, PhD, Lei Chong, MD, PhD, Lorenzo Berra, MD, chonglei |
2020-03-09 |
| Treatment With Mesenchymal Stem Cells for Severe Corona Virus Disease 2019 (COVID-19) |
Coronavirus disease 19 infection |
conventional therapy alone, mesenchymal stem cells alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
302 Military Hospital of China |
Fifth Affiliated Hospital, Sun Yat-Sen University, The Third People’s Hospital of Shenzhen, Tianjin Haihe Hospital, VCANBIO Cell & Gene Engineering Corp Ltd, West China Hospital, Wuhan Huoshenshan Hospital, Wuhan Union Hospital, China |
China |
2020-03-05 |
2021-12-31 |
2020-013-D, NCT04288102 |
Phase 2 Clinical |
Recruiting |
2 |
21 Months |
60 |
Fu-Sheng Wang, Fu-Sheng Wang, MD, PhD, Fu-Sheng Wang, MD,PhD, Lei Shi, MD, PhD, Lei Shi, MD,PhD |
2020-03-11 |
| SOLID-C19: Eculizumab (Soliris) in Covid-19 Infected Patients |
Coronavirus disease 19 infection |
eculizumab alone |
Complement C5 factor inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hudson Medical |
|
US |
|
|
COVID19, NCT04288713, SOLID-C19 |
Phase Not Applicable |
Recruiting |
0 |
|
|
Thomas C Pitts, M.D., Thomas Pitts, M.D. |
2020-03-04 |
| A prospective, randomized, open-label, controlled trial for chloroquine and hydroxychloroquine in patients with severe novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
Chloroquine phosphate alone, Hydroxychloroquine sulfate alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Zhongshan Hospital Xiamen University |
Xiamen Science and Technology Bureau |
China |
2020-02-17 |
2020-05-20 |
ChiCTR2000029992 |
Phase 4 Clinical |
Not yet recruiting |
1 |
3 Months |
100 |
Chen Len, v |
2020-03-19 |
| A pilot study for Integrated Chinese and Western Medicine in the treatment of non-critical novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
standard therapy alone, Variable regimens including Arbidol hydrochloride , Liushen Capsule , favipiravir |
RNA polymerase inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
China Pharma Holdings Inc, Guangzhou Institute Of Respiratory Disease, Sunflower Pharmaceutical Group Co Ltd, The First Affiliated Hospital of Guangzhou Medical College |
|
China |
2020-02-16 |
2020-08-20 |
ChiCTR2000029993 |
Phase 0 Clinical |
Recruiting |
4 |
6 Months |
60 |
Jiang Lihong, Lin Changqing, Xu Xuyan, Yang Zifeng, Ye Feng, Yuan Bing, Zhan Yangqing, Zhang Yunhui, Zhu Jun |
2020-03-02 |
| Study on anxiety of different populations under novel coronavirus (COVID-19) infection |
Anxiety disorder, Coronavirus disease 19 infection |
|
|
Male |
Shanghai Jiao Tong University, The First Affiliated Hospital of Nanchang University, Yichun University |
Shanghai Health and Health Commission |
China |
2020-03-20 |
2020-12-31 |
ChiCTR2000029995 |
Phase Not Applicable |
Recruiting |
3 |
9 Months |
200 |
Jiang Du, Jiang Hong |
2020-03-02 |
| A randomized, open-label, controlled trial for the efficacy and safety of Farpiravir Tablets in the treatment of patients with novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
favipiravir alone |
RNA polymerase inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Beijing Chao-Yang Hospital |
|
China |
2020-02-20 |
2020-04-20 |
ChiCTR2000029996 |
Phase 2 Clinical |
Recruiting |
1 |
2 Months |
60 |
Zhaohong Nie, Zhaohui Tong |
2020-03-04 |
| Clinical trials of mesenchymal stem cells for the treatment of pneumonitis caused by novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
remestemcel-L alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Chinese Academy of Medical Sciences & Peking Union Medical College |
|
China |
2020-01-30 |
2020-03-31 |
ChiCTR2000029990 |
Phase 1/Phase 2 Clinical |
Recruiting |
3 |
2 Months |
60 |
Robert Chunhua Zhao |
2020-03-23 |
| A randomized, controlled trial for high-dose vitamin C in the treatment of severe and critical novel coronavirus pneumonia (COVID-19) patients |
Coronavirus disease 19 infection, Viral pneumonia |
vitamin C alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
The Second Hospital of Xi'An Jiaotong University |
|
China |
2020-02-25 |
2021-02-28 |
ChiCTR2000030135 |
Phase 2 Clinical |
Not yet recruiting |
2 |
12 Months |
39 |
Gao Dengfeng |
2020-03-02 |
| A single arm trial to evaluate the efficacy and safety of anti-2019-nCoV inactivated convalescent plasma in the treatment of novel coronavirus pneumonia patient (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
anti-2019-nCoV inactivated convalescent plasma alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
First People's Hospital of Jiangxia District, Wuhan (Union Jiangnan Hospital) |
China National Biotec Group |
China |
2020-02-07 |
2020-04-07 |
ChiCTR2000030046 |
Phase 0 Clinical |
Recruiting |
3 |
2 Months |
10 |
Bende Liu, Li Li |
2020-03-06 |
| Study on the effect of human placenta biological preparation on the defense of immune function against novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
Routine treatment alone, human placenta biological preparation therapy alone |
|
|
Guangzhou Ruiboyin Health Management Consulting Co Ltd |
|
China |
2020-03-01 |
2021-12-31 |
ChiCTR2000029984 |
Phase 0 Clinical |
Not yet recruiting |
1 |
22 Months |
60 |
Chao Xu, Wei Wei |
2020-03-09 |
| A single-arm, single-center clinical trial for Azivudine tablets in the treatment of adult novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
azvudine alone |
Nucleoside reverse transcriptase inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Zhangnan Hospital |
|
China |
2020-02-01 |
2020-06-30 |
ChiCTR2000030041 |
Phase 2 Clinical |
Not yet recruiting |
1 |
5 Months |
40 |
Cheng Zhenshun, Wan Yuanhao |
2020-03-02 |
| Clinical study for infusing convalescent plasma to treat patients with new coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
convalescent plasma infusion therapy alone, conventional therapy alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
The Affiliated Hospital of Xuzhou Medical University |
|
China |
2020-02-01 |
2020-02-01 |
ChiCTR2000030039 |
Phase Not Applicable |
Recruiting |
7 |
|
90 |
Liping Wang, Xuebing Yan |
2020-03-11 |
| The Clinical Study of Carrimycin on Treatment Patients With COVID-19 |
Coronavirus disease 19 infection |
basic treatment alone, bitespiramycin (oral tablet, bacterial infection), Shenyang Tonglian Group/Institute of Medicinal Biotechnology CAMS alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Beijing YouAn Hospital |
2nd People's Hospital of Fuyang City, First Affiliated Hospital Bengbu Medical College, First Affiliated Hospital of Chongqing Medical University, Huangshi Central Hospital, Institute of Medicinal Biotechnology Chinese Academy of Medical Sciences, Nanyang Central Hospital, Renmin Hospital of Wuhan University, Shenyang Pharmaceutical University, Shenyang Tonglian Group Co Ltd, The Second Affiliated Hospital of Harbin Medical University, The sixth people's hospital of Shenyang |
China |
2020-02-23 |
2021-02-28 |
BEIJINGYOUAN HOSPITAL, NCT04286503 |
Phase 4 Clinical |
Not yet recruiting |
1 |
12 Months |
520 |
Huiguo Ding, Jin Ronghua, Ronghua Jin, Ying Han |
2020-03-02 |
| A randomized, dual-arm, unblinded, pilot, investigator-initiated clinical trial of APN-01 in patients with severe coronavirus infection (COVID-19) |
Coronavirus disease 19 infection |
APN-01 alone |
Angiotensin converting enzyme 2 stimulator |
|
Apeiron Biologics GmbH |
Guangzhou Institute Of Respiratory Disease, St Michaels Hospital, University of British Columbia |
China |
|
|
|
Phase 2 Clinical |
Not yet recruiting |
1 |
|
24 |
Dr. Liqun Zhang, Prof. Arthur Slutsky, Prof. Haibo Zhang, Prof. Josef Penninger, Prof. Nanshan Zhong, Prof. Yimin Li |
2020-03-02 |
| A multicenter, randomized controlled trial for ozone autohemotherapy in the treatment of novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
Autohemotherapy alone, conventional treatment alone, ozone alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Enshi Central Hospital, Tianjin Haihe Hospital, Tianjin Huanhu Hospital, Zhangnan Hospital |
|
China |
2020-02-24 |
2020-05-31 |
ChiCTR2000030102 |
Phase 0 Clinical |
Not yet recruiting |
3 |
3 Months |
180 |
Huang Huiling, Xiaoguang Tong |
2020-03-03 |
| A phase I clinical trial to assess COVID-19 vaccine for the potential treatment of coronavirus disease (COVID-19) |
Coronavirus disease 19 infection |
coronavirus COVID-19 infection (protein subunit vaccine, Matrix-M), Novavax alone |
|
|
Novavax Inc |
Coalition for Epidemic Preparedness Innovations |
|
2020-06-01 |
|
|
Phase 1 Clinical |
Planned |
0 |
|
|
|
2020-03-12 |
| Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19 |
Coronavirus disease 19 infection |
recombinant human angiotensin-converting enzyme 2 (rhACE2) alone, standard of care alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
The Fifth Affiliated Hospital of Guangzhou Medical University |
|
China |
2020-02-29 |
|
GIRH-APN01, NCT04287686 |
Phase 2 Clinical |
Terminated |
1 |
|
|
Yimin Li, PhD, MD |
2020-03-18 |
| A trial to assess Ganovo and Ritonavir combination therapy on 2019 Novel Coronavirus Pneumonia (2019-nCoV) |
Coronavirus disease 19 infection, Viral pneumonia |
danoprevir plus ritonavir |
Cytochrome P450 3A4 inhibitor, HIV protease inhibitor, HIV-1 protease inhibitor, Hepatitis C virus NS3 protease inhibitor |
|
Ascletis Pharma Inc |
|
China |
2020-02-17 |
|
|
Phase Not Applicable |
Recruiting |
1 |
|
|
Dr. Hongyi CHEN |
2020-02-28 |
| The Effect of T-89 on Improving Oxygen Saturation and Clinical Symptoms in Patients With COVID-19 |
Coronavirus disease 19 infection, Viral pneumonia |
T-89 alone, Traditional Chinese Medicine decoction therapy alone, antibacterial therapy alone, antiviral drug therapy alone, oxygen therapy alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Tasly Pharmaceuticals Inc |
|
|
2020-02-26 |
2020-09-15 |
NCT04285190, T89-NCP-01 |
Phase 2 Clinical |
Not yet recruiting |
0 |
6 Months |
120 |
Shuiping Zhou, PhD, Yi He, PhD |
2020-03-02 |
| Study for nucleic acid detection of novel coronavirus pneumonia (COVID-2019) in female vaginal secretions |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Female, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Huazhong University of Science and Technology, Tongji Hospital, Tongji Medical College |
|
China |
2020-02-17 |
2020-05-18 |
ChiCTR2000029981 |
Phase 0 Clinical |
Recruiting |
1 |
3 Months |
60 |
Jinjin Zhang, Shixuan Wang |
2020-03-02 |
| Multicenter study for the treatment of dipyridamole with novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
conventional treatment alone, dipyridamole alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
The First Affiliated Hospital of Guangzhou Medical College |
|
China |
2020-02-10 |
2020-04-10 |
ChiCTR2000030055 |
Phase 4 Clinical |
Recruiting |
6 |
2 Months |
460 |
Changxing Ou, Qingling Zhang |
2020-02-28 |
| A prospective, open-label, randomized-control trial for chloroquine or hydroxychloroquine in patients with mild and common novel coronavirus pulmonary (COVIP-19) |
Coronavirus disease 19 infection, Viral pneumonia |
chloroquine phosphate alone, hydroxychloroquine sulfate alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Zhongshan Hospital Xiamen University |
Xiamen Science and Technology Bureau |
China |
2020-02-22 |
2020-05-21 |
ChiCTR2000030054 |
Phase 0 Clinical |
Not yet recruiting |
3 |
3 Months |
100 |
Chen Lan, Yin Zhenyu |
2020-02-28 |
| Study for Novel Coronavirus Pneumonia (NCP) |
Coronavirus disease 19 infection, Viral pneumonia |
antibiotics alone, antiviral therapy alone, globulin alone, hormones alone, oxygen alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Wuhan Union Hospital, China |
|
China |
2020-02-21 |
2020-07-30 |
NCP01, NCT04283396 |
Phase Not Applicable |
Recruiting |
1 |
5 Months |
2000 |
Jiancai Wu, Yang Jin |
2020-03-18 |
| Clinical comparative study of PD-1 mAb in the treatment of severe and critical patients with novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
PD-1 mAb alone, standard treatment alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
West China Hospital |
|
China |
2020-02-24 |
2020-08-31 |
ChiCTR2000030028 |
Phase 0 Clinical |
Not yet recruiting |
1 |
6 Months |
40 |
Yan Kang |
2020-02-27 |
| Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) to Prevent SARS-CoV-2 Infection |
Coronavirus disease 19 infection |
mRNA-1273 alone |
Moesin modulator |
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
National Institute of Allergy and Infectious Diseases, National Institutes of Health |
ModeRNA Therapeutics |
US |
2020-03-03 |
2021-06-01 |
1UM1AI148373-01, 20-0003, NCT04283461 |
Phase 1 Clinical |
Recruiting |
0 |
14 Months |
45 |
20-0003 Central Contact, Lisa A. Jackson, M.D |
2020-03-23 |
| The clinical application and basic research related to mesenchymal stem cells to treat novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
mesenchymal stem cells alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
The Second Affiliated Hospital of Nanhua University |
|
China |
2020-02-06 |
|
ChiCTR2000030020 |
Phase 2 Clinical |
Recruiting |
1 |
|
20 |
Liu Sha, Luo Zhigang |
2020-02-27 |
| Safety and effectiveness of human umbilical cord mesenchymal stem cells in the treatment of acute respiratory distress syndrome of severe novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Respiratory distress syndrome, Viral pneumonia |
human umbilical cord mesenchymal stem cells alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
The First Affiliated Hospital of Nanchang University |
Science and Technology Agency of Jiangxi province |
China |
2020-02-01 |
2020-08-31 |
ChiCTR2000030116 |
Phase 2 Clinical |
Recruiting |
1 |
7 Months |
16 |
Liu Yu, Zhang Wei |
2020-02-26 |
| A clinical research for the changes of Blood cortisol ACTH level and adrenal morphology in blood cortisol to guide the application of individualized hormone in severe novel coronavirus pneumonia (COVID-19) patients |
Coronavirus disease 19 infection, Viral pneumonia |
basic symptomatic therapy alone, glucocorticoid therapy alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Tongji Hospital, Huazhong University of Science and Technology |
|
China |
2020-02-24 |
2020-04-30 |
ChiCTR2000030115 |
Phase Not Applicable |
Not yet recruiting |
1 |
2 Months |
50 |
Ling Qing, Wang Shaogang |
2020-02-26 |
| Randomized controlled trial for safety and efficacy of Favipiravir in the treatment of novel coronavirus pneumonia (COVID-19) with poorly responsive ritonavir/ritonavir |
Coronavirus disease 19 infection, Viral pneumonia |
favipiravir alone |
RNA polymerase inhibitor |
Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
The Third People’s Hospital of Shenzhen |
|
China |
2020-02-22 |
2020-05-31 |
ChiCTR2000030113 |
Phase 0 Clinical |
Recruiting |
1 |
3 Months |
30 |
Cai Qingxian, Liu Yingxia |
2020-02-26 |
| An observational study of high-dose Vitamin C in the treatment of severe and critical patients with novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
Standard treatment alone, Vitamin C alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Xi'an Jiaotong University |
|
China |
2020-02-18 |
2021-02-28 |
ChiCTR2000029957 |
Phase Not Applicable |
Not yet recruiting |
1 |
12 Months |
56 |
Gao Dengfeng |
2020-02-27 |
| A randomized, double-blind, parallel-controlled, trial to evaluate the efficacy and safety of anti-SARS-CoV-2 virus inactivated plasma in the treatment of severe novel coronavirus pneumonia patients (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
Anti-SARS-CoV-2 virus inactivated plasma alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Sinopharm Wuhan Blood Products Co., Ltd., Wuhan Jinyintan Hospital |
|
China |
2020-02-19 |
2020-05-31 |
ChiCTR2000030010 |
Phase 2 Clinical |
Not yet recruiting |
1 |
3 Months |
100 |
Liu Ying, Zhang Dingyu |
2020-02-27 |
| Multicenter, randomized, controlled trial for rhG-CSF in the treatment of novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
rhG-CSF alone, standard treatment alone |
|
Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
The First Affiliated Hospital of Guangzhou Medical College |
|
China |
2020-02-03 |
2020-04-10 |
ChiCTR2000030007 |
Phase 0 Clinical |
Not yet recruiting |
4 |
2 Months |
200 |
Linling Cheng, Nanshan Zhong |
2020-03-05 |
| Optimization Protocal of Integrated Traditional Chinese and Western Medicine in the Treatment for Novel Coronavirus Pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
Gankeshuangqing alone, Shuanghuanglian alone, traditional chinese medicine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Chengdu University of Traditional Chinese Medicine |
Science & Technology Department of Sichuan Province |
China |
2020-02-19 |
2020-07-01 |
ChiCTR2000030003 |
Phase Not Applicable |
Not yet recruiting |
1 |
4 Months |
480 |
Tang Jianyuan, Tang Shiyun |
2020-02-26 |
| The efficacy and safety of Triazavirin for 2019 novel coronary pneumonia (COVID-19): a multicenter, randomized, double blinded, placebo-controlled trial |
Coronavirus disease 19 infection, Viral pneumonia |
basic treatment alone, triazavirin alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Health department of Heilongjiang Province |
|
China |
2020-02-15 |
2020-05-28 |
ChiCTR2000030001 |
Phase 3 Clinical |
Recruiting |
4 |
3 Months |
240 |
Baofeng Yang, Xiaoke Wu |
2020-03-02 |
| Traditional Chinese Medicine in the treatment of novel coronavirus pneumonia (COVID-19): a multicenter, randomized controlled trial |
Coronavirus disease 19 infection, Viral pneumonia |
Routine treatment of Western Medicine alone, TCM alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Tongde Hospital of Zhejiang Province |
|
China |
2020-02-01 |
2020-06-30 |
ChiCTR2000030034 |
Phase Not Applicable |
Recruiting |
6 |
5 Months |
132 |
Kequn Chai, Yaping Li |
2020-02-26 |
| Basic and clinical study of inhalation of inactivated mycobacterium vaccine in the treatment of novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
mycobacterium vaccine injection alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Guangxi Medical University, The Fourth People’s Hospital of Nanning |
|
China |
2020-02-04 |
2022-12-31 |
ChiCTR2000030016 |
Phase 4 Clinical |
Recruiting |
1 |
34 Months |
60 |
Chaoqian Li, Jianlin Huang |
2020-02-26 |
| Effect of early pulmonary training on lung function and quality of life for novel coronavirus pneumonia (COVID-19) patients |
Coronavirus disease 19 infection, Viral pneumonia |
pulmonary training alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Puai Hospital |
|
China |
2020-02-19 |
2020-06-30 |
ChiCTR2000030014 |
Phase 0 Clinical |
Recruiting |
1 |
4 Months |
300 |
CAI YU, Zhu Pengfei |
2020-02-26 |
| A prospective clinical study for recombinant human interferon alpha 1b spray in the prevention of novel coronavirus (COVID-19) infection in highly exposed medical staffs |
Coronavirus disease 19 infection, Viral pneumonia |
recombinant human interferon alpha 1b alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Chinese PLA General Hospital |
|
China |
2020-02-20 |
2020-06-30 |
ChiCTR2000030013 |
Phase 4 Clinical |
Not yet recruiting |
4 |
4 Months |
600 |
Feng Cao, Yabin Wang |
2020-02-26 |
| Development of anti-2019-nCoV therapeutic antibody from the recovered novel coronavirus pneumonia patients (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
First People's Hospital of Chenzhou |
|
China |
2020-02-19 |
|
ChiCTR2000030012 |
Phase 0 Clinical |
Not yet recruiting |
1 |
|
20 |
XiaoWang Qu, YaBin Hu |
2020-02-26 |
| A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in mild/common patients with novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
phosphoric chloroquine alone |
|
|
Qingyuan City People's Hospital |
Guangzhou Regenerative Medicine and Health Guangdong Laboratory |
China |
2020-02-20 |
2021-03-20 |
ChiCTR2000030031 |
Phase 4 Clinical |
Recruiting |
2 |
13 Months |
120 |
Jingwei Miao, Ying Deng |
2020-02-26 |
| An open, controlled clinical trial for evaluation of Ganovo combined with ritonavir and integrated traditional Chinese and Western medicine in the treatment of novel coronavirus infection (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
Coriolus alone, Novaferon alone, Spray inhalation alone, peginterferon alfa-2a alone, traditional Chinese medicine alone, danoprevir plus ritonavir |
Cytochrome P450 3A4 inhibitor, HIV protease inhibitor, HIV-1 protease inhibitor, Hepatitis C virus NS3 protease inhibitor, Interferon alpha 2 ligand |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Nanchang Ninth Hospital |
Ascletis Pharma Inc |
China |
2020-02-16 |
|
ChiCTR2000030000 |
Phase 4 Clinical |
Recruiting |
1 |
|
50 |
Hongyi Chen |
2020-03-03 |
| A clinical study for probiotics in the regulation of intestinal function and microflora structure of novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
probiotics alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Shanghai 10th People's Hospital |
|
China |
2020-02-06 |
|
ChiCTR2000029999 |
Phase 0 Clinical |
Not yet recruiting |
3 |
|
60 |
Pan Dengdeng, Peng Hu |
2020-02-25 |
| Single-arm study for exploration of chloroquine phosphate aerosol inhalation in the treatment of novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
chloroquine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
First Hospital of Jilin University |
Jilin Provincial Science & Technology Department |
China |
2020-02-24 |
2020-05-31 |
ChiCTR2000029975 |
Phase 4 Clinical |
Not yet recruiting |
1 |
3 Months |
|
Hua Shucheng, Jie Jing |
2020-02-26 |
| A prospective, multicenter, open-label, randomized, parallel-controlled trial for probiotics to evaluate efficacy and safety in patients infected with 2019 novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
Bacillus coagulans plus Clostridium butyricum (oral capsule, live, digestive symptoms), Qingdao Eastsea Pharmaceuticals |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Qilu Hospital of Shandong University, Qingdao Eastsea Pharmaceuticals Ltd |
|
China |
2020-02-09 |
2020-08-31 |
ChiCTR2000029974 |
Phase 0 Clinical |
Recruiting |
7 |
6 Months |
300 |
CHEN Ying, Dong Liang |
2020-02-25 |
| A multicenter study on the efficacy and safety of suramin sodium in adult patients with novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
suramin sodium alone |
P2X purinoceptor antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
The First Affiliated Hospital of college of medicine Zhejiang University |
|
China |
2020-01-31 |
2020-05-30 |
ChiCTR2000030029 |
Phase 0 Clinical |
Not yet recruiting |
1 |
4 Months |
20 |
Shentu Jianzhong, Wu Guolan, Wu Lihua |
2020-02-25 |
| Clinical Study of Chloroquine Phosphate in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19) |
Coronavirus disease 19 infection |
chloroquine phosphate alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Zhangnan Hospital |
Hubei Medical University |
China |
2020-02-13 |
2020-05-31 |
ChiCTR2000029988 |
Phase 4 Clinical |
Recruiting |
1 |
3 Months |
80 |
Zhao Yan, Zhou Xianlong |
2020-02-25 |
| The Investigation of the Neonates With or With Risk of COVID-19 |
Coronavirus disease 19 infection |
biological sampling alone |
|
Newborn Infants (up to 5 months) |
Children's Hospital of Fudan University |
|
China |
2020-02-01 |
2020-12-31 |
CHFUDANU_NNICU14, NCT04279899 |
Phase Not Applicable |
Recruiting |
2 |
11 Months |
100 |
Shiwen Xia, M.D., Wenhao Zhou, Doctor |
2020-02-25 |
| Clinical Trial for Human Mesenchymal Stem Cells in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
human umbilical cord mesenchymal stem cells (UC-MSC) alone |
|
Male, Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Chinese PLA General Hospital |
|
China |
2020-02-24 |
2020-05-31 |
ChiCTR2000030138 |
Phase 2 Clinical |
Not yet recruiting |
1 |
3 Months |
60 |
Chuanzhu Li, Jian Bo |
2020-02-25 |
| A clinical study for the efficacy and safety of Adalimumab Injection in the treatment of patients with severe novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
adalimumab alone, conventional treatment alone |
TNF alpha ligand inhibitor, TNF binding agent |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Shanghai Changzheng Hospital |
|
China |
2020-02-28 |
2020-08-31 |
ChiCTR2000030089 |
Phase 4 Clinical |
Not yet recruiting |
1 |
6 Months |
60 |
Huji Xu, Ling Zhou |
2020-02-25 |
| Umbilical cord Wharton's Jelly derived mesenchymal stem cells in the treatment of severe novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
Wharton's Jelly mesenchymal stem cells alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
302 Military Hospital of China, Navy General Hospital |
|
China |
2020-03-01 |
2021-12-31 |
ChiCTR2000030088 |
Phase 0 Clinical |
Not yet recruiting |
2 |
22 Months |
40 |
Lianru Gao, Ningkun Zhang |
2020-02-25 |
| Study for the effects on medical providers' infection rate and mental health after performing different anesthesia schemes in cesarean section for novel coronavirus pneumonia (COVID-19) puerperae |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
|
Union Hospital Tongji Medical School Huazhong University Of Science & Technology |
|
China |
2020-02-22 |
|
ChiCTR2000030086 |
Phase Not Applicable |
Recruiting |
2 |
|
210 |
Haifa Xia, Shujun Sun, Xiangdong Chen |
2020-02-25 |
| Study on the false positive rate of IgM / IgG antibody test kit for COVID-19 in different inpatients |
Coronavirus disease 19 infection, Viral pneumonia |
IgMIgG antibody detection kit alone |
|
Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Affiliated Hospital of Zunyi Medical College |
|
China |
2020-02-22 |
2020-12-31 |
ChiCTR2000030085 |
Phase 0 Clinical |
Recruiting |
1 |
10 Months |
500 |
Hehua Song, Zairong Wei |
2020-02-25 |
| Fingolimod in COVID-19 |
Coronavirus disease 19 infection, Viral pneumonia |
fingolimod alone |
Cannabinoid receptor antagonist, Sphingosine-1-phosphate receptor-1 modulator, Sphingosine-1-phosphate receptor-3 modulator, Sphingosine-1-phosphate receptor-4 modulator, Sphingosine-1-phosphate receptor-5 modulator |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
First Affiliated Hospital of Fujian Medical University |
|
China |
2020-02-22 |
2020-07-01 |
MRCTA, ECFAH OF FMU [2020]027, NCT04280588 |
Phase 2 Clinical |
Recruiting |
1 |
4 Months |
30 |
Ning Wang, MD, Wan-Jin Chen, MD, Ying Fu |
2020-02-25 |
| Randomized controlled trial for the efficacy of dihydroartemisinine piperaquine in the treatment of mild/common novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
antiviral treatment alone, dihydroartemisinin piperaquine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
The First Affiliated Hospital of Nanchang University |
|
China |
2020-02-23 |
2020-04-30 |
ChiCTR2000030082 |
Phase 4 Clinical |
Recruiting |
1 |
2 Months |
40 |
Hong tao, Huang Xianbao |
2020-02-25 |
| A multicenter, randomized, double-blind, controlled clinical trial for leflunomide in the treatment of novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Pneumonia, Viral pneumonia |
leflunomide alone |
Dihydroorotate dehydrogenase inhibitor, Protein tyrosine kinase inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Renmin Hospital of Wuhan University |
Science and Technology Department of Hubei Province |
China |
2020-03-01 |
2020-05-30 |
ChiCTR2000030058 |
Phase 3 Clinical |
Not yet recruiting |
3 |
2 Months |
200 |
Ke Hu |
2020-02-25 |
| Detection of 2019 Novel Coronavirus in Multiple Organ System and Its Relationship With Clinical Manifestations |
Coronavirus disease 19 infection |
biological sampling alone, quantitative real-time polymerase chain reaction alone |
|
|
The Third Affiliated Hospital of Sun Yat-Sen University |
|
China |
2020-01-20 |
2021-02-28 |
NCT04279795, PL11 |
Phase Not Applicable |
Recruiting |
1 |
13 Months |
20 |
Liang Peng, Doctor, Wenxiong Xu, Doctor |
2020-02-25 |
| Clinical Features of Suspected and Confirmed Patients of 2019 Novel Coronavirus Infection |
Coronavirus disease 19 infection |
antibiotics therapy alone, antiviral therapy alone, chest computed tomography alone, supportive therapy alone, symptomatic treatment alone |
|
|
The Third Affiliated Hospital of Sun Yat-Sen University |
|
China |
2020-01-20 |
2021-02-28 |
NCT04279782, XWX3 |
Phase Not Applicable |
Recruiting |
1 |
13 Months |
100 |
Liang Peng, Doctor, Wenxiong Xu, Doctor |
2020-02-25 |
| NK Cells Treatment for Novel Coronavirus Pneumonia |
Coronavirus disease 19 infection |
NK cells alone, standard therapy alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
XinXiang Medical University |
The First Affiliated Hospital of Xinjiang Medical University |
China |
2020-02-20 |
2020-12-30 |
NCT04280224, XINXIANGM |
Phase 1 Clinical |
Recruiting |
1 |
10 Months |
30 |
GUO, Professor, ZHU, Professor |
2020-02-25 |
| Adaptive COVID-19 Treatment Trial |
Coronavirus disease 19 infection |
remdesivir alone |
RNA polymerase modulator |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
National Institute of Allergy and Infectious Diseases, Tan Tock Seng Hospital |
|
Singapore, US, South Korea |
2020-02-21 |
2023-04-01 |
20-0006, NCT04280705 |
Phase 2 Clinical |
Recruiting |
4 |
37 Months |
394 |
David Lye, Diego Lopez de Castilla, Dr David Lye Chian Boon, John Beigel |
2020-03-20 |
| Yinhu Qingwen Decoction for the Treatment of Mild/Common CoVID-19 |
Coronavirus disease 19 infection |
Standard western medicine alone, YinHu QingWen decoction alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
China Academy of Chinese Medical Sciences |
|
China |
2020-02-27 |
2021-01-31 |
NCT04278963, YHQW-V3.0 |
Phase 2/Phase 3 Clinical |
No longer recruiting |
6 |
11 Months |
300 |
Jiang-Rong Huang, M.D., Wei Zhang, Xiao-Dong Li, M.D., Zhe Wu, Zhong Wang, Professor |
2020-03-19 |
| Immunity and Safety of Covid-19 Synthetic Minigene Vaccine |
Coronavirus disease 19 infection |
LV-DC/SMENP alone, antigen-specific cytotoxic T-cells alone |
|
Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Shenzhen Geno-Immune Medical Institute |
Shenzhen Second People's Hospital, The Third People’s Hospital of Shenzhen |
China |
2020-03-24 |
2024-12-31 |
GIMI-IRB-20001, NCT04276896 |
Phase 1/Phase 2 Clinical |
Recruiting |
3 |
57 Months |
100 |
Lung-Ji Chang, PhD |
2020-03-20 |
| A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia |
Coronavirus disease 19 infection |
MSCs-derived exosomes alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Rui Jin Hospital |
Cellular Biomedicine Group Ltd., Shanghai Public Health Clinical Center, Wuhan Jinyintan Hospital |
China |
2020-02-15 |
2020-07-31 |
MEXCOVID, NCT04276987 |
Phase 1 Clinical |
Not yet recruiting |
1 |
5 Months |
30 |
Jie-ming Qu, MD.,PhD. |
2020-02-26 |
| Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia |
Coronavirus disease 19 infection, Viral pneumonia |
Variable regimens including Xiyanping , alpha-interferon , lopinavir , ritonavir |
Cytochrome P450 3A4 inhibitor, HIV protease inhibitor, HIV-1 protease inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Jiangxi Qingfeng Medical Investment Group, Shanghai Public Health Clinical Center |
|
China |
2020-02-14 |
2021-12-14 |
ChiCTR2000030117, NCT04275388, QF-XYP2001-1 |
Phase 4 Clinical |
Recruiting |
1 |
22 Months |
348 |
Hongzhou Lu, Hongzhou Lu, Master, Wenjun Lin |
2020-02-25 |
| Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia |
Coronavirus disease 19 infection |
meplazumab plus methylprednisolone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Tangdu Hospital, the Fourth Military Medical University |
|
China |
2020-02-03 |
2020-12-31 |
20200101, NCT04275245 |
Phase 1/Phase 2 Clinical |
Recruiting |
1 |
10 Months |
20 |
Huijie Bian, PhD, Jianqi Lian, MD, Sicao Li |
2020-02-21 |
| A Multicenter, Randomized-controlled Trial for the Efficacy and Safety of Alpha Lipoic Acid (iv) in the Treatment of Patients of Severe Novel Coronavirus Pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
alpha lipoic acid (ALA) alone, conventional therapy alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Shanghai Zhongshan Hospital |
Fudan University |
China |
2020-02-27 |
2020-03-10 |
ChiCTR2000029851 |
Phase 4 Clinical |
Not yet recruiting |
3 |
|
68 |
Aijun Sun, Lei Xu |
2020-02-25 |
| Lopinavir/Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment |
Coronavirus disease 19 infection |
standard care alone, Variable regimens including interferon beta-1b , lopinavir + ritonavir , ribavirin |
HIV protease inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
The University of Hong Kong |
Hospital Authority,Hong Kong |
Hong Kong |
2020-02-10 |
2022-07-31 |
NCT04276688, UW-20-074 |
Phase 2 Clinical |
Recruiting |
2 |
29 Months |
70 |
Ivan FN Hung, MD FRCP, KY Yuen, MD FRCPath, Kelvin To, MD FRCPath |
2020-03-02 |
| BEST-CP: Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia |
Coronavirus disease 19 infection, Viral pneumonia |
Other treatment alone, bevacizumab alone |
VEGF ligand inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Qilu Hospital of Shandong University |
|
China |
2020-02-29 |
2020-05-31 |
BEST-CP, NCT04275414, QLEMER20200214 |
Phase 2/Phase 3 Clinical |
Recruiting |
1 |
3 Months |
20 |
Jiaojiao Pang, Jiaojiao Pang, Dr, Yuguo Chen, Dr |
2020-02-24 |
| Study on Convalescent Plasma Treatment for Severe Patients With Novel Coronavirus Pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
convalescent plasma therapy alone, standardized comprehensive therapy alone |
|
Male, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
The First Affiliated Hospital of college of medicine Zhejiang University |
|
China |
2020-02-15 |
2022-02-15 |
ChiCTR2000029850 |
Phase 0 Clinical |
Recruiting |
1 |
24 Months |
20 |
Liang Yu, Xiaowei Xu |
2020-02-25 |
| Immunomodulatory Therapy for Severe Novel Coronavirus Pneumonia (COVID-19) |
Coronavirus disease 19 infection, Lymphocytopenia, Viral pneumonia |
camrelizumab alone, thymosin alone |
Programmed cell death protein 1 inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
The Affiliated Zhongda Hospital of Southeast University |
Chinese Ministry of Science and Technology |
China |
2020-01-01 |
2021-01-31 |
ChiCTR2000029806 |
Phase 2 Clinical |
Recruiting |
1 |
13 Months |
120 |
Liu Ying, Xia Jiaan |
2020-02-21 |
| Study for the efficacy and safety of GD31 in patients with novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection |
GD31 alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Guangzhou Municipal Twelfth People's Hospital |
|
China |
2020-02-16 |
2020-12-31 |
ChiCTR2000029895 |
Phase 1/Phase 2 Clinical |
Recruiting |
1 |
10 Months |
160 |
Linghua Li, Weiping Cai |
2020-02-24 |
| A multicenter, randomized, open, controlled trial for the efficacy and safety of Shen-Qi Fu-Zheng injection in the treatment of novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection |
Routine treatment alone, Variable regimens including Shenqi Fuzheng injection |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Huazhong University of Science and Technology |
|
China |
2020-02-06 |
2020-06-09 |
ChiCTR2000029780, ChiMCTR2000003004 |
Phase 4 Clinical |
Recruiting |
6 |
4 Months |
160 |
Hong Sun, Xin Zheng |
2020-02-21 |
| The Application Value of Non-contact Infrared Thermometers in Temperature Screening in the General Population |
Coronavirus disease 19 infection |
non-contact infrared thermometer alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Ningbo First Hospital |
|
China |
2020-02-14 |
2020-02-20 |
NCT04274621, WT2020-V1.0 |
Phase Not Applicable |
Completed |
1 |
|
572 |
|
2020-03-04 |
| Clinical Study for Traditional Chinese Medicine Combined With Western Medicine in Treatment of Novel Coronavirus Pneumonia (COVID-19) |
Coronavirus disease 19 infection |
QFPD decoction alone, SFJD capsule alone, Traditional Chinese Medicine alone, conventional treatment alone |
|
|
Shanghai Public Health Clinical Center, Shanghai University of Traditional Chinese Medicine |
|
China |
2020-02-14 |
2020-05-13 |
ChiCTR2000029778, ChiMCTR2000003003 |
Phase 0 Clinical |
Recruiting |
1 |
3 Months |
600 |
Wei Zhang, Xuan Chen |
2020-02-21 |
| A multicenter, randomized, controlled study for integrated chinese and western medicine in the treatment of novel coronavirus pneumonia (COVID-19) based on the 'Truncated Torsion' strategy |
Coronavirus disease 19 infection |
Truncation and Torsion Formula alone, Western Medicine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Huangshi Hospital of Traditional Chinese Medicine, LaoHeKou Tradiational Chinese Medicine Hospital, Longhua Hospital Shanghai University of TCM, The Second Hospital of Xi'An Jiaotong University, Tongji Hospital, Huazhong University of Science and Technology |
Shanghai University of Traditional Chinese Medicine |
China |
|
|
ChiCTR2000029777, ChiMCTR2000003002 |
Phase 0 Clinical |
Recruiting |
3 |
|
160 |
Bangjiang Fang, Gang Wang, Jianguo Zuo, Jun Feng, Tingrong Huang, Wen Zhang |
2020-02-21 |
| A randomized, open-label, blank-controlled, multicenter trial for Polyinosinic-Polycytidylic Acid Injection in the treatment of novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection |
conventional therapy alone, Variable regimens including polyinosinic-polycytidylic acid injection |
|
|
The First Affiliated Hospital of Wenzhou Medical University, The Second Hospital and Yuying Children's Hospital of Wenzhou Medical University |
|
China |
2020-02-11 |
2020-12-31 |
ChiCTR2000029776 |
Phase 4 Clinical |
Recruiting |
2 |
10 Months |
|
Peiliang Wu, Xiaoyin Huang |
2020-02-20 |
| The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia |
Coronavirus disease 19 infection |
thalidomide, Celgene alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
The First Affiliated Hospital of Wenzhou Medical University |
The Second Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou Central Hospital |
China |
2020-02-20 |
2020-06-30 |
20200214-COVID-19-M-T, NCT04273529 |
Phase 2 Clinical |
Not yet recruiting |
1 |
4 Months |
100 |
Jinglin Xia, MD |
2020-02-24 |
| Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19) |
Coronavirus disease 19 infection, Pneumonia |
Variable regimens including arbidol hydrochloride , bromhexine hydrochloride , recombinant human interferon alpha2b |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
The Second Hospital and Yuying Children's Hospital of Wenzhou Medical University |
Zhejiang Wanbang Pharmaceutical Co Ltd |
China |
2020-02-16 |
2020-04-30 |
2019NCP1.0, NCT04273763 |
Phase 2 Clinical |
Recruiting |
1 |
2 Months |
60 |
XIAN SHEN, phd |
2020-02-21 |
| A multicenter, randomized, controlled trial for integrated Chinese and western medicine in the treatment of ordinary novel coronavirus pneumonia (COVID-19) based on the ' Internal and External Relieving -Truncated Torsion' strategy |
Coronavirus disease 19 infection, Viral pneumonia |
Routine treatment of Western Medicine alone, Truncated Torsion Formula method alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Huangshi Hospital of Traditional Chinese Medicine, LaoHeKou Tradiational Chinese Medicine Hospital, Longhua Hospital Shanghai University of TCM, The Second Hospital of Xi'An Jiaotong University, Tongji Hospital, Huazhong University of Science and Technology |
Shanghai Traditional Chinese Medicine Hospital |
China |
2020-02-01 |
2020-06-30 |
ChiCTR2000029869, ChiMCTR2000003019 |
Phase 4 Clinical |
Not yet recruiting |
3 |
5 Months |
300 |
Bangjiang Fang, Gang Wang, Jianguo Zuo, Jun Feng, Tingrong Huang, Wen Zhang |
2020-02-20 |
| Hydroxychloroquine treating novel coronavirus pneumonia (COVID-19): a multicenter, randomized controlled trial |
Coronavirus disease 19 infection, Viral pneumonia |
hydroxychloroquine sulfate alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Rui Jin Hospital |
Shanghai Zhongxi Pharmaceutical Ltd |
China |
2020-02-06 |
2020-07-31 |
ChiCTR2000029868 |
Phase 4 Clinical |
Recruiting |
4 |
5 Months |
200 |
Guochao Shi |
2020-02-20 |
| A Single-blind, Randomized, Controlled Clinical Trial for Chloroquine Phosphate in the treatment of Novel Coronavirus Pneumonia 2019 (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
chloroquine phosphate alone, conventional treatment alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
The 2nd People's Hospital of Ningbo |
|
China |
2020-02-06 |
2021-02-06 |
ChiCTR2000029939 |
Phase 2 Clinical |
Recruiting |
1 |
12 Months |
100 |
Ting Cai |
2020-02-21 |
| A randomized, open, controlled trial for diammonium glycyrrhizinate enteric-coated capsules combined with vitamin C tablets in the treatment of common novel coronavirus pneumonia (COVID-19) in the basic of clinical standard antiviral treatment to evaluate the safety and efficiency |
Coronavirus disease 19 infection, Viral pneumonia |
Vitamin C alone, clinical standard antiviral treatment alone, Variable regimens including Diammonium Glycyrrhizinate Enteric-coated Capsules |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Zhangnan Hospital |
|
|
2020-02-12 |
2020-05-12 |
ChiCTR2000029768 |
Phase 0 Clinical |
Recruiting |
0 |
3 Months |
60 |
Liu Jingjing, Peng Liang |
2020-03-03 |
| The efficacy and safety of carrimycin treatment in patients with novel coronavirus pneumonia (COVID-19): a multicenter, randomized, open-label, controlled trial |
Coronavirus disease 19 infection, Viral pneumonia |
carrimycin alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
2nd People's Hospital of Fuyang City, Beijing YouAn Hospital, First Affiliated Hospital Bengbu Medical College, Huangshi Central Hospital, Institute of Medicinal Biotechnology Chinese Academy of Medical Sciences, Shenyang Pharmaceutical University, Shenyang Tonglian Group Co Ltd, The Second Affiliated Hospital of Harbin Medical University, The people’s hospital of Heilongjiang province |
Ministry of Science and Technology of the People´s Republic of China |
China |
2020-02-15 |
2021-02-28 |
ChiCTR2000029867 |
Phase 4 Clinical |
Recruiting |
9 |
12 Months |
520 |
Ronghua Jin, Ying Han |
2020-02-20 |
| The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe COVID-19 |
Coronavirus disease 19 infection |
Variable regimens including Abidol , alpha-interferon , methylprednisolone , thalidomide |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
The First Affiliated Hospital of Wenzhou Medical University |
The Second Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou Central Hospital |
China |
2020-02-18 |
2020-05-30 |
20200214-COVID-19-S-T, NCT04273581 |
Phase 2 Clinical |
Not yet recruiting |
1 |
3 Months |
40 |
Jinglin Xia, MD |
2020-02-24 |
| Clinical study on the safety and effectiveness of hydroxychloroquine sulfate tablets in the treatment of patients with novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
conventional therapy alone, hydroxychloroquine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
First Affiliated Hospital of Chongqing Medical University |
Chongqing Municipal Health Bureau |
China |
2020-02-13 |
2020-04-30 |
ChiCTR2000029761 |
Phase 4 Clinical |
Recruiting |
4 |
2 Months |
240 |
Jiajun Li, Wenxiang Huang |
2020-02-20 |
| Efficacy and Safety of Corticosteroids in COVID-19 |
Coronavirus disease 19 infection |
methylprednisolone alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Beijing Chao-Yang Hospital |
|
China |
2020-02-14 |
2020-05-30 |
METHYLPREDNISOLONE IN COVID-19, NCT04273321 |
Phase 2 Clinical |
Recruiting |
5 |
3 Months |
400 |
Bing Sun, MD, Jianchu Zhang, MD, Jixian Zhang, MD, Jixiang Ni, MD, Ke Hu, MD, Limin Liu, MD, Shi Huanzhong, Xiao Tang, MD |
2020-02-25 |
| Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Novel Coronavirus Severe Pneumonia |
Coronavirus disease 19 infection |
conventional treatment alone, human umbilical cord mesenchymal stem cells alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Wuhan Union Hospital, China |
Wuhan Hamilton Biotechnology Co., Ltd |
China |
2020-02-16 |
2022-02-15 |
202001, NCT04273646 |
Phase 2 Clinical |
Not yet recruiting |
1 |
24 Months |
48 |
Yang Jin, Yang Jin, MD |
2020-02-22 |
| A study for the efficacy of hydroxychloroquine for mild and moderate COVID-19 infectious diseases |
Coronavirus disease 19 infection |
hydroxychloroquine alone |
|
|
The Second Affiliated Hospital, Chongqing Medical University |
Chongqing Medical University |
China |
2020-02-12 |
2020-08-11 |
ChiCTR2000029760 |
Phase 4 Clinical |
Recruiting |
2 |
6 Months |
240 |
Huawei Mao, Yanli Yang |
2020-02-20 |
| A multicenter, randomized, open-label, controlled trial for the efficacy and safety of ASC-09/ritonavir compound tablets and lopinavir/ritonavir (Kaletra) and Arbidol tablets in the treatment of novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
ASC-09 + ritonavir (HIV infection/COVID-19, oral tablet), Ascletis Pharma plus interferon |
HIV-1 protease inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Chongqing Three Gorges Central Hospital, The Second Affiliated Hospital, Chongqing Medical University |
|
China |
2020-02-15 |
2020-05-01 |
ChiCTR2000029759 |
Phase 0 Clinical |
Recruiting |
2 |
2 Months |
60 |
Peng Hu |
2020-02-20 |
| A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
conventional therapy alone, Variable regimens including tocilizumab |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Anhui Provincial Hospital, First Affiliated Hospital of Anhui Medical University |
|
China |
2020-02-10 |
2020-05-10 |
ChiCTR2000029765 |
Phase 4 Clinical |
Recruiting |
1 |
3 Months |
188 |
Dongsheng Wang, Xiaoling Xu |
2020-02-24 |
| A Single-arm Clinical Trial for Chloroquine Phosphate in the treatment of Novel Coronavirus Pneumonia 2019 (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
chloroquine phosphate alone, conventional treatment alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
The 2nd People's Hospital of Ningbo |
|
China |
2020-02-06 |
2021-02-06 |
ChiCTR2000029935 |
Phase 2 Clinical |
Recruiting |
1 |
12 Months |
100 |
Honghua Ye, Ting Cai |
2020-02-20 |
| Clinical study of nebulized Xiyanping injection in the treatment of novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Pneumonia |
Xiyanping alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Renmin Hospital of Wuhan University |
|
China |
2020-02-15 |
2022-02-15 |
ChiCTR2000029756, ChiMCTR2000003000 |
Phase 0 Clinical |
Recruiting |
1 |
24 Months |
238 |
Shoumeng Han, Zhan Zhang |
2020-02-20 |
| Early warning prediction of patients with severe novel coronavirus pneumonia (COVID-19) based on multiomics |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Taizhou Enze Hospital |
|
China |
2020-02-16 |
2020-05-31 |
ChiCTR2000029866 |
Phase Not Applicable |
Recruiting |
1 |
3 Months |
120 |
Jiang Yongpo, Lyu Dongqing |
2020-02-20 |
| Descriptive study on the clinical characteristics and outcomes of novel coronavirus pneumonia (COVID-19) in cardiovascular patients |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Union Hospital Tongji Medical School Huazhong University Of Science & Technology |
Huazhong University of Science and Technology |
China |
2020-02-20 |
2020-04-20 |
ChiCTR2000029865 |
Phase Not Applicable |
Recruiting |
1 |
2 Months |
1200 |
Peng Yudong |
2020-02-21 |
| Clinical Trial for TanReQing Capsules in the Treatment of Novel Coronavirus Pneumonia (COVID-19) |
Coronavirus disease 19 infection, Pneumonia |
TanReQing alone, conventional treatment alone, lopinavir + ritonavir plus ribavirin |
HIV protease inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Shanghai Public Health Clinical Center |
Shanghai Municipal Development and Reform Commission |
China |
2020-02-14 |
2020-08-14 |
ChiCTR2000029813 |
Phase 0 Clinical |
Recruiting |
1 |
6 Months |
72 |
Hongzhou Lu, Xiaorong Chen |
2020-02-21 |
| Clinical Study for Umbilical Cord Blood Mononuclear Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19) |
Coronavirus disease 19 infection, Pneumonia |
conventional treatment alone, umbilical cord blood mononuclear cells alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Guangzhou reborn health management consultancy co., LTD |
|
China |
2020-02-20 |
2021-02-20 |
ChiCTR2000029812 |
Phase 0 Clinical |
Not yet recruiting |
1 |
12 Months |
60 |
Chao Xu |
2020-02-19 |
| A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in mild/common patients with novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Pneumonia |
phosphoric chloroquine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Jingzhou Central Hospital |
|
China |
2020-02-17 |
2020-03-17 |
ChiCTR2000029837 |
Phase 4 Clinical |
Not yet recruiting |
1 |
1 Month |
120 |
Jinghua Mao, Xu Zhen |
2020-02-19 |
| The efficacy of traditional chinese medicine on Novel Coronavirus Pneumonia (COVID-19) patients treated in square cabin hospital: a prospective, randomized controlled trial |
Coronavirus disease 19 infection |
Traditional Chinese Medicine alone, general treatment alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
China Academy of Chinese Medical Sciences, Zhangnan Hospital |
Ministry of National Science and Technology, National Key Technologies R&D Program |
China |
2020-02-12 |
2020-05-31 |
ChiCTR2000029763, ChiMCTR2000003001 |
Phase Not Applicable |
Recruiting |
1 |
3 Months |
408 |
Huang Luqi, Li Zhiqiang, Zhao Chen |
2020-02-25 |
| COVID-19: Clinical study for the effect and safety of hydroxychloroquine sulfate tablets in the treatment of patients with severe novel coronavirus pneumonia |
Coronavirus disease 19 infection |
conventional treatment alone, hydroxychloroquine alone |
|
|
First Affiliated Hospital of Chongqing Medical University |
Chongqing Municipal Health Bureau |
China |
2020-02-12 |
|
COVID-19, ChiCTR2000029762 |
Phase 4 Clinical |
Recruiting |
3 |
|
60 |
Jiajun Li, Wenxiang Huang |
2020-03-20 |
| Efficacy of Chloroquine and Lopinavir/ Ritonavir in mild/general novel coronavirus (CoVID-19) infections: a prospective, open-label, multicenter randomized controlled clinical study |
Coronavirus disease 19 infection |
chloroquine phosphate alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Sun Yat-Sen University |
|
China |
2020-02-11 |
2020-12-31 |
ChiCTR2000029741, ZDWY.GRBK.011 |
Phase 4 Clinical |
Recruiting |
1 |
10 Months |
112 |
Liu Xi, Xia Jinyu |
2020-02-24 |
| Efficacy of therapeutic effects of hydroxycholoroquine in novel coronavirus pneumonia (COVID-19) patients |
Coronavirus disease 19 infection |
hydroxycholoroquine alone |
|
Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Peking University First Hospital |
|
China |
2020-02-11 |
2020-02-29 |
ChiCTR2000029740 |
Phase 4 Clinical |
Recruiting |
1 |
|
200 |
Yu Wang, Zhuoli Zhang |
2020-03-20 |
| A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in serious/critically ill patients with novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Pneumonia |
phosphoric chloroquine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Jingzhou Central Hospital |
|
China |
2020-02-17 |
2020-03-17 |
ChiCTR2000029826 |
Phase 4 Clinical |
Not yet recruiting |
1 |
1 Month |
45 |
Jinghua Mao, Xu Zhen |
2020-02-19 |
| ased on Delphi Method to Preliminarily Construct a Recommended Protocol for the Prevention of Novel Coronavirus Pneumonia (COVID-19) in Deyang Area by Using Chinese Medicine Technology and its Clinical Application Evaluation |
Coronavirus disease 19 infection, Pneumonia |
Delphy Method alone, traditional Chinese medicine alone |
|
Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Deyang Integrated Traditional Chinese and Western Medicine Hospital |
|
China |
2020-02-15 |
2020-06-01 |
ChiCTR2000029821 |
Phase Not Applicable |
Not yet recruiting |
3 |
3 Months |
400 |
He Bo, Qiu Jun |
2020-02-19 |
| Clinical Study for Umbilical Cord Blood Plasma in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19) |
Coronavirus disease 19 infection, Pneumonia |
conventional treatment alone, umbilical cord blood plasma alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Guangzhou reborn health management consultancy co., LTD |
|
China |
2020-02-20 |
2021-02-20 |
ChiCTR2000029818 |
Phase 0 Clinical |
Not yet recruiting |
1 |
12 Months |
60 |
Chao Xu |
2020-02-19 |
| Clinical Study for Cord Blood Mesenchymal Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19) |
Coronavirus disease 19 infection, Pneumonia |
cord blood NK cells plus cord blood mesenchymal stem cells |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Guangzhou Institutes of Biomedicine and Health, Guangzhou reborn health management consultancy co., LTD, Sun Yat-Sen Memorial Hospital (2) |
|
China |
2020-02-20 |
2021-02-20 |
ChiCTR2000029816, ChiCTR2000029817 |
Phase 0 Clinical |
Not yet recruiting |
1 |
12 Months |
60 |
Chao Xu |
2020-02-19 |
| Washed Microbiota Transplantation for Patients With 2019-nCoV Infection |
Coronavirus disease 19 infection, Viral pneumonia |
standard therapy alone, washed microbiota transplantation (WMT) alone |
|
Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Second Affiliated Hospital Nanjing Medical University |
|
China |
2020-02-05 |
|
NCT04251767, WMT-YJ-202001 |
Phase Not Applicable |
Terminated |
1 |
|
|
Faming Zhang, MD, PHD |
2020-03-18 |
| A randomized, parallel-controlled trial for the efficacy and safety of sodium aescinate injection in the treatment of patients with pneumonia (COVID-19) |
Coronavirus disease 19 infection |
conventional treatment alone, sodium aescinate alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Tongji Medical College |
Shandong Luye Pharmaceutical Co Ltd |
China |
2020-02-10 |
2020-12-31 |
ChiCTR2000029742 |
Phase 4 Clinical |
Recruiting |
1 |
10 Months |
90 |
Meifang Han, Qin Ning, Yang Yang |
2020-03-20 |
| A real world study for traditional Chinese Medicine in the treatment of novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
traditional chinese medicine alone |
|
|
Shanghai Public Health Clinical Center |
Shanghai Health and Health Commission |
China |
2020-02-08 |
2021-02-07 |
ChiCTR2000029624, ChiMCTR2000002977 |
Phase Not Applicable |
Not yet recruiting |
1 |
12 Months |
500 |
Lu Hongzhou, Lyu Ying |
2020-02-26 |
| Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia |
Coronavirus disease 19 infection, Viral pneumonia |
vitamin C alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Zhangnan Hospital |
|
China |
2020-02-14 |
2020-09-30 |
2020001, NCT04264533 |
Phase 2 Clinical |
Recruiting |
1 |
7 Months |
140 |
ZhiYong Peng, Zhiyong Peng, professor |
2020-03-11 |
| Evaluating and Comparing the Safety and Efficiency of ASC-09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection |
Coronavirus disease 19 infection, Viral pneumonia |
ASC-09 + ritonavir (HIV infection/COVID-19, oral tablet), Ascletis Pharma alone, conventional standardized treatment alone |
HIV-1 protease inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
The First Affiliated Hospital of college of medicine Zhejiang University |
Ascletis Pharma Inc |
|
2020-02-07 |
2020-06-30 |
ASC09F-CTP-ZY-01, NCT04261907 |
Phase 2 Clinical |
Not yet recruiting |
0 |
4 Months |
160 |
Jian Liu, Master, Xiaowei Xu, Master, Yunqing Qiu, Master |
2020-02-26 |
| The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia |
Coronavirus disease 19 infection, Viral pneumonia |
basic symptomatic supportive treatment alone, methylprednisolone alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Tongji Hospital |
|
China |
2020-02-01 |
2020-07-01 |
NCT04263402, TJ20200201 |
Phase 4 Clinical |
Recruiting |
2 |
5 Months |
100 |
Meifang Han, Professor, Meifang Han, professor, Qin Ning, Qin Ning, professor, Qing Ning, Professor |
2020-03-18 |
| Clinical study for safety and efficacy of Favipiravir in the treatment of 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP) |
Coronavirus disease 19 infection, Viral pneumonia |
alpha-Interferon atomization alone, Variable regimens including favipiravir |
RNA polymerase inhibitor |
Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
The Third People’s Hospital of Shenzhen |
|
China |
2020-01-30 |
2020-04-29 |
ChiCTR2000029600 |
Phase 0 Clinical |
Recruiting |
1 |
3 Months |
90 |
Liao Xuejiao, Liu Yingxia |
2020-03-23 |
| A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC-09F and Ritonavir for 2019-nCoV Pneumonia |
Coronavirus disease 19 infection, Pneumonia |
oseltamivir alone, Variable regimens including TMC-310911 , oseltamivir , ritonavir |
Cytochrome P450 3A4 inhibitor, Exo-alpha sialidase inhibitor, HIV protease inhibitor, HIV-1 protease inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Tongji Hospital |
|
China |
2020-02-01 |
2020-07-01 |
ASC09F-CTP-TJ-01, NCT04261270 |
Phase 3 Clinical |
Recruiting |
1 |
5 Months |
60 |
Meifang Han, Professor, Meifang Han, professor, Qin Ning, professor, Qing Ning, Professor |
2020-03-18 |
| Severe 2019-nCoV Remdesivir RCT |
Coronavirus disease 19 infection |
remdesivir alone |
RNA polymerase modulator |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Capital Medical University, China-Japan Friendship Hospital |
Gilead Sciences Inc |
China |
2020-02-06 |
2020-05-01 |
CAP-CHINA REMDESIVIR 2, NCT04257656 |
Phase 3 Clinical |
Recruiting |
3 |
2 Months |
453 |
Bin Cao, Professor, Yeming Wang, Doctor |
2020-03-17 |
| ELACOI: The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection |
Coronavirus disease 19 infection |
Standard treatment alone, lopinavir + ritonavir alone |
HIV protease inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Guangzhou 8th People's Hospital |
|
China |
2020-01-28 |
2020-07-31 |
ELACOI, GZ8H-V1.0 20200122, NCT04252885 |
Phase 4 Clinical |
Recruiting |
1 |
6 Months |
125 |
Linghua Li, MD, PhD, Rong Zhou, Yueping Li, MD, Master |
2020-03-23 |
| Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With 2019 Novel Coronavirus |
Coronavirus disease 19 infection, Pneumonia |
conventional treatment alone, mesenchymal stem cells alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
302 Military Hospital of China |
Fifth Affiliated Hospital, Sun Yat-Sen University, The Third People’s Hospital of Shenzhen, Tianjin Haihe Hospital, VCANBIO Cell & Gene Engineering Corp Ltd, Wuhan Jinyintan Hospital |
China |
2020-01-27 |
2021-12-31 |
2020003D, NCT04252118 |
Phase 1 Clinical |
Recruiting |
1 |
23 Months |
20 |
Fu-Sheng Wang, Fusheng Wang, MD,PhD, Lei Shi, MD, PhD, Lei Shi, MD,PhD |
2020-02-27 |
| Treatment and Prevention of Traditional Chinese Medicines (TCMs) on 2019-nCoV Infection |
Coronavirus disease 19 infection |
Oxygen therapy alone, Traditional Chinese medicine alone, alfa interferon plus lopinavir + ritonavir |
HIV protease inhibitor |
Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
302 Military Hospital of China |
|
China |
2020-01-22 |
2021-01-22 |
2020001D, NCT04251871 |
Phase 2 Clinical |
Recruiting |
2 |
12 Months |
150 |
Jia-bo Wang, PD., Rui-lin Wang, Dr., Xiao-he Xiao, PD., Xiaohe Xiao |
2020-03-23 |
| A Prospective/Retrospective, Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia |
Coronavirus disease 19 infection |
abidol hydrochloride alone, abidol hydrochloride plus peginterferon alfa-2a |
Interferon alpha 2 ligand |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Tongji Hospital |
|
China |
2020-02-01 |
2020-07-01 |
NCT04254874, TJ20200131 |
Phase 4 Clinical |
Recruiting |
1 |
5 Months |
100 |
Meifang Han, Professor, Meifang Han, professor, Qin Ning, professor, Qing Ning, Professor |
2020-03-23 |
| DACO-nCoV: Efficacy and Safety of Darunavir and Cobicistat for Treatment of Pneumonia Caused by 2019-nCoV |
Coronavirus disease 19 infection, Viral pneumonia |
conventional treatment alone, cobicistat plus darunavir |
Cytochrome P450 3 inhibitor, HIV-1 protease inhibitor |
|
Shanghai Public Health Clinical Center |
|
China |
2020-01-30 |
2020-12-31 |
DACO-NCOV, DACO-nCoV, NCT04252274 |
Phase 3 Clinical |
Recruiting |
1 |
11 Months |
30 |
Hongzhou Lu, Hongzhou Lu, PI, Hongzhou Lu, Ph.D |
2020-03-23 |
| Mild/Moderate 2019-nCoV Remdesivir RCT |
Coronavirus disease 19 infection |
remdesivir alone, standard of care alone |
RNA polymerase modulator |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Capital Medical University, China-Japan Friendship Hospital |
Chinese Academy of Medical Sciences, Gilead Sciences Inc |
China |
2020-02-12 |
2020-04-27 |
CAP-CHINA REMDESIVIR 1, NCT04252664 |
Phase 3 Clinical |
Recruiting |
3 |
2 Months |
308 |
Bin Cao, Bin Cao, Professor, Yeming Wang, Doctor, Ying Liu |
2020-03-23 |
| A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia |
Coronavirus disease 19 infection, Viral pneumonia |
arbidol hydrochloride alone, lopinavir + ritonavir alone, oseltamivir alone |
Exo-alpha sialidase inhibitor, HIV protease inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Tongji Hospital |
|
China |
2020-02-01 |
2020-07-01 |
NCT04255017, TJ20200128 |
Phase 4 Clinical |
Recruiting |
2 |
5 Months |
400 |
Meifang Han, Professor, Meifang Han, professor, Qin Ning, Qin Ning, professor, Qing Ning, Professor |
2020-03-18 |
| LOTUS China: A randomized, controlled open-label trial to evaluate the efficacy and safety of lopinavir-ritonavir in hospitalized patients with novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
conventional standardized treatment alone, lopinavir + ritonavir alone |
HIV protease inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
China-Japan Friendship Hospital, Wuhan Jinyintan Hospital |
|
China |
2020-01-10 |
2021-01-10 |
ChiCTR2000029308, LOTUS China |
Phase 2 Clinical |
Recruiting |
1 |
12 Months |
160 |
Liu Ying, Zhang Dingyu |
2020-03-20 |